Document:

<Page>

                                                                   Exhibit 10.11

                  RESEARCH, LICENSE AND COLLABORATION AGREEMENT

                                     BETWEEN

                             CELLTECH R & D LIMITED

                                       AND

                         NEOGENESIS DRUG DISCOVERY, INC.

                               DATED JULY 11, 2001

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

<PAGE>

                                TABLE OF CONTENTS

<Table>
<Caption>
                                                                                                   PAGE
                                                                                                   ----
<S>                                                                                                <C>
ARTICLE I.   DEFINITIONS.............................................................................1
         Section 1.1.  AAA...........................................................................2
         Section 1.2.  AFFILIATE.....................................................................2
         Section 1.3.  AGREEMENT.....................................................................2
         Section 1.4.  ALIS..........................................................................2
         Section 1.5.  APPLICABLE LAWS...............................................................2
         Section 1.6.  APPROVAL LETTER...............................................................2
         Section 1.7.  APPROVED TARGET(S)............................................................2
         Section 1.8.  APPROVED TARGET EXCLUSIVITY PERIOD............................................2
         Section 1.9.  CELLTECH INDEMNIFIED PARTY....................................................3
         Section 1.10.  CELLTECH TECHNOLOGY..........................................................3
         Section 1.11.  CELLTECH DERIVATIVES.........................................................3
         Section 1.12.  CIP..........................................................................3
         Section 1.13.  COMMERCIALIZATION............................................................3
         Section 1.14.  COMMERCIALLY REASONABLE EFFORTS..............................................3
         Section 1.15.  CONFIDENTIAL INFORMATION.....................................................4
         Section 1.16.  CONTROL OR CONTROLLED........................................................4
         Section 1.17.  DESIGNATED COMPOUND..........................................................4
         Section 1.18.  DISCLOSING PARTY.............................................................4
         Section 1.19.  EFFECTIVE DATE...............................................................4
         Section 1.20.  FDA..........................................................................4
         Section 1.21.  FD&C ACT.....................................................................4
         Section 1.22.  FIRST COMMERCIAL SALE........................................................4
         Section 1.23.  FOB..........................................................................5
         Section 1.24.  FORCE MAJEURE................................................................5
         Section 1.25.  FTE..........................................................................5
         Section 1.26.  GOOD CLINICAL PRACTICE.......................................................5
         Section 1.27.  GOOD LABORATORY PRACTICE.....................................................5
         Section 1.28.  GOOD MANUFACTURING PRACTICE..................................................5
         Section 1.29.  INDEMNIFIED PARTY(IES).......................................................6
         Section 1.30.  INDEMNIFYING PARTY...........................................................6
         Section 1.31.  KNOW-HOW.....................................................................6
         Section 1.32.  LICENSED PRODUCT(S)..........................................................6
         Section 1.33.  LOCK UP PERIOD...............................................................6
         Section 1.34.  MAJOR COUNTRY................................................................6
         Section 1.35.  MANUFACTURING................................................................6
         Section 1.36.  MASK.........................................................................6
         Section 1.37.  NDA..........................................................................7
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -i-

<Page>

<Table>
<S>                                                                                                <C>
         Section 1.38.  NEOGENESIS INDEMNIFIED PARTY(IES)............................................7
         Section 1.39.  NEOGENESIS TARGET............................................................7
         Section 1.40.  NEOGENESIS TECHNOLOGY........................................................7
         Section 1.41.  NEOGENESIS DERIVATIVES.......................................................7
         Section 1.42.  NEOMORPH CHEMISTRY...........................................................7
         Section 1.43.  NEOMORPH FOCUSED LIBRARIES...................................................7
         Section 1.44.  NEOMORPH SCREENING LIBRARY...................................................7
         Section 1.45.  NET SALES....................................................................7
         Section 1.46.  PATENTS......................................................................8
         Section 1.47.  PERSON.......................................................................9
         Section 1.48.  PHASE I CLINICAL TRIALS......................................................9
         Section 1.49.  PHASE III CLINICAL TRIALS....................................................9
         Section 1.50.  PRELIMINARY COMPOUND.........................................................9
         Section 1.51.  PRELIMINARY COMPOUND EXCLUSIVITY PERIOD......................................9
         Section 1.52.  PRIMARY ACTIVE COMPOUND......................................................9
         Section 1.53.  PRIMARY ACTIVE COMPOUND EXCLUSIVITY PERIOD...................................9
         Section 1.54.  PROGRAM TECHNOLOGY...........................................................9
         Section 1.55.  PROPRIETARY TARGET...........................................................10
         Section 1.56.  PUBLIC TARGET................................................................10
         Section 1.57.  QSCD.........................................................................10
         Section 1.58.  QSCD PRELIMINARY COMPOUNDS...................................................10
         Section 1.59.  QSCD PRIMARY ACTIVE COMPOUNDS................................................10
         Section 1.60.  QUARTER......................................................................10
         Section 1.61.  R&D PROGRAM..................................................................10
         Section 1.62.  RECEIVING PARTY..............................................................10
         Section 1.63.  REGULATORY APPROVALS.........................................................10
         Section 1.64.  REGULATORY AUTHORITY.........................................................11
         Section 1.65.  RESEARCH COLLABORATION.......................................................11
         Section 1.66.  RESEARCH COLLABORATION PLAN..................................................11
         Section 1.67.  RESEARCH TERM................................................................11
         Section 1.68.  STEERING COMMITTEE...........................................................11
         Section 1.69.  STOCK PURCHASE AGREEMENT.....................................................11
         Section 1.70.  TARGET.......................................................................11
         Section 1.71.  TARGET GUIDELINES............................................................11
         Section 1.72.  TERM.........................................................................11
         Section 1.73.  TERRITORY....................................................................11
         Section 1.74.  THIRD PARTY (THIRD PARTIES)..................................................12
         Section 1.75.  THIRD PARTY CLAIM............................................................12

ARTICLE II.   GRANT, RIGHTS AND RESTRICTIONS.........................................................12
         Section 2.1.  GRANT OF RESEARCH LICENSE.....................................................12
         Section 2.2.  NEOGENESIS GRANT OF LICENSE...................................................12
         Section 2.3.  RETAINED RIGHTS...............................................................13
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -ii-

<Page>

<Table>
<S>                                                                                                <C>
ARTICLE III.   RESEARCH COLLABORATION PLAN...........................................................13
         Section 3.1.  DILIGENCE.....................................................................13
         Section 3.2.  RESEARCH COLLABORATION........................................................13
         Section 3.3.  NUMBER OF TARGETS.............................................................13

ARTICLE IV.   STEERING COMMITTEE.....................................................................14
         Section 4.1.  STEERING COMMITTEE............................................................14
                  (a)  STEERING COMMITTEE ACTIVITIES.................................................14
                  (b)  STEERING COMMITTEE MEETINGS...................................................14
                  (c)  STEERING COMMITTEE GOVERNANCE.................................................15

ARTICLE V.   RESEARCH FUNDING........................................................................15
         Section 5.1.  RESEARCH COLLABORATION FUNDING................................................15
                  (a)  STOCK PURCHASE................................................................15
                  (b)  FTE FUNDING...................................................................15
                  (c)  QUARTERLY PAYMENTS............................................................16

ARTICLE VI.   MILESTONES AND ROYALTY PAYMENTS........................................................16
         Section 6.1.  MILESTONES....................................................................16
                  (a)  PHASE I.......................................................................16
                  (b)  PHASE III.....................................................................16
                  (c)  APPROVAL LETTER...............................................................16
                  (d)  MILESTONE FREQUENCY...........................................................17
         Section 6.2.  ROYALTIES.....................................................................17
                  (a)  NON-QSCD DISCOVERED COMPOUNDS.................................................17
                  (b)  QSCD DISCOVERED COMPOUNDS.....................................................17
                  (c)  ROYALTY PAYMENTS AND TERM.....................................................17
                  (d)  ROYALTY ADJUSTMENTS...........................................................18
         Section 6.3.  REMITTANCE....................................................................18
                  (a)  FUNDS/EXCHANGE RATE...........................................................18
                  (b)  INTEREST......................................................................18
         Section 6.4.  RECORDS.......................................................................18
         Section 6.5.  INSPECTION....................................................................19
                  (a)  AUDIT.........................................................................19
                  (b)  DISPUTES......................................................................19
         Section 6.6.  TAXES.........................................................................19

ARTICLE VII.   REGULATORY AND MARKETING OBLIGATIONS..................................................20
         Section 7.1.  PRODUCT DEVELOPMENT...........................................................20
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     -iii-

<Page>

<Table>
<S>                                                                                                <C>
         Section 7.2.  MANUFACTURE OF PRODUCT........................................................20
         Section 7.3.  REGULATORY MATTERS............................................................20
         Section 7.4.  MARKETING AND SALE............................................................20
                  (a)  RESPONSIBILITY................................................................20
                  (b)  MARKING.......................................................................20
                  (c)  THIRD PARTY LICENSES..........................................................21
         Section 7.5.  PERIODIC REVIEW...............................................................21

ARTICLE VIII.   RIGHTS IN TECHNOLOGY, PATENTS AND KNOW-HOW...........................................21
         Section 8.1.  OWNERSHIP OF PROGRAM TECHNOLOGY...............................................21
                  (a)  CELLTECH OWNED PROGRAM TECHNOLOGY.............................................21
                  (b)  NEOGENESIS OWNED PROGRAM TECHNOLOGY...........................................22
                  (c)  JOINTLY OWNED PROGRAM TECHNOLOGY..............................................22
         Section 8.2.  DISCLOSURE BY EMPLOYEES, AGENTS OR INDEPENDENT CONTRACTORS....................22
         Section 8.3.  PATENT PROSECUTION AND RELATED ACTIVITIES.....................................23
                  (a)  NEOGENESIS OWNED PROGRAM TECHNOLOGY...........................................23
                  (b)  CELLTECH OWNED PROGRAM TECHNOLOGY.............................................23
                  (c)  JOINTLY OWNED PROGRAM TECHNOLOGY..............................................24
                  (d)  COOPERATION...................................................................24
         Section 8.4.  THIRD PARTY INFRINGEMENT......................................................24
                  (a)  ENFORCEMENT...................................................................24
                  (b)  FAILURE TO ENFORCE............................................................25
                  (c)  DIVISION OF RECOVERIES........................................................25
                  (d)  COOPERATION...................................................................26
         Section 8.5.  INFRINGEMENT CLAIMS BY THIRD PARTIES..........................................26
                  (a)  THIRD PARTY CLAIMS............................................................26
                  (b)  RESPONSE TO THIRD PARTY CLAIMS................................................26

ARTICLE IX.  CONFIDENTIALITY.........................................................................27
         Section 9.1.  CONFIDENTIALITY...............................................................27
         Section 9.2.  OBLIGATIONS OF CONFIDENTIALITY................................................27
         Section 9.3.  LEGAL DISCLOSURE..............................................................27
         Section 9.4.  OWNERSHIP OF INFORMATION......................................................28
         Section 9.5.  EXPIRATION OR TERMINATION.....................................................28
         Section 9.6.  PUBLICITY.....................................................................29
         Section 9.7.  PUBLICATION...................................................................29

ARTICLE X.   REPRESENTATIONS AND WARRANTIES..........................................................30
         Section 10.1.  NEOGENESIS REPRESENTATIONS AND WARRANTIES....................................30
                  (a)  ORGANIZATION..................................................................30
                  (b)  AUTHORITY.....................................................................30
                  (c)  GOVERNMENTAL CONSENTS.........................................................30
                  (d)  NO CONFLICT WITH OTHER AGREEMENTS.............................................30
                  (e)  PATENT INFRINGEMENT...........................................................31
                  (f)  DEBARRED......................................................................31
                  (g)  DISCLAIMER....................................................................31
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -iv-

<Page>

<Table>
<S>                                                                                                <C>
         Section 10.2.  CELLTECH REPRESENTATIONS AND WARRANTIES......................................31
                  (a)  ORGANIZATION..................................................................31
                  (b)  AUTHORITY.....................................................................32
                  (c)  GOVERNMENTAL CONSENTS.........................................................32
                  (d)  NO CONFLICT WITH OTHER AGREEMENTS.............................................32
                  (e)  DISCLAIMER....................................................................32

ARTICLE XI.  INDEMNIFICATION.........................................................................33
         Section 11.0.  LIMITATION OF LIABILITY......................................................33
         Section 11.1.  INFRINGEMENT INDEMNIFICATION.................................................33
                  (a)  NEOGENESIS....................................................................33
                  (b)  CELLTECH......................................................................34
         Section 11.2.  OTHER CLAIMS.................................................................34
                  (a)  NEOGENESIS....................................................................34
                  (b)  CELLTECH......................................................................34
         Section 11.3.  PROCEDURE....................................................................35

ARTICLE XII.   TERM AND TERMINATION..................................................................35
         Section 12.1.  TERM.........................................................................35
         Section 12.2.  TERMINATION..................................................................36
                  (a)  MATERIAL BREACH...............................................................36
                  (b)  BANKRUPTCY OR RECEIVERSHIP OF A PARTY.........................................36
                  (c)  TERMINATION BY CELLTECH.......................................................36
         Section 12.3.  EFFECT OF TERMINATION........................................................36
                  (a)  TERMINATION ACTIVITIES........................................................36
                  (b)  RETURN OF CONFIDENTIAL INFORMATION............................................37
                  (c)  RIGHTS UPON TERMINATION.......................................................37
                  (d)  NO RELEASE OF MATURED OBLIGATION..............................................37
         Section 12.4  SURVIVAL......................................................................37

ARTICLE XIII.   GENERAL PROVISIONS...................................................................38
         Section 13.1.  ISSUE RESOLUTION.............................................................38
                  (a)  NOTIFICATION OF DISPUTE.......................................................38
                  (b)  LIMITATIONS...................................................................38
                  (c)  ARBITRATION RULES.............................................................38
                  (d)  APPLICABLE LAW................................................................39
                  (e)  RESTRICTIONS ON DAMAGES.......................................................39
         Section 13.2.  GOVERNING LAW................................................................39
         Section 13.3.  AMENDMENT AND WAIVER.........................................................40
         Section 13.4.  INDEPENDENT CONTRACTORS......................................................40
         Section 13.5.  ASSIGNMENT...................................................................40
         Section 13.6.  SUCCESSORS AND ASSIGNS.......................................................41
         Section 13.7.  NOTICES......................................................................41
         Section 13.8.  SEVERABILITY.................................................................41
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -v-

<Page>

<Table>
<S>                                                                                                <C>
         Section 13.9.  CAPTIONS.....................................................................41
         Section 13.10.  WORD MEANINGS...............................................................41
         Section 13.11.  ENTIRE AGREEMENT............................................................41
         Section 13.12.  RULES OF CONSTRUCTION.......................................................42
         Section 13.13.  COUNTERPARTS................................................................42
         Section 13.14.  FORCE MAJEURE...............................................................42
         Section 13.15.  FURTHER ASSURANCES..........................................................42

EXHIBIT A...........................................................................................A-1

EXHIBIT B...........................................................................................B-1
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -vi-

<PAGE>

                  RESEARCH, LICENSE AND COLLABORATION AGREEMENT

       This Research, License and Collaboration Agreement (the "Agreement") is
entered into as of July 11, 2001 ("Effective Date") by and between Celltech R &
D Limited whose registered office is situate at 208 Bath Road, Slough, Berkshire
SL1 3WE, England ("Celltech") and NeoGenesis Drug Discovery, Inc., having an
address of 840 Memorial Drive, Cambridge, MA 02139, USA ("NeoGenesis"). Each of
Celltech and NeoGenesis may individually be referred to as a "Party" and
collectively as "Parties".

       WHEREAS, Celltech is a biopharmaceutical company with an ongoing interest
in research, development and commercialization of pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high affinity and functional activity to protein targets for the
development, manufacture and commercialization of pharmaceutical products;

       WHEREAS, NeoGenesis is a chemical genomics based drug discovery company
and has certain technology and know-how, including screening processes of
libraries of mass-encoded small molecule compounds built around an expanding set
of diverse cores, relating to the identification, discovery, validation and
optimization of chemical compounds that exhibit a high affinity to protein
targets useful for development of pharmaceutical products;

       WHEREAS, Celltech has certain technology and know-how relating to the
identification of protein targets implicated in disease;

       WHEREAS, Celltech and NeoGenesis desire to jointly collaborate in
research to identify compounds from NeoGenesis' libraries that exhibit high
affinity and functional activity to specific protein targets provided by
Celltech;

       NOW THEREFORE, in consideration of the mutual covenants and promises
contained in this Agreement, Celltech and NeoGenesis agree as follows:

                                   ARTICLE I.
                                   DEFINITIONS

       Capitalized terms used in this Agreement and not otherwise defined herein
shall have the meaning set forth below.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -1-

<Page>

       SECTION 1.1. AAA shall have the meaning set forth in Section 13.1 (c)
hereof.

       SECTION 1.2. AFFILIATE shall mean with respect to either Party, any
Person that, directly or indirectly, is controlled by, controls or is under
common control with such Party. For purposes of this definition, control means,
with respect to any Person, the direct or indirect ownership of more than [*] of
the voting or income interest in such Person or the possession otherwise,
directly or indirectly, of the power to direct the management or policies of
such Person.

       SECTION 1.3. AGREEMENT shall mean this Research, License and
Collaboration Agreement and any Exhibits or Schedules appended hereto, as the
same may be amended from time to time by the Parties in accordance with Section
3.2 or Section 13.3, as applicable.

       SECTION 1.4. ALIS shall mean the Automated Ligand Identification System,
an automated, ultra-high throughput ligand selection system proprietary to
NeoGenesis that is used to identify multiple classes of chemical compounds
against target proteins.

       SECTION 1.5. APPLICABLE LAWS shall mean all laws, statutes, regulations
and ordinances of any Regulatory Authority, including without limitation the
FD&C Act.

       SECTION 1.6. APPROVAL LETTER shall have the meaning set forth in Section
6.1(c) hereof.

       SECTION 1.7. APPROVED TARGET(S) shall mean any Target that NeoGenesis has
approved for entry into the Research Collaboration based on the Target
Guidelines.

       SECTION 1.8. APPROVED TARGET EXCLUSIVITY PERIOD shall mean the period of
time during which NeoGenesis will not approve or screen an Approved Target for a
Third Party. For a Public Target and homologs thereof that are [*] homologus at
the peptide level such exclusivity period shall begin upon NeoGenesis' approval
of such Target as set forth in Exhibit A, paragraph 1(a) or paragraph 1(b) of
the Research Collaboration Plan and end [*] thereafter. For a Proprietary
Target, such exclusivity period shall begin upon NeoGenesis' approval of such
Approved Target as set forth in Exhibit A, paragraph 1(a) or paragraph 1(b) of
the Research Collaboration Plan and end as follows: (i) where a patent(s) has
issued to Celltech or an Affiliate, in any Major Country in the Territory
claiming such target, the exclusivity period shall end when the last of the
patent(s) expires, lapses, or is held invalid or

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -2-

<Page>

unenforceable by a final decision, which is unappealed or unappealable, of a
court of competent jurisdiction or of an administrative agency having authority
over patents; and (ii) where a patent application has been filed and such patent
application has not been the subject of a rejection notice from which an appeal
cannot be taken or in respect of which the applicable period of appeal has not
expired, the exclusivity period shall end on the later of: (A) the date that is
[*] after the priority date of such patent application (measured from the
original filing date) or (B) the date that is [*] after NeoGenesis' receipt of
such Approved Target from Celltech. Where a patent issues from a patent
application as described in (ii) above, such patent shall be covered under (i)
as set forth above.

       SECTION 1.9. CELLTECH INDEMNIFIED PARTY shall have the meaning set forth
in Section 11.1 (a) hereof.

       SECTION 1.10. CELLTECH TECHNOLOGY shall mean any and all Patents and
Know-How that are owned or Controlled by Celltech necessary for the performance
of this Agreement, as determined by Celltech. The term Celltech Technology,
however, does not include the NeoGenesis Technology or any Know-How, after such
time as it becomes generally available to the public.

       SECTION 1.11. CELLTECH DERIVATIVES shall mean those derivatives of
Designated Compounds that are developed through optimizations performed by
Celltech and that have a Kd [*] and are functionally active against the relevant
Approved Target, functional activity being deemed if IC50 is [*]. Derivatives
shall include, but not be limited to analogs, isomers, chemical homologs and
salts thereof.

       SECTION 1.12. CIP shall mean "Carriage and Insurance Paid", as that
expression is defined in INCOTERMS 2000, ICC Publishing S.A.

       SECTION 1.13. COMMERCIALIZATION shall mean any and all activities of
using, importing, exporting, marketing, promoting, distributing, offering for
sale and selling a Licensed Product. When used as a verb, "COMMERCIALIZE" means
to engage in Commercialization.

       SECTION 1.14. COMMERCIALLY REASONABLE EFFORTS shall mean, with respect to
(i) any objective by any Party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (ii) with respect to any
objective relating to the development or Commercialization of any Licensed
Product by any Party efforts and resources normally used by such Party with
respect to a product owned by such Party or to which such

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -3-

<Page>

Party has similar rights which is of similar market potential at a similar stage
in the development or life of such product, taking into account issues of
safety, efficacy, product profile, the competitiveness of the marketplace, the
proprietary position of the product, the regulatory structure involved,
profitability of the product and other relevant commercial factors.

       SECTION 1.15. CONFIDENTIAL INFORMATION shall have the meaning set forth
in Section 9. l.

       SECTION 1.16. CONTROL OR CONTROLLED shall mean with respect to any (a)
item of information or (b) intellectual property right, including, without
limitation, Celltech Technology and NeoGenesis Technology, the possession
(whether by ownership or license, other than pursuant to this Agreement) by a
Party or an Affiliate thereof of the ability to grant to the other Party access
or a license under such item or right without violating the terms of any
agreement or other arrangements, between such Party or its Affiliate and any
Third Party, existing before or after the Effective Date.

       SECTION 1.17. DESIGNATED COMPOUND shall mean any (a) Preliminary
Compound(s), Primary Active Compound, QSCD Preliminary Compound(s), QSCD Primary
Active Compound(s) designated by Celltech pursuant to paragraph 4(a) of the
Research Collaboration Plan and (b) NeoGenesis Derivatives of such compounds
designated from Primary Active Compounds and QSCD Primary Active Compounds but
not designated from Preliminary Compounds or QSCD Preliminary Compounds
provided, that such NeoGenesis Derivatives have a Kd [*] and are functionally
active against the relevant Approved Target, functional activity being deemed if
IC50 is [*].

       SECTION 1.18. DISCLOSING PARTY shall have the meaning set forth in
Section 9.1.

       SECTION 1.19. EFFECTIVE DATE shall mean the date first written above.

       SECTION 1.20. FDA shall mean the United States Food and Drug
Administration or any successor entity thereto.

       SECTION 1.21. FD&C ACT shall mean the United States Federal Food, Drug
and Cosmetic Act of 1938, as amended.

       SECTION 1.22. FIRST COMMERCIAL SALE shall mean the first transfer for
value in an arms-length transaction to an independent Third Party

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -4-

<Page>

distributor, agent or end user after obtaining all necessary Regulatory
Approvals as may be necessary for such transfer of Licensed Product(s).

       SECTION 1.23. FOB means "Free On Board", as that expression is defined in
INCOTERMS 2000, ICC Publishing S.A.

       SECTION 1.24. FORCE MAJEURE shall mean any event beyond the control of
the Parties, including, without limitation, failures of computers,
computer-related equipment, hardware or software, fire, flood, riots, strikes,
epidemics, war (declared or undeclared and including the continuance, expansion
or new outbreak of any war or conflict now in existence), embargoes and
governmental actions or decrees.

       SECTION 1.25. FTE shall mean the per annum rate of a full time,
(including reasonable and customary vacations, sick days and holidays), work of
a NeoGenesis employee who is adequately trained to perform screening and
optimization and who performs screening and optimization activities pursuant to
this Agreement.

       SECTION 1.26. GOOD CLINICAL PRACTICE shall mean the then current
standards for clinical trials for pharmaceuticals, as set forth in the FD&C Act
and applicable regulations promulgated thereunder, as amended from time to time,
and such standards of good clinical practice as are required by the European
Union and other Regulatory Authorities in countries in which the Licensed
Product is intended to be sold, to the extent such standards are not in
contravention with United States Good Clinical Practices.

       SECTION 1.27. GOOD LABORATORY PRACTICE shall mean the then current
standards for laboratory activities for pharmaceuticals, as set forth in the
FD&C Act and applicable regulations promulgated thereunder, as amended from time
to time, and such standards of good laboratory practice as are required by the
European Union and other Regulatory Authorities in countries in which the
Product is intended to be sold, to the extent such standards are not in
contravention with United States Good Laboratory Practices.

       SECTION 1.28. GOOD MANUFACTURING PRACTICE shall mean the current
standards for the manufacture of pharmaceuticals, as set forth in the FD&C Act
and applicable regulations promulgated thereunder, as amended from time to time,
and such standards of good manufacturing practice as are required by the
European Union and other Regulatory Authorities in countries in which the
Product is intended to be sold, to the extent such standards are not in
contravention with United States Good Manufacturing Practices.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -5-

<Page>

       SECTION 1.29. INDEMNIFIED PARTY(IES) shall mean a Celltech Indemnified
Party or NeoGenesis Indemnified Party, as the case may be.

       SECTION 1.30. INDEMNIFYING PARTY shall have the meaning set forth in
Section 11.3.

       SECTION 1.31. KNOW-HOW shall mean, to the extent not publicly known, any
information and materials relating to, or discoveries made (whether in
electronic, magnetic, graphic or written form), including, without limitation,
regulatory approvals, processes, techniques, formulas, data, database
information, methods, equipment designs, know-how, show-how and trade secrets,
discoveries, practices, knowledge, ideas, skill, experience, inventions,
technology, manufacturing procedures, test procedures, purification and
isolation techniques, instructions, technical and scientific data, pre-clinical
and clinical data, test data and other intellectual property, whether or not
patentable, tangible or intangible. Know-How does not include Patents.

       SECTION 1.32. LICENSED PRODUCT(S) shall mean any product (a) whose
pharmaceutical composition contains any formulation or dosage of a Designated
Compound or any Celltech Derivatives or improvements thereof as a
pharmaceutically active ingredient and (b) the development, manufacture, use, or
sale of which, absent the rights assigned and licenses granted to Celltech under
this Agreement, would infringe the NeoGenesis Technology or which makes use of
any Patents comprised in Program Technology with respect to which NeoGenesis is
an inventor.

       SECTION 1.33. LOCK UP PERIOD shall mean the period of time ending [*]
from the Effective Date.

       SECTION 1.34. MAJOR COUNTRY shall mean any or all of the United States,
the United Kingdom, France, Germany, and Japan, as the case may be.

       SECTION 1.35. MANUFACTURING shall mean any and all activities involved in
the production of a Licensed Product to be developed and/or Commercialized under
this Agreement. When used as a verb, Manufacture means to engage in
Manufacturing.

       SECTION 1.36. MASK shall mean the process whereby NeoGenesis shall take
all necessary steps to prevent a Preliminary Compound or Primary Active Compound
from being identified or revealed as a ligand against any Third Party targets
during the Preliminary Compound Exclusivity Period or Primary Active Compound
Exclusivity Period, as the case may be.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -6-

<Page>

       SECTION 1.37. NDA shall mean a new drug application as defined in the
FD&C Act and applicable regulations thereunder.

       SECTION 1.38. NEOGENESIS INDEMNIFIED PARTY(IES) shall have the meaning
set forth in Section 11.1 (b)

       SECTION 1.39. NEOGENESIS TARGET shall mean a target that is the subject
of an ongoing research project for NeoGenesis at the time NeoGenesis is
requested by Celltech to determine whether it can accept a Target for entry into
the Research Collaboration by reference to the Target Guidelines.

       SECTION 1.40. NEOGENESIS TECHNOLOGY shall mean any and all Patents and
Know-How that are owned or Controlled by NeoGenesis necessary for the
performance of this Agreement. The term NeoGenesis Technology, HOWEVER, does not
include any Celltech Technology or any Know-How, after such time as such
Know-How becomes generally available to the public.

       SECTION 1.41. NEOGENESIS DERIVATIVES shall mean those derivatives of
Designated Compounds that are developed through optimizations performed by
NeoGenesis and that have a Kd [*] and are functionally active against the
relevant Approved Target, functional activity being deemed if IC50 is [*].
Derivatives shall include, but not be limited to analogs, isomers, chemical
homologs and salts thereof.

       SECTION 1.42. NEOMORPH CHEMISTRY shall mean the process, proprietary to
NeoGenesis, of forming libraries and sub-libraries of discrete compounds by
coupling a broad set of diverse cores with diverse sets of building blocks
employing proprietary mass-coding algorithms.

       SECTION 1.43. NEOMORPH FOCUSED LIBRARIES shall mean those compounds
synthesized by NeoGenesis during the optimization of either the Preliminary
Compounds identified from the NeoMorph Screening Library or further optimization
of compounds identified in any rounds of optimization.

       SECTION 1.44. NEOMORPH SCREENING LIBRARY shall mean the constantly
expanding collection of libraries consisting of mass-encoded small molecule
organic compounds owned by NeoGenesis and developed with NeoMorph Chemistry,
currently comprising about 10,000,000 unique compounds.

       SECTION 1.45. NET SALES means the aggregate amounts invoiced for the
first sale or transfer for value of Licensed Products by Celltech, its
Affiliates or any of its sublicensees to an independent non-sublicensee Third

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -7-

<Page>

Party distributor, agent or end user in the Territory (other than sales of
Licensed Products at cost by Celltech, its Affiliates or sublicensees to a
non-sublicensee Third Party for use in a clinical study prior to Regulatory
Approval of such Licensed Product in a Major Country) less the following
deductions: (a) credits, refunds, allowances and price adjustments separately
and actually credited to such customers for defective, spoiled, damaged,
outdated, and returned Licensed Products, (b) offered and taken trade and cash
discounts and rebates in amounts customary to the trade and as required to do
business in the country in which they are made, (c) sales, excise, value added,
turnover, use, and other like taxes, and customs duties, paid, absorbed or
allowed excluding net income tax, and (d) special outbound packing,
transportation, insurance and handling charges separately billed to Celltech,
its Affiliates or sublicensees or prepaid. Net Sales shall not include revenue
received by Celltech, its Affiliates or sublicensees from transactions with an
Affiliate or sublicensee, where the Licensed Product in question will be resold
to an independent non-sublicensee Third Party distributor, agent or end user by
the Affiliate or sublicensee PROVIDED such revenue received by the Affiliate or
sublicensee from such resale is included in Net Sales. Net Sales received by
Celltech (or any of its Affiliates) from transactions with an Affiliate, where
the Licensed Product in question is used by the Affiliate solely for such
Affiliate's internal purposes shall not be included in Net Sales. In the event
that a Licensed Product is sold as part of a kit or combination product, Net
Sales from the kit or combination product for the purposes of determining
royalty payments, shall be determined by multiplying the Net Sales (as defined
above) of the combination product by the fraction, A/(A+B) where A is the
average sale price of the Licensed Product when sold separately in finished form
and B is the average sale price of the other product(s) sold separately in
finished form, so that A+B is the average sale price of the product(s) together.
In the event that such average sale price cannot be determined for both the
Licensed Product and such other product(s) in combination, Net Sales shall be
determined by good faith negotiation between the parties, and that failing, by
arbitration in accordance with Section 13.

       SECTION 1.46. PATENTS shall mean (i) any foreign or domestic patent
applications and patents, and all patents and patent applications based on, or
claiming or corresponding to the priority date(s), of any of the foregoing; (ii)
any reissues, extensions (or other governmental actions that provide exclusive
rights to the patent holder in the patented subject matter beyond the original
patent expiration date), substitutions, confirmations, registrations,
revalidations, re-examinations, additions, continuations, continued
prosecutions, continuations-in-part, or divisions of or to any of the foregoing;
and (iii) any supplementary protection certificates.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -8-

<Page>

       SECTION 1.47. PERSON shall mean any individual, corporation, association,
partnership (general or limited), joint venture, trust, estate, limited
liability company, limited liability partnership, unincorporated organization,
government (or any agency or political subdivision thereof) or other legal
entity or organization.

       SECTION 1.48. PHASE I CLINICAL TRIALS shall have the meaning set forth in
Section 6.1(a).

       SECTION 1.49. PHASE III CLINICAL TRIALS shall have the meaning set forth
in Section 6.1(b).

       SECTION 1.50. PRELIMINARY COMPOUND shall mean any NeoGenesis compound
identified from the NeoMorph Screening Library which binds an Approved Target
with a minimum affinity set by the Steering Committee on an Approved Target by
Approved Target basis.

       SECTION 1.51. PRELIMINARY COMPOUND EXCLUSIVITY PERIOD shall mean the
period of time from the identification of a Preliminary Compound until Celltech
abandons the Preliminary Compound. Abandonment shall occur on a specific
Preliminary Compound upon the first to occur of the following: [*].

       SECTION 1.52. PRIMARY ACTIVE COMPOUND shall mean any Preliminary Compound
which demonstrates an activity in a cell-based functional assay as set forth in
paragraph 3(b) of the research Collaboration Plan.

       SECTION 1.53. PRIMARY ACTIVE COMPOUND EXCLUSIVITY PERIOD shall mean the
period of time from the identification of a Primary Active Compound until
Celltech abandons the Primary Active Compound. [*].

       SECTION 1.54. PROGRAM TECHNOLOGY shall mean individually and collectively
all Patents, Know-How, discoveries, inventions, techniques, methodologies,
modifications, improvements, works of authorship, designs and data (whether or
not protectable under patent, copyright, trade secrecy or similar laws) that are
conceived, created, discovered, developed, or reduced to practice or tangible
medium of expression during the Research Term in the course of the Research
Collaboration Plan, including without limitation, all Preliminary Compound(s),
NeoMorph Focused Libraries, Primary Active Compound(s), QSCD Preliminary
Compound(s), QSCD Primary Active Compound(s) and Designated Compound(s), (a)
solely by one or more employees or consultants of NeoGenesis; (b) jointly by one
or more employees

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -9-

<Page>

or consultants of NeoGenesis and one or more employees or consultants of
Celltech, or (c) solely by one or more employees or consultants of Celltech.

       SECTION 1.55. PROPRIETARY TARGET shall mean a Target for which (a) a
patent has issued to and is Controlled by Celltech or an Affiliate, in any Major
Country in the Territory claiming such target and such patent has not expired,
lapsed, or been held invalid or unenforceable by a final decision, which is
unappealed or unappealable, of a court of competent jurisdiction or of an
administrative agency having authority over patents; or (b) a patent application
has been filed and is Controlled by Celltech or an affiliate and such patent
application has not been the subject of a rejection notice from which an appeal
cannot be taken or in respect of which the applicable period for appeal has not
expired.

       SECTION 1.56. PUBLIC TARGET shall mean any target that is not a
Proprietary Target.

       SECTION 1.57. QSCD shall mean Quantisized Surface Complementary
Diversity, a technology proprietary to NeoGenesis, in terms of which discrete
chemical complements to the surfaces of Approved Targets may be defined.

       SECTION 1.58. QSCD PRELIMINARY COMPOUNDS shall have the meaning set forth
in Exhibit A, paragraph 3(e).

       SECTION 1.59. QSCD PRIMARY ACTIVE COMPOUNDS shall have the meaning set
forth in Exhibit A, paragraph 3(e).

       SECTION 1.60. QUARTER shall mean a three (3) month period ending March
31, June 30, September 30 and December 31.

       SECTION 1.61. R&D PROGRAM means on a Designated Compound-by-Designated
Compound and country-by-country basis the activities necessary or desirable to
be undertaken in connection with the research and development of such Designated
Compound prior to obtaining Regulatory Approval for a Licensed Product in such
country (regardless of the country in which such activities are conducted).

       SECTION 1.62. RECEIVING PARTY shall have the meaning set forth in Section
9.1.

       SECTION 1.63. REGULATORY APPROVALS shall mean, for any country in the
Territory, those authorizations by the appropriate Regulatory Authority(ies)
required for the manufacture, importation, marketing, promotion, pricing and
sale of the Licensed Product(s) in such country.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -10-

<Page>

         SECTION 1.64. REGULATORY AUTHORITY shall mean any national,
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity in the Territory, including,
without limitation, the FDA.

       SECTION 1.65. RESEARCH COLLABORATION means the joint effort between
Celltech and NeoGenesis to identify compounds from NeoGenesis' libraries that
exhibit high affinity and functional activity to specific Targets.

       SECTION 1.66. RESEARCH COLLABORATION PLAN shall mean the screening
program for each Approved Target described on Exhibit A as the same may be
amended during the Research Term by the Steering Committee (as defined below).
The goals of the Plan will be directed toward the discovery and development of
Preliminary Compounds, QSCD Preliminary Compounds, Primary Active Compounds,
QSCD Primary Active Compounds and Designated Compounds for the Approved Targets.

       SECTION 1.67. RESEARCH TERM shall have the meaning set forth in Section
3.2 hereof.

       SECTION 1.68. STEERING COMMITTEE shall have the meaning set forth in
Section 4.1.

       SECTION 1.69. STOCK PURCHASE AGREEMENT shall mean the Subscription
Agreement between Celltech and NeoGenesis signed contemporaneously with this
Agreement pursuant to which Celltech is purchasing NeoGenesis Series E Preferred
Stock.

       SECTION 1.70. TARGET shall mean a specific polypeptide sequence or
protein selected by Celltech to enter the Research Collaboration.

       SECTION 1.71. TARGET GUIDELINES shall mean the following parameters
pursuant to which NeoGenesis shall be able to reject a Target from entering the
Research Collaboration: the Target is [*] at the peptide level with (1) a target
that is subject to an exclusivity period in an ongoing agreement between
NeoGenesis and a Third Party at the time Celltech requests inclusion of the
Target in the Research Collaboration or (2) the Target is a NeoGenesis Target.

       SECTION 1.72. TERM shall have the meaning set forth in Section 12.1
hereof.

       SECTION 1.73. TERRITORY shall mean all the countries of the world.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -11-

<Page>

       SECTION 1.74. THIRD PARTY (THIRD PARTIES) shall mean any person other
than NeoGenesis and its Affiliates and Celltech and its Affiliates.

       SECTION 1.75. THIRD PARTY CLAIM shall have the meaning set forth in
Section 8.5.

                                   ARTICLE II.
                         GRANT, RIGHTS AND RESTRICTIONS

       SECTION 2.1. GRANT OF RESEARCH LICENSE. Subject to the terms and
conditions of this Agreement, Celltech hereby grants to NeoGenesis and
NeoGenesis hereby accepts, a nonexclusive, nonsublicenseable; nontransferable,
non-assignable, royalty-free license to Celltech Technology solely for purposes
of performing NeoGenesis' obligations to Celltech under the Research
Collaboration Plan during the Research Term. NeoGenesis shall not use Celltech
Technology for any other purpose. NeoGenesis shall not (i) grant, or attempt to
grant, a sub-license to Celltech Technology to any Person, (ii) perform any
tests on any Approved Target(s) other than as part of the Research Collaboration
Plan, or (iii) modify the Approved Targets supplied by Celltech, including,
without limitation, the making of any derivatives, analogs or components
thereof. In the event that NeoGenesis does not consume all of the Approved
Target(s) supplied by Celltech in performance of the Research Collaboration
Plan, NeoGenesis shall, upon Celltech's request, promptly return to Celltech any
remaining quantities of such Approved Target(s).

       SECTION 2.2. NEOGENESIS GRANT OF LICENSE. Subject to the terms and
conditions of this Agreement, including the payment of all applicable fees,
NeoGenesis hereby grants to Celltech, and its Affiliates:

       (a) an exclusive, worldwide, right and license, within the Territory to
NeoGenesis Technology and NeoGenesis' interest in any Program Technology, as
embodied in or related to any Preliminary Compound(s), Primary Active
Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and
Designated Compounds solely for the purpose of conducting Celltech's activities
under the Research Collaboration, to research, develop, make, have made, use and
import Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary
Compound(s), QSCD Primary Active Compound(s) and Designated Compounds to develop
Licensed Product(s); and

       (b) an exclusive, worldwide, right and license, within the Territory, to
the NeoGenesis Technology and NeoGenesis' interest in any Program Technology, as
embodied in or related to any Designated Compounds,

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -12-

<Page>

necessary to make, have made, develop, have developed, use, distribute for sale,
promote, market, offer for sale, sell, have sold, import and export Licensed
Product(s).

       (c) Celltech and its Affiliates may grant sublicenses of its rights under
this Section 2.2; PROVIDED that Celltech obtains each sublicensee's written
agreement to be subject to similar obligations as is Celltech and its Affiliates
under Sections 2.3, 6.4-6.6, 7.4(b) and all of Article IX of this Agreement (or
substantially identical provisions).

       SECTION 2.3. RETAINED RIGHTS. This Agreement does not convey to
NeoGenesis any ownership rights in any Celltech Technology by implication,
estoppel or otherwise except for the rights expressly granted in Section 2.1 and
Section 8.1. This Agreement does not convey to Celltech any ownership rights in
any NeoGenesis Technology by implication, estoppel or otherwise except for the
rights expressly granted in Section 2.2 and Section 8.1.

                                  ARTICLE III.
                           RESEARCH COLLABORATION PLAN

       SECTION 3.1. DILIGENCE. The Parties hereto agree to use Commercially
Reasonable Efforts to conduct the Research Collaboration under this Agreement
during the Research Term.

       SECTION 3.2. RESEARCH COLLABORATION. The Research Collaboration shall be
carried out in accordance with the Research Collaboration Plan, as detailed in
Exhibit A, as may be amended from time to time by the Steering Committee during
the Research Term. The Research Term shall begin on the Effective Date and end
December 31, 2005, unless earlier terminated pursuant to Article XII ("Research
Term"). The Research Term may be amended by the Parties consistent with the
terms of the Agreement.

       SECTION 3.3. NUMBER OF TARGETS. NeoGenesis shall fulfill its obligations
under the Research Collaboration Plan for a minimum of [*] Approved Targets
during the Research Term. The following schedule may be utilized by the Steering
Committee as a general guideline for the number of Approved Targets to be
completed per year under the Research Collaboration Plan. Any Approved Targets
not completed in a given year shall carryover to any of the following years
until [*] Approved Targets have completed pursuant to the Research Collaboration
Plan.

                                 TARGET SCHEDULE
<Table>
<Caption>
-----------------------------------------------------------------------------------------------------------
  YEAR                                                APPROVED TARGETS
-----------------------------------------------------------------------------------------------------------
<S>                                                   <C>
  2001                                                [*]
-----------------------------------------------------------------------------------------------------------
</Table>

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -13-

<Page>

<Table>
<S>                                                   <C>
-----------------------------------------------------------------------------------------------------------
  2002                                                [*]
-----------------------------------------------------------------------------------------------------------
  2003                                                [*]
-----------------------------------------------------------------------------------------------------------
  2004                                                [*]
-----------------------------------------------------------------------------------------------------------
  2005                                                [*]
-----------------------------------------------------------------------------------------------------------
  TOTAL                                               [*]
-----------------------------------------------------------------------------------------------------------
</Table>

                                   ARTICLE IV.
                               STEERING COMMITTEE

       SECTION 4.1. STEERING COMMITTEE. The Steering Committee shall consist of
six members, three members to be appointed by each of NeoGenesis and Celltech
("Steering Committee"). Each Party may, with written notice to the other,
substitute any of its members serving on the Steering Committee. The initial
Celltech members shall be [*] and the initial NeoGenesis members shall be [*].

       (a) STEERING COMMITTEE ACTIVITIES. The Steering Committee shall be
responsible for the management and conduct of the Research Collaboration Plan
during the Research Term and shall in particular: (i) consider, review and amend
the Research Collaboration Plan from time to time in such manner as may be
appropriate; (ii) monitor progress of the Research Collaboration Plan; (iii)
report regularly to the management of both Parties upon the progress of the
Research Collaboration Plan; and (iv) be the initial medium for transfer of
information between the Parties. All oversight activities and governance rights
of the Steering Committee shall terminate, on a compound by compound basis, on a
compound has been designated as a Designated Compound. Upon conclusion of the
Research Term, the Steering Committee shall only perform the functions set forth
in Article VIII hereof, or as otherwise agreed by the Parties in writing.

       (b) STEERING COMMITTEE MEETINGS. The Steering Committee shall hold
meetings as mutually agreed by the Parties (but in no event less than Quarterly
during the Research Term) to review the Research Collaboration Plan. The first
meeting of the Steering Committee shall be held within forty-five (45) days of
the Effective Date and shall be held in Cambridge, MA. Thereafter, meetings may
be held by telephone or video conference if requested by either Party in writing
to the other, PROVIDED that the Steering Committee shall meet in person at least
once per annum during the Research Term. Minutes of all meetings setting forth
decisions of the Steering Committee relative to the Research Collaboration Plan
shall be prepared by the host Party and circulated to both Parties within
fifteen (15) days after each meeting. The minutes shall not become official
until approved by both

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -14-

<Page>

Parties (the Parties shall use Commercially Reasonable Efforts to give approval
within thirty (30) days of receipt of such minutes).

       (c) STEERING COMMITTEE GOVERNANCE. The quorum for Steering Committee
meetings shall be four (4) members, provided that at least two (2) members from
each of NeoGenesis and Celltech are present. Each member of the Steering
Committee will have one vote and all decisions of the Steering Committee will
[*]. [*] on all issues relating to (i) the Research Collaboration Plan as set
forth in Exhibit A, (provided, that in the event and to the extent that any
disagreement concerns whether or not the budgeted FTE funding for a particular
period has been exhausted in accordance with the provisions of this Agreement
(including Exhibit B), such matter shall be resolved in accordance with the
procedure specified immediately below) and (ii) the timing for filing and the
contents of any patent applications that contain or are based on any Celltech
data or information. Any other disagreements at the Steering Committee shall be
resolved via good-faith discussions; PROVIDED, that in the event of a
disagreement that cannot be resolved within thirty (30) days after the date on
which the disagreement arose, the matter shall be referred to designees selected
by the Chief Executive Officer of each of Celltech and NeoGenesis for
resolution; PROVIDED, that such designees shall not be members of the Steering
Committee. Thereafter, if any such disagreement is not resolved within sixty
(60) days, the matter shall be resolved using the procedure specified in Section
13. l, where applicable.

                                   ARTICLE V.
                                RESEARCH FUNDING

       SECTION 5.1. RESEARCH COLLABORATION FUNDING.

       (a) STOCK PURCHASE. As partial consideration for the Research
Collaboration activities under this Agreement, Celltech shall, contemporaneously
with this Agreement, execute a Stock Purchase Agreement with NeoGenesis for the
purchase of Ten Million US Dollars ($10,000,000.00) of NeoGenesis Series E
Convertible Preferred Stock at a price of Five and 97/100's US Dollars per
share.

       (b) FTE FUNDING. As additional consideration for the activities
undertaken pursuant to this Agreement and subject to NeoGenesis' performance of
its obligations hereunder and under the Research Collaboration Plan, Celltech
shall fund FTEs at the rate of [*] per FTE per annum during the Research Term
according to the FTE schedule set forth below.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -15-

<Page>

                                  FTE SCHEDULE

<Table>
<Caption>
-----------------------------------------------------------------------------------------------------------
         PERIOD                MINIMUM FTES                      TOTAL PAYMENT           QUARTERLY PAYMENTS
-----------------------------------------------------------------------------------------------------------
<S>                            <C>                               <C>                     <C>
  Last 1/2 of 2001                  [*]                                  [*]                     [*]
-----------------------------------------------------------------------------------------------------------
  2002                              [*]                                  [*]                     [*]
-----------------------------------------------------------------------------------------------------------
  2003                              [*]                                  [*]                     [*]
-----------------------------------------------------------------------------------------------------------
  2004                              [*]                                  [*]                     [*]
-----------------------------------------------------------------------------------------------------------
  2005                              [*]                                  [*]                     [*]
-----------------------------------------------------------------------------------------------------------
  TOTAL                             [*]                                  [*]
-----------------------------------------------------------------------------------------------------------
</Table>

       (c) QUARTERLY PAYMENTS. Invoicing and payment for FTEs shall be as set
forth on Exhibit B hereto.

                                   ARTICLE VI.
                         MILESTONES AND ROYALTY PAYMENTS

       SECTION 6.1. MILESTONES. In further consideration of the rights granted
by NeoGenesis to Celltech hereunder, Celltech shall pay NeoGenesis each of the
following milestone payments in respect of Licensed Product as specified in this
Section 6.1.

       (a) PHASE I. Within thirty (30) days following the date on which Celltech
first administers any Licensed Product to a human subject in a Phase I Clinical
Trial, Celltech shall pay NeoGenesis [*]. "Phase I Clinical Trial" shall mean
any clinical study in any Major Country which provides for the initial trials of
a Licensed Product for the primary purpose of making a preliminary determination
of safety of the Licensed Product for its intended use in healthy individuals or
patients to support its continued testing in similar clinical trials prescribed
by the relevant Regulatory Authority.

       (b) PHASE III. Within thirty (30) days following the date on which
Celltech first administers any Licensed Product to a human subject in a Phase
III Clinical Trial on a Licensed Product, Celltech shall pay NeoGenesis [*].
"Phase III Clinical Trial" shall mean any clinical study in any Major Country of
a Licensed Product, the primary purpose of which is evaluating statistical
significance of the safety and efficacy of the Licensed Product in patients with
the disease target being studied as required by the relevant Regulatory
Authority to evaluate the overall benefit-risk relationship of the drug and to
provide an adequate basis for physician labeling.

       (c) APPROVAL LETTER. Within thirty (30) days following the date on which
Celltech receives an Approval Letter covering a Licensed Product, Celltech shall
pay NeoGenesis [*]. "Approval Letter" shall mean a written

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -16-

<Page>

communication to Celltech from the FDA approving an NDA on a Licensed Product.

       (d) MILESTONE FREQUENCY. Milestones identified in Section 6.1(a)-(c)
shall be due once for each Licensed Product meeting such milestone, but shall
not include improvements or derivatives thereof or new indications for the same
Licensed Product. On the date any one milestone with respect to any Licensed
Product is achieved, all lower numbered unachieved milestones shall be deemed to
have been achieved with respect to that Licensed Product; PROVIDED that with
respect to the milestone specified in Section 6.1(a), no payment of such
milestone amount shall be due upon the achievement of the milestone specified in
Section 6.1 (b) if Phase I Clinical Trials are not required but such milestone
shall be paid upon the achievement of the milestone specified in Section 6.1(c).

       SECTION 6.2. ROYALTIES. In further consideration of the rights granted by
NeoGenesis to Celltech hereunder, Celltech shall pay NeoGenesis the following
royalties on a per annum basis commencing with the First Commercial Sale of
Licensed Product(s) by Celltech, its Affiliates or sublicensees in the
Territory:

       (a) NON-QSCD DISCOVERED COMPOUNDS. On all Licensed Products which were
not discovered using QSCD, Celltech shall pay royalties of [*] of Net Sales of
Licensed Product [*] per annum and [*] of Net Sales of Licensed Product [*] per
annum;

       (b) QSCD DISCOVERED COMPOUNDS. On all Licensed Products which were
discovered using QSCD, as verified in writing by the Steering Committee prior to
the performance of such QSCD, Celltech shall pay royalties of [*] of Net Sales
of License Product [*] per annum and [*] of Net Sales of Licensed Product [*]
per annum.

       (c) ROYALTY PAYMENTS AND TERM. Celltech shall pay to NeoGenesis the above
royalties no later than [*] following each Quarter commencing with the First
Commercial Sale of Licensed Product by Celltech, its Affiliates or sublicensees
in the Territory. Celltech shall make the royalty payments with respect to each
Licensed Product sold by Celltech, its Affiliates and sublicensees on a country
by country basis until the later of (1) expiration or revocation or rejection or
complete abandonment of the last to expire or to be revoked or to be abandoned
of any issued NeoGenesis patent right covering such Licensed Product in the
country in which the Licensed Product is manufactured or sold or the issuance of
a final decision, which is unappealed or unappealable, of a court of competent
jurisdiction or of an administrative

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -17-

<Page>

agency having authority over patents, that all patents covering such Licensed
Product are invalid, unpatentable or unenforceable, or (2) if no NeoGenesis
patent right exists in the relevant country covering the manufacture, use or
sale of the Licensed Product, until [*] from the First Commercial Sale of such
Licensed Product in the relevant country. Upon expiration of such period,
Celltech's license under Section 2.2 shall be deemed to be fully paid and
Celltech shall be able to continue Commercialization of the relevant Licensed
Product in the relevant country(ies) without any further liability to
NeoGenesis.

       (d) ROYALTY ADJUSTMENTS. The royalty rates set forth in this Section 6.2
are subject to reduction pursuant to Section 8.5(b)(iv), hereof.

       SECTION 6.3. REMITTANCE.

       (a) FUNDS/EXCHANGE RATE. All royalties and milestone payments required
under Section 6 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales were made. For the purpose
of computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
exchange rate for buying United States Dollars in effect on the close of
business on the last business day of the Quarter by Chase Bank, New York, New
York.

       (b) INTEREST. In the event that any undisputed payment due NeoGenesis
under this Agreement is not made when due, NeoGenesis may collect interest
calculated at an annual rate equal to one percent (1%) above the prime interest
rate as published on the close of business by Chase Bank, New York, New York on
the due date. Such payment when made shall be accompanied by all interest so
accrued.

       SECTION 6.4. RECORDS. Beginning after the First Commercial Sale of
Licensed Product, on a Licensed Product by Licensed Product basis, Celltech, its
Affiliates and sublicenses shall keep and maintain for a period of at least two
(2) years from the date of each payment of royalties, records (prepared in
accordance with United States Generally Accepted Accounting Principles,
consistently applied) sufficient to determine the amounts of Net Sales and
payments due under Section 6.2. Within sixty (60) days following each Quarter in
which payments are due under Section 6.2, Celltech shall provide NeoGenesis with
a report including at least: (a) the quantities of Licensed Products that
Celltech, its Affiliate(s) and sublicensee(s) sold during the preceding quarter
in each country in which Licensed Products were sold; (b) the monetary amount,
in the national currency of such country, of such sales;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -18-

<Page>

(c) actual Net Sales, by country; (d) the currency conversion rate used and U.S.
dollar-equivalent of such sales as calculated pursuant to 6.3(a); and (e) the
total royalties so computed and due NeoGenesis. Such reports shall be submitted
to NeoGenesis whether or not any sales of Licensed Product have been made during
such period. Upon delivery of the report due for the period ending December 31
of each year, Celltech shall also report to NeoGenesis the aggregate royalties
paid to NeoGenesis for the entire preceding year.

       SECTION 6.5. INSPECTION.

       (a) AUDIT. Celltech and its Affiliates shall, and Celltech shall provide
in any agreements with its sublicensees that such sublicensees shall, each make
its records available for audit by an independent certified public accountant
selected by NeoGenesis and reasonably acceptable to Celltech, during regular
business hours at such place or places where such records are customarily kept,
upon reasonable notice from NeoGenesis, solely to verify the accuracy of the
reports and payments set forth in Section 6.4 hereof. Celltech and its
Affiliates shall only disclose such records relating to the accuracy of the
royalty payments to NeoGenesis. Such audit right shall not be exercised more
than once in any calendar year nor more than once with respect to sales of
Licensed Products in any given payment period. NeoGenesis agrees to hold all
information learned from such audits as Confidential Information, except to the
extent necessary for NeoGenesis to reveal such information in order to enforce
its rights under this Agreement. Any person or entity conducting such audit or
inspection must agree in writing with NeoGenesis to treat all records reviewed
in the course of the audit or inspection as the Confidential Information of
Celltech under terms and conditions no less restrictive than the terms contained
in Article IX. The results of each audit shall be binding on both Parties. The
independent accountant shall simultaneously supply both Celltech and NeoGenesis
with a copy of any report prepared as a result of such audit. NeoGenesis shall
pay for such inspections, except that in the event there is any upward
adjustment in aggregate royalties payable for any year shown by such inspection
of more than five percent (5%) of the amount paid, Celltech shall pay for such
inspection.

       (b) DISPUTES. All reports and payments not disputed as to correctness by
either Party within two (2) years after receipt thereof shall thereafter
conclusively be deemed correct.

       SECTION 6.6. TAXES. Except for income taxes that may be assessed against
NeoGenesis, all taxes and charges that may be imposed by any government taxing
authority on the amounts paid by Celltech to NeoGenesis

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -19-

<Page>

under this Agreement shall be paid by Celltech for NeoGenesis' account. In the
event Celltech is required to pay the taxes or charges for the account of
NeoGenesis, and therefore withholds such taxes or charges from the amounts paid
to NeoGenesis under this Agreement, Celltech shall deliver to NeoGenesis true
copies of the receipts and/or returns covering all such payments and the
appropriate documentation which is necessary to obtain a tax credit, to the
extent such tax credit can be obtained, as determined by NeoGenesis. Each Party
shall provide assistance to the other Party in seeking any benefits available to
such Party with respect to government tax withholdings by any relevant law or
double tax treaty.

                                  ARTICLE VII.
                      REGULATORY AND MARKETING OBLIGATIONS

       SECTION 7.1. PRODUCT DEVELOPMENT. Celltech, at its sole expense, shall be
responsible for and shall use Commercially Reasonable Efforts with respect to
conducting the R&D Program related to Designated Compounds and Licensed Products
and for obtaining Regulatory Approvals for Licensed Products.

       SECTION 7.2. MANUFACTURE OF PRODUCT. Celltech, at its sole expense, shall
be responsible for and shall use Commercially Reasonable Efforts with respect to
the Manufacture of the Licensed Products in accordance with the Regulatory
Approvals, Applicable Laws, Good Laboratory Practices and Good Manufacturing
Practices.

       SECTION 7.3. REGULATORY MATTERS. Celltech, at its sole expense, shall be
responsible for and shall use Commercially Reasonable Efforts with respect to
the preparation and filing with the appropriate Regulatory Authorities, of all
documents that are necessary to conduct clinical studies of Licensed Products
and Regulatory Approval applications that are necessary to market and sell
Licensed Products. Celltech shall notify NeoGenesis, in writing, that such
regulatory filing has been made.

       SECTION 7.4. MARKETING AND SALE.

       (a) RESPONSIBILITY. Celltech, at its sole expense, shall be responsible
for and shall use Commercially Reasonable Efforts with respect to the
Commercialization of Licensed Products in the Territory. Celltech shall be
solely responsible for establishing the price of each Licensed Product sold by
or on behalf of it pursuant to this Agreement.

       (b) MARKING. Celltech, its Affiliates and sublicensees shall mark or have
marked all containers or packages of Licensed Product(s) that are the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -20-

<Page>

subject of the License granted under Section 2.2 in accordance with the patent
marking laws of the jurisdiction in which such Licensed Product(s) are sold.

       (c) THIRD PARTY LICENSES. Celltech shall be solely responsible, at its
sole discretion, for (a) obtaining any and all licenses from third parties
necessary or desirable to perform the R&D Program and/or to Commercialize any
Licensed Product and (b) except as otherwise provided in Section 6.2(d), any and
all consideration payable with respect to such licenses.

       SECTION 7.5. PERIODIC REVIEW. Celltech and NeoGenesis shall meet, at such
times and places as are mutually agreed upon, for Celltech to provide NeoGenesis
with an update on the status of the progress of Celltech's Commercialization of
each Licensed Product; provided, however, that such meetings shall occur no more
than once per calendar year unless the parties agree, in writing, to meet more
often. Celltech and NeoGenesis shall each be responsible for its own expenses
incurred in connection with attending such meetings.

                                  ARTICLE VIII.
                   RIGHTS IN TECHNOLOGY, PATENTS AND KNOW-HOW

       SECTION 8.1. OWNERSHIP OF PROGRAM TECHNOLOGY. Subject to the terms of
this Agreement, the Parties ownership rights in Program Technology, regardless
of inventorship, are as follows:

       (a) CELLTECH OWNED PROGRAM TECHNOLOGY. As between Celltech and
NeoGenesis, Celltech shall have and retain all right, title and interest in and
to any and all Program Technology solely related to Targets or the uses thereof,
Celltech cell-based or biochemical assays, Designated Compound(s) and Licensed
Product(s) and any method of manufacturing or using any Designated Compound(s)
or Licensed Product(s), and to the extent that any of the forgoing shall have
been invented by NeoGenesis employees or consultants (whether solely or jointly
with Celltech employees or consultants), NeoGenesis hereby assigns all right,
title and interest therein throughout the Territory and shall use Commercially
Reasonable Efforts to assign all right, title and interest therein; PROVIDED,
HOWEVER, that notwithstanding any provision of this Agreement (including the
Research Collaboration Plan) to the contrary, NeoGenesis shall not be required
to assign to Celltech all right title and interest in more than: (i) [*]
Designated Compounds when the optimization as set forth in paragraph 3(d) of the
Research Collaboration Plan is performed by Celltech and such Designated
Compounds are taken directly from the NeoMorph Screening Library or (ii)

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -21-

<Page>

[*] Designated Compounds when the optimization as set forth in paragraph 3(d) of
the Research Collaboration Plan is performed by NeoGenesis and such Designated
Compounds are taken from NeoMorph Focused Libraries. In the event that Celltech
undesignates any Designated Compound in and to whose right, title and interest
has been assigned by NeoGenesis under this Section 8.1 (a) using the procedure
specified in Paragraph 4(a) of the Research Collaboration Plan, Celltech shall,
upon written request by NeoGenesis, (i) return the Designated Compound to
NeoGenesis and (ii) assign all right title and interest in such Designated
Compound back to NeoGenesis, including any patents or patent applications (if
any) Controlled by Celltech or any Affiliate, provided such patents or patent
applications cover solely such undesignated Designated Compound. To the extent
that such patents or patent applications cover more than such Designated
Compound, Celltech shall grant an exclusive license to NeoGenesis for such
patents or patent applications to the extent they cover such Designated
Compound. In the event of an assignment of all right title and interest in such
undesignated Designated Compound, NeoGenesis shall reimburse Celltech for all
reasonable costs associated with filing, prosecuting or maintaining such patents
or patent applications. It is understood that Celltech shall be under no
obligation to assign or license to NeoGenesis any Celltech Derivatives. Any
restrictions with respect to an undesignated Designated Compound shall expire
and NeoGenesis shall be permitted to use such undesignated Designated Compound
for any purpose not otherwise prohibited by this Agreement.

       (b) NEOGENESIS OWNED PROGRAM TECHNOLOGY. As between NeoGenesis and
Celltech, NeoGenesis shall have and retain all right, title and interest in and
to any Preliminary Compound(s), Primary Active Compound(s), NeoMorph Focused
Libraries, QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and
NeoMorph Screening Library(s) unless and until they become Designated Compounds
and all Program Technology solely related to ALIS screening technology or QSCD.

       (c) JOINTLY OWNED PROGRAM TECHNOLOGY. As between Celltech and NeoGenesis,
each Party shall own an undivided one-half interest in and title to all Program
Technology not specifically accounted for in Section 8.1 (a) and (b).

       SECTION 8.2. DISCLOSURE BY EMPLOYEES, AGENTS OR INDEPENDENT CONTRACTORS.
Celltech and NeoGenesis agree that, as to any employees, agents or independent
contractors of Celltech and NeoGenesis presently in their employ, or who are
hired or retained by either Party, to perform, manage performance of, or
participate in the research done pursuant to this

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -22-

<Page>

Agreement, Celltech and NeoGenesis shall ensure that such employees, agents and
independent contractors will promptly disclose and assign to the Party engaging
them any and all rights to inventions, developments or improvements (whether
patentable or not), conceived and/or reduced to practice during the course of
their duties.

       SECTION 8.3. PATENT PROSECUTION AND RELATED ACTIVITIES. Upon notification
by either Party of the existence of any Program Technology, the Parties shall
confer through the Steering Committee as to appropriate protection for such
Program Technology. In addition, subject to Section 4.1(c), the Steering
Committee shall determine the timing of all patent filings on all Program
Technology.

       (a) NEOGENESIS OWNED PROGRAM TECHNOLOGY. NeoGenesis shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
NeoGenesis' sole expense, any Patent(s) on the Program Technology set forth in
Section 8.1(b) throughout the Territory. In the event that NeoGenesis elects not
to file for patent protection or elects not to prosecute or maintain a Patent(s)
on the Program Technology set forth in Section 8.1(b), it shall notify Celltech
in writing of such decision and provide Celltech a one (1) month period from
receipt of such written notification in which to respond to such notice before
abandoning and/or discontinuing its obligations to file, prosecute or maintain
such Patent(s). Celltech shall have the right, but not the obligation to assume
the responsibility therefor, at its own cost and expense. If Celltech responds
within such one (1) month response period that it wishes to file, prosecute or
maintain such Patent(s), then NeoGenesis shall promptly transfer and assign all
right, title and interest in and to such Patent(s) to Celltech and shall
continue to file, prosecute and maintain such Patent(s) until such transfer and
assignment become effective. Celltech shall reimburse NeoGenesis for all
reasonable costs associated with filing, prosecuting or maintaining such
Patent(s). Upon such transfer and assignment becoming effective, NeoGenesis
shall reasonably assist Celltech in the filing, prosecuting and maintaining such
Patent(s).

       (b) CELLTECH OWNED PROGRAM TECHNOLOGY. Celltech shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
Celltech's sole expense, any Patent(s) on the Program Technology set forth in
Section 8.1 (a) throughout the Territory. In the event that Celltech elects not
to prepare or file for patent protection or elects not to prosecute or maintain
a Patent(s) on Celltech Program Technology set forth in Section 8.1(a), it shall
notify NeoGenesis but shall have no obligation to continue with the filing,
preparing, prosecuting or maintaining any Patent(s).

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -23-

<Page>

       (c) JOINTLY OWNED PROGRAM TECHNOLOGY. NeoGenesis shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
NeoGenesis' expense, any Patent(s) on Program Technology set forth in Section
8.1(c) throughout the Territory. NeoGenesis shall keep Celltech currently
advised as to the status of all Patent(s) with respect to the Program
Technology set forth in Section 8.1(c) and shall supply Celltech promptly
with copies of all patents, patent applications, substantive patent office
actions, substantive responses received or filed in connection with such
applications. Celltech may itself or through its attorney offer comments and
suggestions with respect to the matters that are the subject of this Section
8.3(c) and NeoGenesis agrees to consider such comments and suggestions;
PROVIDED that nothing herein shall obligate NeoGenesis to adopt or follow
such comments or suggestions. In the event that NeoGenesis elects not to file
for patent protection or elects not to prosecute or maintain a Patent(s) on
the Program Technology set forth in Section 8.1(c), it shall notify Celltech
in writing of such decision and provide Celltech a one (1) month period from
receipt of such written notification in which to respond to such notice
before abandoning and/or discontinuing its obligations to file, prosecute or
maintain such Patent(s). Celltech shall have the right, but not the
obligation to assume the responsibility therefore, at its own cost and
expense. If Celltech responds within such one (1) month response period that
it wishes to file, prosecute or maintain such Patent(s), then NeoGenesis
shall promptly transfer and assign all right, title and interest in and to
such Patent(s) to Celltech and shall continue to file, prosecute and maintain
such Patent(s) until such transfer and assignment become effective. Celltech
shall reimburse NeoGenesis for all reasonable costs associated with filing,
prosecuting or maintaining such Patent(s) from date it notifies NeoGenesis it
wishes to assume responsibility for the patent(s) until the transfer and
assignment becomes effective shall be paid by Celltech. Upon such transfer
and assignment becoming effective, NeoGenesis shall reasonably assist
Celltech in the filing, prosecuting and maintaining of such Patent(s).

       (d) COOPERATION. Each Party shall keep the Steering Committee informed as
to the status of patent matters set forth in this Section 8.3 during the
Research Term. To the extent necessary, and at the requesting Party's expense,
each Party shall use Commercially Reasonable Efforts to cooperate and assist the
other Party with the preparation, filing and prosecution of Patent(s).

       SECTION 8.4. THIRD PARTY INFRINGEMENT.

       (a) ENFORCEMENT. In the event that either Party becomes aware that any
NeoGenesis Technology, or Program Technology are infringed or

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -24-

<Page>

misappropriated by a Third Party or are subject to a declaratory judgment
action, the Party becoming aware of such event shall promptly notify the other
Party. The Party with the right to prepare, file, prosecute, and maintain a
Patent(s) with respect to such NeoGenesis Technology, or Program technology, as
the case may be, and which is then maintaining said Patent(s), in its sole
discretion, shall have the right and shall be solely responsible for pursuing
any action for infringement or misappropriation against Third Parties or
defending any declaratory judgment action relating thereto. To the extent that
the Program Technology being pursued is Program Technology as set forth in
Section 8.1(c), the Party not having the right to prepare, file, prosecute, and
maintain a Patent(s) with respect to such NeoGenesis Technology, or Program
technology, as the case may be, and which is not then actually maintaining said
Patent(s) shall have the option to participate in such action at its sole
expense.

       (b) FAILURE TO ENFORCE. If the Party with the right to pursue any action
for infringement or misappropriation against Third Parties or defending any
declaratory judgment action as set forth in Section 8.4(a) above fails to pursue
or defend such action relating to Program Technology set forth in Section 8.1
(c) within sixty (60) days written notice by the other Party of its desire to
proceed, then the other Party shall have the option to pursue or defend such
actions; PROVIDED, that such Party pays all costs and expenses related to the
same, and keeps the other Party reasonably informed of its progress and provides
copies of any documents related to such proceedings and reasonable notice of all
proceedings relating to same. A Party electing to exercise its option to proceed
under this Section 8.4(b) shall notify the other Party of its decision to
exercise its option as soon as possible.

       (c) DIVISION OF RECOVERIES. Any recovery of damages received in
connection with a suit (including by way of settlement) under Section 8.4(a)
involving Program Technology set forth in Section 8.1 (a) or (b) shall be
retained by the Party that owns said Program Technology; PROVIDED that any
recovery of ordinary damages (including by way of settlement) based upon
infringement of Program Technology set forth in Section 8.1 (a) shall be deemed
to be Net Sales and Celltech shall pay NeoGenesis an amount calculated in
accordance with Section 6.2 to reimburse NeoGenesis for royalties due in respect
of lost sales of Licensed Products represented by such ordinary damages. Any
recovery of damages received in connection with a suit (including by way of
settlement) under Section 8.4(a) involving the Program Technology set forth in
Section 8.1 (c) brought by NeoGenesis or Celltech shall be retained by the Party
that conducted such suit. Any recovery of damages received in connection with a
suit (including by way of settlement) jointly brought by NeoGenesis and Celltech
(other than the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -25-

<Page>

assistance that each party is required to provide to the litigating party
pursuant to Section 8.4(d) and for which it has been reimbursed) shall be used
first to reimburse the Parties, on a pro-rata basis, for all expenses actually
incurred in such suit, and any remainder shall divided equally between Celltech
and NeoGenesis after payment by Celltech of any obligations it may have to any
sublicensee in relation to any recovery.

       (d) COOPERATION. In any claim, suit or proceeding under Section 8.4 which
either Party may become involved, the other Party shall, at the request and
expense of the Party initiating or defending the claim, suit or proceeding,
cooperate and assist such Party in all reasonable respects, including having its
employees testify when requested and making available relevant records, papers,
information, specimens and the like.

       SECTION 8.5. INFRINGEMENT CLAIMS BY THIRD PARTIES.

       (a) THIRD PARTY CLAIMS. If the making, having made, using, distributing
for sale, promoting, marketing, offering for sale, selling, having sold,
importing or exporting of any Licensed Products results in an assertion or a
claim against a Party of infringement or misappropriation of any Third Party's
intellectual property right ("Third Party Claim"), the Party first having notice
of a Third Party Claim shall promptly notify the other Party in writing
specifying in reasonable detail the alleged grounds or basis for the Third Party
Claim.

       (b) RESPONSE TO THIRD PARTY CLAIMS. In the event of a Third Party Claim,
the Parties agree to respond to and/or defend against the Third Party Claim as
follows:

            (i) Each Party shall use Commercially Reasonable Efforts in
responding to and defending against such Third Party Claim, and will render such
reasonable assistance as the other Party may request, at the requesting Party's
expense, in defending such Third Party Claim.

            (ii) Neither Party shall settle any Third Party Claim in a manner
that is prejudicial to either Party without the other Party's prior written
consent.

            (iii) Each Party shall be responsible for its own fees and costs of
attorneys and consultants, together with court costs, incurred in defending
against the Third Party Claim.

            (iv) If Celltech, by court order, settlement or other agreement
entered into in good faith, is required to pay royalties and/or damages to any

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -26-

<Page>

Third Parties in connection with the disposition of a Third Party Claim to
avoid infringement by any Licensed Product of such Third Party patent(s),
then Celltech shall be entitled, beginning from the date Celltech commences
payment to any such Third Parties, to reduce the royalties payable to
NeoGenesis by [*] of the amount of any such royalties and/or damages payable
to such Third Parties; provided that: (1) such infringement is on a Licensed
Product provided that such infringement is primarily related to the
pharmaceutically active ingredient of the Licensed Product and (2) such
deductions reduce by no more than [*] the royalties otherwise due NeoGenesis
under Section 6.2 with respect to such Licensed Product.

                                   ARTICLE IX.
                                 CONFIDENTIALITY

       SECTION 9.1. CONFIDENTIALITY. As used in this Agreement, the term
"Confidential Information" shall mean any and all non-public, proprietary or
otherwise confidential information pertaining to or developed under this
Agreement furnished to either Party ("Receiving Party") by or on behalf of the
other Party ("Disclosing Party"). Such Confidential Information includes, but is
not limited to, trade secrets, know-how, inventions, formulations, compositions,
technical data or specifications, testing methods, business or financial
information, research and development activities, product and marketing plans
and customer and supplier information together with all portions of analysis,
studies and other documents prepared by or for the benefit of a Party.

       SECTION 9.2. OBLIGATIONS OF CONFIDENTIALITY. The Receiving Party shall:
(a) maintain all Confidential Information in strict confidence, except that the
Receiving Party may disclose or permit the disclosure of any Confidential
Information to its directors, officers, employees, consultants and advisors who
are obligated to maintain the confidential nature of such Confidential
Information and who need to know such Confidential Information to perform this
Agreement; (b) use all Confidential Information solely for purposes of
performing its obligations or exercising its rights under this Agreement; and
(c) reproduce the Confidential Information only to the extent necessary to
perform this Agreement, with all such reproductions being considered
Confidential Information.

       SECTION 9.3. LEGAL DISCLOSURE. The obligations of the Receiving Party
under Section 9.2 hereof shall not apply to the extent that the Receiving Party
can demonstrate by competent written documentation that certain Confidential
Information; (a) was in the public domain prior to the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -27-

<Page>

time of its disclosure under this Agreement; (b) entered the public domain after
the time of its disclosure under this Agreement through means other than an
unauthorized disclosure resulting from an act or omission by the Receiving
Party; (c) was independently developed or discovered by the Receiving Party
prior to the time of its disclosure under this Agreement, as evidenced by the
Receiving Party's records; (d) is or was disclosed to the Receiving Party at any
time, whether prior to or after the time of its disclosure under this Agreement,
by third Party having no fiduciary relationship with the Disclosing Party and
having no obligation of confidentiality with respect to such Confidential
Information. Nothing herein shall prevent the Receiving Party from disclosing
all or part of the Confidential Information as necessary pursuant to the lawful
requirement of a governmental agency or when disclosure is required by operation
of law; PROVIDED that prior to any such disclosure, the Receiving Party shall
use reasonable efforts to: (i) promptly notify the Disclosing Party in writing
of such requirement to disclose; and (ii) cooperate fully with the Disclosing
Party in protecting against any such disclosure or obtaining a protective order.
A Party's Confidential Information shall not be deemed to be within any of the
foregoing exceptions merely because it is embraced by general disclosures within
such exceptions, nor shall a Party's Confidential Information be deemed to be
within any of the foregoing exceptions merely because individual items are in
such exceptions.

       SECTION 9.4. OWNERSHIP OF INFORMATION. Except as provided in this
Agreement with respect to ownership of Program Technology, the Receiving Party
agrees that the Disclosing Party (or any Third Party entrusting its own
Confidential Information to the Disclosing Party) is and shall remain the
exclusive owner of the Confidential Information disclosed by the Disclosing
Party and all patent, copyright, trademark, trade secret, and other intellectual
property rights in, or arising from, such Confidential Information. No option,
license, or conveyance of such rights to the Receiving Party is granted or
implied under this Agreement unless expressly set forth herein. If any such
rights are to be granted to the Receiving Party outside of this Agreement, such
grant shall be expressly set forth in a separate written instrument.

       SECTION 9.5. EXPIRATION OR TERMINATION. Upon the expiration or
termination, by either Party, of this Agreement, the Receiving Party shall
return to the Disclosing Party all originals, copies, and summaries of
documents, materials, and other tangible manifestations of Confidential
Information owned by the Disclosing Party and in the possession or control of
the Receiving Party, except to the extent the Receiving Party has the right to
continue to use such information pursuant to Section 12.3. The obligation of

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -28-

<Page>

confidentiality set forth in this Article IX shall remain in effect for a period
[*] after such termination or expiration hereof. Each Party may keep one (1)
copy of such Confidential Information in its legal files to monitor any
continuing obligations under this Agreement.

       SECTION 9.6. PUBLICITY. Except as is necessary to comply with applicable
laws and regulations or to enforce their respective rights under this Agreement,
or to a Party's legal or financial advisors, and except as otherwise agreed to
by the Parties in writing, the Parties shall: keep the material terms of this
Agreement confidential, agree upon the text and the exact timing of an initial
public announcement relating to the transactions contemplated by this Agreement
as soon as practicable after the Effective Date (such agreement not to be
unreasonably withheld or delayed) and agree on the text and the timing of any
subsequent public announcements regarding this Agreement or the transactions
contemplated herein.

       SECTION 9.7. PUBLICATION. Celltech and NeoGenesis shall not publish, in
any form, the other Party's Confidential Information. However, each Party
acknowledges the importance of publication and that a Party may desire to
publicize results from the Research Collaboration at seminars, meetings,
conferences, and in peer reviewed journals. A Party shall have the right to
publish the results from the Research Collaboration, PROVIDED ALWAYS, that prior
to submission for publication or presentation of any results based on the
Research Collaboration, the publishing Party shall provide the other Party
thirty (30) days to review and comment upon the manuscript or other material for
such publication. If requested in writing during the aforementioned review
period of thirty (30) days, by the reviewing Party, the publishing Party shall,
at the sole discretion of the reviewing Party either, (i) delay publication for
an additional ninety (90) days to allow for filing of a patent application; or
(ii) preclude publication in the event the reviewing Party believes the
publication contains Confidential Information of such other party. In such event
of an objection to publication based upon Section 9.7(ii), the publishing Party
shall modify or delete the Confidential Information before the reviewing Party
is obligated to grant approval to publish the modified publication. If the
reviewing Party does not request in writing that the publishing Party delay the
publication under Section 9.7(i) or (ii) during the aforementioned review period
of thirty (30) days, then the publishing Party may publish the results of the
Research Collaboration accordingly.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -29-

<Page>

                                   ARTICLE X.
                         REPRESENTATIONS AND WARRANTIES

       SECTION 10.1. NEOGENESIS REPRESENTATIONS AND WARRANTIES. NeoGenesis
represents and warrants to Celltech as follows:

       (a) ORGANIZATION. NeoGenesis is a corporation duly organized, validly
existing and in good standing under the laws Delaware, and has all requisite
corporate power and authority to carry on its business as now conducted and as
proposed to be conducted. NeoGenesis is duly qualified to transact business and
is in good standing in each jurisdiction in which the failure so to qualify
would have a material adverse effect on its business or properties.

       (b) AUTHORITY. All corporate action on the part of NeoGenesis, its
officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement has been taken or will be taken prior to or as of
the Effective Date. NeoGenesis has the requisite corporate power to enter into
this Agreement and carry out and perform its obligations under the terms of this
Agreement. This Agreement has been duly authorized, executed and delivered by
NeoGenesis and, upon due execution and delivery by Celltech, this Agreement will
be a legal, valid and binding agreement of NeoGenesis enforceable against
NeoGenesis in accordance with its terms, except as limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws of general application
affecting creditors' rights generally or as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable
remedies.

       (c) GOVERNMENTAL CONSENTS. To the best of NeoGenesis' knowledge, no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state, local or provincial
governmental authority on the part of NeoGenesis is required in connection with
the consummation of the transactions contemplated by this Agreement.

       (d) NO CONFLICT WITH OTHER AGREEMENTS. The execution, delivery and
performance of this Agreement will not result in any violation of, be in
conflict with, or constitute a default under, with or without the passage of
time or the giving of notice: (a) any provision of NeoGenesis' Certificate of
Incorporation or Bylaws as either are currently in effect; (b) any provision of
any judgment, decree or order to which NeoGenesis is a party or by which it is
bound; (c) any material contract, obligation or commitment to which NeoGenesis
is a party or by which it is bound; or (d) to NeoGenesis'

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -30-

<Page>

knowledge, any statute, rule or governmental regulation applicable to
NeoGenesis.

       (e) PATENT INFRINGEMENT. As of the Effective Date, (i) there are no
pending or, to the best of NeoGenesis' knowledge, threatened actions, suits or
claims against it with respect to any NeoGenesis Technology, and (ii) NeoGenesis
is not aware of any patents owned or controlled by a Third Party that would be
infringed by the activities of NeoGenesis contemplated under the Research
Collaboration Plan.

       (f) DEBARRED. NeoGenesis certifies that it is not debarred under 21 USC
335(a) or (b) of the Federal Food, Drug, and Cosmetic Act and that it has not
used and will not use in any capacity the services of any Person debarred under
such laws with respect to services to be performed under the Agreement.

       (g) DISCLAIMER. EXCEPT FOR THE WARRANTIES EXPRESSLY MADE BY NEOGENESIS IN
SECTION 10.1(a)-(f), NEOGENESIS MAKES NO OTHER REPRESENTATION OR WARRANTY,
EITHER EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT
LIMITATION ANY WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER
INTELLECTUAL PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY,
THE NEOMORPH FOCUSED LIBRARIES, QSCD, THE PRELIMINARY COMPOUNDS, THE PRIMARY
ACTIVE COMPOUNDS, THE DESIGNATED COMPOUNDS, THE LICENSED PRODUCTS, THE
NEOGENESIS TECHNOLOGY, THE SCOPE, VALIDITY OR ENFORCEABILITY OF ANY NEOGENESIS
PATENT RIGHTS OR NEOGENESIS' OBLIGATIONS UNDER THIS AGREEMENT. THE
REPRESENTATIONS AND WARRANTIES OF NEOGENESIS EXTEND ONLY TO CELLTECH AND ITS
AFFILIATES. NEOGENESIS SHALL NOT BE LIABLE FOR ANY CLAIM OR DEMAND AGAINST
CELLTECH BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN SECTIONS 11.1-11.2.

       SECTION 10.2. CELLTECH REPRESENTATIONS AND WARRANTIES.

       (a) ORGANIZATION. Celltech is a corporation duly organized, validly
existing and in good standing under the laws of England, and has all requisite
corporate power and authority to carry on their business as now conducted and as
proposed to be conducted. Celltech is duly qualified to

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -31-

<Page>

transact business and is in good standing in each jurisdiction in which the
failure so to qualify would have a material adverse effect on its business or
properties.

       (b) AUTHORITY. All corporate action on the part of Celltech, its
officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement has been taken or will be taken prior to or as of
the Effective Date. Celltech has the requisite corporate power to enter into
this Agreement and carry out and perform its obligations under the terms of this
Agreement. This Agreement has been duly authorized, executed and delivered by
Celltech and, upon due execution and delivery by NeoGenesis, this Agreement will
be a legal, valid and binding agreement of the Celltech enforceable against
Celltech in accordance with its terms, except as limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws of general application
affecting creditors' rights generally or as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable
remedies.

       (c) GOVERNMENTAL CONSENTS. To the best of Celltech's knowledge, no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state, local or provincial
governmental authority on the part of Celltech is required in connection with
the consummation of the transactions contemplated by this Agreement.

       (d) NO CONFLICT WITH OTHER AGREEMENTS. The execution, delivery and
performance of this Agreement will not result in any violation of, be in
conflict with, or constitute a default under, with or without the passage of
time or the giving of notice: (a) any provision of Celltech's Certificate of
Incorporation or Bylaws as either are currently in effect; (b) any provision of
any judgment, decree or order to which Celltech is a party or by which it is
bound; (c) any material contract, obligation or commitment to which Celltech is
a party or by which it is bound; or (d) to Celltech's knowledge, any statute,
rule or governmental regulation applicable to Celltech.

       (e) DISCLAIMER. EXCEPT FOR THE WARRANTIES EXPRESSLY MADE BY CELLTECH IN
SECTION 10.2(a)-(d), CELLTECH MAKES NO OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE APPROVED TARGETS, THE CELLTECH

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -32-

<Page>

TECHNOLOGY, THE SCOPE, VALIDITY OR ENFORCEABILITY OF ANY CELLTECH PATENT OR
CELLTECH'S OBLIGATIONS UNDER THIS AGREEMENT. THE REPRESENTATIONS AND WARRANTIES
OF CELLTECH EXTEND ONLY TO NEOGENESIS AND ITS AFFILIATES. CELLTECH SHALL NOT BE
LIABLE FOR ANY CLAIM OR DEMAND AGAINST NEOGENESIS BY A THIRD PARTY, EXCEPT TO
THE EXTENT PROVIDED IN SECTIONS 11.1 AND 11.2.

                                   ARTICLE XI.
                                 INDEMNIFICATION

       SECTION 11.0. LIMITATION OF LIABILITY. EXCEPT FOR INFRINGEMENT OF THE
OTHER PARTY'S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER ARTICLE 9 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS
11.1-11.2 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE
LIABLE TO THE OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

       SECTION 11.1. INFRINGEMENT INDEMNIFICATION.

       (a) NEOGENESIS. Subject to the provisions of Section 11.3 and
notwithstanding Section 10.1(g), NeoGenesis shall defend, indemnify and hold
harmless Celltech, its subsidiaries, parent corporations, Affiliates, officers,
directors, independent contractors, partners, members, employees, agents,
successors and assigns (collectively, "Celltech Indemnified Parties") from and
against any claim, suit, demand, loss, damage, expense (including reasonable
attorney's fees of indemnitee(s) and those that may be asserted by a Third
Party) or liability imposed upon them by any Third Party and arising from a
Third Party claim that (i) use of NeoGenesis Technology or (ii) practice of any
NeoGenesis Patents by Celltech in accordance with the terms of this Agreement
violates or infringes the intellectual property rights of any Third Party.
NeoGenesis shall have no liability or obligation to Celltech under this Section
11.1 (a) in the event and to the extent that the alleged infringement is caused
by (1) modifications, alterations, combinations or enhancements of the
Designated Compounds not created by NeoGenesis, or (2) willful misconduct or
negligent acts or omissions of Celltech or its Affiliates, or its or their
respective employees, officers, directors or agents.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -33-

<Page>

       (b) CELLTECH. Subject to the provisions of Section 11.3 and
notwithstanding Section 10.2(e), Celltech shall defend, indemnify and hold
harmless NeoGenesis, its subsidiaries, parent corporations, Affiliates,
officers, directors, independent contractors, partners, shareholders, employees,
agents, successors and assigns (collectively, "NeoGenesis Indemnified Parties")
from and against any losses imposed upon them by any Third Party and arising
from a Third Party claim that (i) the use of the Celltech Technology, or (ii)
the practice of any Celltech Patents by NeoGenesis in accordance with the terms
of this Agreement violates or infringes the intellectual property rights of any
Third Party. Celltech shall have no obligation or liability to NeoGenesis under
this Section 11.1(b) in the event and to the extent that the alleged
infringement (1) is covered by Section 11.1 (a) or (2) results from willful
misconduct or negligent acts or omissions of NeoGenesis or its Affiliates, or
its or their respective employees, officers, directors or agents.

       SECTION 11.2. OTHER CLAIMS.

       (a) NEOGENESIS. NeoGenesis will indemnify and be liable to the Celltech
Indemnified Party(s), for any losses suffered by Celltech Indemnified Party(s)
arising from or related to: (i) any material breach of the NeoGenesis'
representations and warranties under this Agreement; (ii) any negligence or
intentional misconduct by NeoGenesis (or its employees, agents or
representatives) in performing its obligations under this Agreement, including
the performance of the Research Collaboration Plan; or (iii) the breach of its
obligations hereunder. The foregoing shall not apply in the event and to the
extent that a court of competent jurisdiction determines that such losses arose
as a result of any Celltech Indemnified Party's negligence, intentional
misconduct or breach of this Agreement.

       (b) CELLTECH. Celltech will indemnify and be liable to the NeoGenesis
Indemnified Party(s) for any losses suffered by a NeoGenesis Indemnified
Party(s) arising from: (i) any material breach of Celltech's representations and
warranties under this Agreement; (ii) any negligence or intentional misconduct
by Celltech (or its employees, agents or representatives) or by an Affiliate,
licensee, sublicensee, distributor or agent of Celltech in performing its
obligations under this Agreement, including the performance of the R&D Program;
or (iii) the labeling, packaging, package insert, other materials or promotional
claims with respect to any Licensed Product or the testing, Manufacturing,
Commercialization, use or other disposition of any Licensed Product by Celltech
or by an Affiliate, licensee, sublicensee, distributor or agent of Celltech. The
foregoing shall not apply in the event and to the extent that a court of
competent jurisdiction determines that such losses arose as a

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -34-

<Page>

result of any NeoGenesis Indemnified Party's negligence, intentional misconduct
or breach of this Agreement.

       SECTION 11.3. PROCEDURE. To receive the benefit of indemnification under
Sections 11. 1 or 11.2, the Indemnified Party must (a) promptly notify the Party
from whom indemnification is sought (the "Indemnifying Party") in writing of a
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations except where, and solely
to the extent that, such failure actually and materially prejudices the rights
of Indemnifying Party); (b) provide reasonable cooperation (at the Indemnifying
Party's expense); and (c) with respect to claims under Section 11.1, tender to
the Indemnifying Party (and its insurer) full authority to defend or settle the
claim or suit; PROVIDED that no settlement requiring any admission by the
Indemnified Party or that imposes any obligation on the Indemnified Party shall
be made without the Indemnified Party's prior written consent. Neither Party has
any obligation to indemnify the other Party under Section 11.1 in connection
with any settlement made without the Indemnifying Party's written consent. The
Indemnified Party has the right to participate at its own expense in the claim
or suit and in selecting counsel therefor. The Indemnified Party shall cooperate
with Indemnifying Party (and its insurer), as reasonably requested, at
Indemnifying Party's cost and expense.

                                  ARTICLE XII.
                              TERM AND TERMINATION

       SECTION 12.1. TERM. This Agreement shall take effect on the Effective
Date and shall remain in effect until the later of (A) the expiration of the
Research Term or (B) if any compound is designated as a Designated Compound or
becomes a Licensed Product, then until (i) the later of the expiration of the
last to expire of the patents embodied in or related to such Licensed Products,
or (ii) the obligation to pay royalties hereunder expires due to the failure of
any patent to issue in respect of such Licensed Product or the expiration, lapse
of all patents covering such Licensed Product or the issuance of a final
decision, which is unappealed or unappealable, of a court of competent
jurisdiction or of an administrative agency having authority over patents, that
all patents covering such Licensed Product are invalid, unpatentable or
unenforceable, unless sooner terminated in accordance with Section 12.2,
collectively the ("Term").

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -35-

<Page>

       SECTION 12.2. TERMINATION.

       (a) MATERIAL BREACH. Subject to Section 11.2 and 12.3(c), either Party
may terminate this Agreement and the rights granted hereunder with sixty (60)
days notice to the other Party if the other Party commits a material breach
hereof unless the breach is cured within the sixty (60) day notice period. In
addition, NeoGenesis may suspend work pursuant to the Research Collaboration
Plan with notice to Celltech if Celltech fails to pay NeoGenesis any amount due
NeoGenesis under this Agreement.

       (b) BANKRUPTCY OR RECEIVERSHIP OF A PARTY. Either Party may terminate
this Agreement and the rights granted hereunder with upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other Party; PROVIDED, HOWEVER, in the case of
any involuntary bankruptcy proceeding such right to terminate shall only become
effective if the other Party consents to the involuntary bankruptcy or such
proceeding is not dismissed within ninety (90) days after the filing thereof.

       (c) TERMINATION BY CELLTECH. Upon the conclusion of the Lock Up Period,
Celltech may terminate this Agreement upon ninety (90) days written notice to
NeoGenesis.

       SECTION 12.3. EFFECT OF TERMINATION.

       (a) TERMINATION ACTIVITIES. Upon termination (including expiration) of
this Agreement as permitted herein: (i) NeoGenesis will terminate all tasks in
process at the date of termination in an orderly manner, as soon as practical
and in accordance with a schedule agreed to by Celltech and NeoGenesis; (ii)
NeoGenesis shall deliver to Celltech all materials developed through the
termination of this Agreement; (iii) Celltech shall pay NeoGenesis any monies
due and owing NeoGenesis up to the termination date, for services actually
performed, PROVIDED, such fee shall not exceed the total FTE funding specified
in Section 5.1(b) of this Agreement (unless Celltech has requested additional
work for which a separate fee has been agreed to by the parties); (iv)
NeoGenesis shall destroy all NeoMorph Focused Libraries developed for Celltech;
and (v) within thirty (30) days following termination (including expiration) of
this Agreement, NeoGenesis shall deliver to Celltech a reasonably-detailed
written report describing the results of the research performed up to the date
of such termination. In addition, if Celltech terminates this Agreement in
accordance with Section 12.2(c), Celltech shall pay NeoGenesis as liquidated
damages an amount equal to the aggregate budgeted FTE fee for the 90-day period
following the date Celltech delivers notice of termination pursuant to Section
12.2(c) to the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -36-

<Page>

extent such funding has not already been received by NeoGenesis as of the date
Celltech delivers such termination notice to reimburse NeoGenesis for
non-cancelable commitments with respect to NeoGenesis staff allocated to the
performance of the Research Collaboration.

       (b) RETURN OF CONFIDENTIAL INFORMATION. Except as provided in Section
9.5, upon termination (including expiration) of this Agreement as permitted
herein, each Party shall return to the other Party or certify in writing to the
other Party that it has destroyed all documents and other tangible items it or
its employees or agents have received or created pertaining, referring or
relating to the Confidential Information of the other Party.

       (c) RIGHTS UPON TERMINATION. The licenses and assignments granted by
NeoGenesis under Section 2.2 and 8.1(a) shall survive any expiration or
termination of the Research Collaboration Plan or Research Term or this
Agreement with respect to any Designated Compound or Licensed Product and
Celltech shall continue to have the right to develop, have developed, make, have
made, use, distribute for sale, promote, market, offer for sale, have sold,
import, export and sell Licensed Products relating to such Designated Compounds;
subject to payment to NeoGenesis of milestone fees and royalties as required by
Section 6.1 and 6.2 and compliance with Sections 6.3 - 6.6. In the event the
license granted to Celltech under Section 2.2 terminates for any reason, each of
Celltech's sublicensees at such time shall continue to have the rights and
license set forth in their sublicense agreements, PROVIDED such sublicensee
agrees in writing that NeoGenesis is entitled to enforce all relevant provisions
directly against such sublicensee.

       (d) NO RELEASE OF MATURED OBLIGATION. Nothing herein shall be construed
to release either Party of any obligation which matured prior to the effective
date of any termination, or shall be deemed a waiver of any rights under Section
11.2. Except as otherwise provided herein, neither party shall be liable to the
other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section12.

       SECTION 12.4 SURVIVAL. In addition to those provisions which survive upon
a breach by a Party hereto, Articles I, VI, IX, X, XI, XIII, Section 8.1 and
Section 8.5 shall survive any termination or expiration of this Agreement;
provided, that Article VI shall not survive expiration of this Agreement with
respect to any Licensed Product upon the expiration of the last to expire of the
patents embodied in or related to such Licensed Product.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -37-

<Page>

                                  ARTICLE XIII.
                               GENERAL PROVISIONS

       SECTION 13.1. ISSUE RESOLUTION. The Parties shall use their best efforts
to resolve any controversy or dispute that arises under or relates to this
Agreement through good faith discussions.

       (a) NOTIFICATION OF DISPUTE. In the event of a controversy or dispute,
the Parties shall initiate dispute discussions using the following procedure:
Either Party shall notify the other Party of the nature of the controversy or
dispute (a "Dispute Notice"). Representatives of the Parties shall meet within
thirty (30) days after the date that the non-sending Party receives the Dispute
Notice to attempt to reach an agreement about the nature of the dispute and a
resolution of the dispute. If they are unable to resolve the dispute within
thirty (30) days, and they do not agree to extend the time period for resolving
the dispute, or if the terms and conditions of the resolution or settlement of
the dispute are breached, the dispute shall be resolved by arbitration pursuant
to the provisions of Section 13.1(b)-(e). Pending resolution of any dispute
covered by this Section 13.1, both Parties will continue their performance under
this Agreement including, without limitation, the payment of all amounts due to
the other Party that are not in dispute.

       (b) LIMITATIONS. Except in the case of a dispute related to the
ownership, validity or enforceability of intellectual property rights of a
Party, any claim, dispute, or controversy arising out of or relating to this
Agreement that is not resolved in accordance with the provisions of Section
13.1(a) within the time period specified in Section 13.1(a) will be submitted by
the Parties to arbitration in accordance with the terms of Section 13.1(b)-(d).
Any dispute related to the ownership, validity or enforceability of intellectual
property rights of a Party or any action following termination for cause due to
a material breach hereof, may be brought in a court of competent jurisdiction in
the country where such rights arise.

       (c) ARBITRATION RULES. Any arbitration shall be conducted pursuant to the
International Arbitration Rules of the American Arbitration Association ("AAA"),
under the rules then in effect for the AAA, as such rules may be modified by
this Agreement or by agreement of the Parties. Any such arbitration shall be
conducted in New York City by one arbitrator. Each Party irrevocably and
unconditionally (i) consents to the jurisdiction of any such proceeding; and
(ii) knowingly and voluntarily waives its rights to have disputes tried and
adjudicated by a judge and jury except as otherwise expressly provided herein.
The Parties will cooperate with each other in

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -38-

<Page>

causing the arbitration to be held in as efficient and expeditious a manner as
practicable. The Parties will attempt to agree upon a mutually acceptable
arbitrator within thirty (30) days of receipt of the notice of intent to
arbitrate such arbitrator shall have fifteen (15) years legal standing with
experience in such matters. If the Parties are unable to agree upon a single
arbitrator within such thirty (30) day period or any extension of time which is
mutually agreed upon, three (3) arbitrators shall be used, one selected by each
Party within ten (10) days after the conclusion of the thirty (30) day period
and a third selected by the first two within ten (10) days thereafter. Unless
the Parties agree otherwise, they shall be limited in their discovery to
directly relevant documents. Responses or objections to a document request shall
be served twenty (20) days after receipt of the request. The arbitrator(s) shall
resolve any discovery disputes. Nothing herein shall prevent the Parties from
settling any dispute at any time by mutual agreement of the Parties.

       (d) APPLICABLE LAW. The arbitrator(s) shall apply the substantive laws of
New York when construing this Agreement and attempting to resolve any dispute
relating to the transactions contemplated by this Agreement, without regard for
any choice or conflict of laws rule or principle that would result in the
application of the substantive law of any other jurisdiction. The arbitration
shall be of each Party's individual claims only, and no claim of any Third Party
shall be subject to arbitration in such proceeding. Except as otherwise required
by law, the Parties and the arbitrator(s) shall maintain as confidential all
information or documents obtained during the arbitration process, including the
resolution of the dispute.

       (e) RESTRICTIONS ON DAMAGES. The arbitrator(s) shall not have the
authority to award exemplary or punitive damages, and the Parties expressly
waive any claimed right to such damages. The arbitrator(s) shall have the
authority to award actual money damages (with interest on unpaid amounts from
the date due) and may grant equitable relief as is just and provided by the AAA
Rules, in each case except as specifically provided to the contrary herein, the
costs and expenses of the arbitration, but not the costs and expenses of the
Parties, shall be shared equally by the Parties. Any award rendered by the
arbitrator(s) shall be final and binding upon the Parties. Judgment upon the
award may be entered in any court of competent jurisdiction. If a Party fails to
proceed with arbitration, unsuccessfully challenges the arbitration award, or
fails to comply with the arbitration award, the other Party is entitled to
costs, including reasonable attorneys' fees, for having to compel arbitration or
defend or enforce the award.

       SECTION 13.2. GOVERNING LAW. This Agreement shall be governed and
construed in accordance with the internal, substantive laws of the New

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -39-

<Page>

York to the exclusion of any choice or conflict of laws rule or provision that
would result in the application of the substantive law of any other
jurisdiction. Notwithstanding the foregoing, the laws of the applicable
jurisdiction in the Territory shall be used for purposes of governing and
construing Section 10.1(e) of this Agreement.

       SECTION 13.3. AMENDMENT AND WAIVER. No provision of or right under this
Agreement shall be deemed to have been waived by any act or acquiescence on the
part of either Party, its agents or employees, but only by an instrument in
writing signed by an authorized officer of each Party. No waiver by either Party
of any breach of this Agreement by the other Party shall be effective as to any
other breach, whether of the same or any other term or condition and whether
occurring before or after the date of such waiver.

       SECTION 13.4. INDEPENDENT CONTRACTORS. Each Party represents that it is
acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of any Third Party. This Agreement and the relations
hereby established by and between Celltech and NeoGenesis do not constitute a
partnership, joint venture, franchise, agency or contract of employment. Neither
Party is granted, and neither Party shall exercise, the right or authority to
assume or create any obligation or responsibility on behalf of or in the name of
the other Party or its Affiliates. NeoGenesis shall be solely responsible for
compensating all its personnel and for payment of all related FICA, workers'
compensation, unemployment and withholding taxes. Celltech shall not provide
NeoGenesis personnel with any benefits, including but not limited to
compensation for insurance premiums, paid sick leave or retirement benefits.

       SECTION 13.5. ASSIGNMENT. Neither Party may assign this Agreement or any
of its rights and obligations under this Agreement without the prior written
consent of the other Party; PROVIDED, that either Party may assign this
Agreement to (a) any Person to which such Party transfers all or substantially
all of its assets or with which such Party is consolidated or merged; (b) any
Person that owns a majority of the voting stock of such Party; or (c) a single
Person of which such Party owns a majority of the voting stock; PROVIDED,
FURTHER, that in each instance the assignee expressly assumes all obligations
imposed on the assigning Party by this Agreement in writing and the other Party
is notified in advance of such assignment. Notwithstanding the foregoing,
Celltech shall have the right to assign its rights to Designated Compounds and
Licensed Products without the consent of NeoGenesis PROVIDED that any such
assignee expressly assumes all obligations imposed on Celltech by this Agreement
and agrees in writing that NeoGenesis shall

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -40-

<Page>

have the right to enforce the terms of this Agreement directly against such
assignee.

       SECTION 13.6. SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure
to the benefit of the Parties hereto and their respective successors and
permitted assigns.

       SECTION 13.7. NOTICES. Unless otherwise provided herein, any notice,
report, payment or document to be given by one Party to the other shall be in
writing and shall be deemed given when delivered personally or sent by an
internationally recognized overnight courier (such notice sent by courier to be
effective one business day after it is deposited with such courier), or sent by
telefax (such notice sent by telefax to be effective when sent, if confirmed by
overnight courier as aforesaid) to the address set forth on the signature page
to this Agreement or to such other address as any Party may designate as to
itself by written notice to the other Party.

       SECTION 13.8. SEVERABILITY. In the event any provision of this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other term or provision hereof. The Parties agree that they will negotiate in
good faith or will permit a court or arbitrator to replace any provision hereof
so held invalid, illegal or unenforceable with a valid provision which is as
similar as possible in substance to the invalid, illegal or unenforceable
provision.

       SECTION 13.9. CAPTIONS. Captions of the sections and subsections of this
Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or
construction of the terms and conditions hereof.

       SECTION 13.10. WORD MEANINGS. Words such as herein, hereinafter, hereof
and hereunder refer to this Agreement as a whole and not merely to a section or
paragraph in which such words appear, unless the context otherwise requires. The
singular shall include the plural, and each masculine, feminine and neuter
reference shall include and refer also to the others, unless the context
otherwise requires.

       SECTION 13.11. ENTIRE AGREEMENT. The terms and provisions contained in
this Agreement (including any Attachments or Exhibits) and the Stock Purchase
Agreement (including any Attachments and Exhibits) constitute the entire
understanding of the Parties with respect to the transactions and matters
contemplated by the Parties and supersede all previous communications,
representations, agreements and understandings

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -41-

<Page>

relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the Parties not contained in
this Agreement or the Stock Purchase Agreement shall be of any force or effect.
No agreement or understanding extending this Agreement or varying its terms
(including any inconsistent terms in any purchase order, acknowledgment or
similar form) shall be binding upon either Party unless it is in a writing
specifically referring to this Agreement and signed by a duly authorized
representative of the applicable Party.

       SECTION 13.12. RULES OF CONSTRUCTION. The Parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be construed against either Party by
reason of the extent to which such Party or its professional advisors
participated in the preparation of this Agreement.

       SECTION 13.13. COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. In making proof of this
Agreement, it shall not be necessary to produce or account for more than one
such counterpart.

       SECTION 13.14. FORCE MAJEURE. Except as otherwise provided in this
Agreement, in the event that a delay or failure of a Party to comply with any
obligation, other than a payment obligation, created by this Agreement is caused
by a Force Majeure condition, that obligation shall be suspended during the
continuance of the Force Majeure condition.

       SECTION 13.15. FURTHER ASSURANCES. Each Party covenants and agrees that,
subsequent to the execution and delivery of this Agreement and without any
additional consideration, it will execute and deliver any further legal
instruments and perform any acts which are or may become reasonably necessary to
effectuate the purposes of this Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -42-

<PAGE>

       IN WITNESS WHEREOF the Parties have caused this Agreement to be executed
on their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

NEOGENESIS DRUG DISCOVERY, INC.            CELLTECH R & D LIMITED

BY: /s/ ALLEN H. MICHELS                   BY: /s/ MELANIE C. LEE
-------------------------------------      -------------------------------------
Allen H. Michels, Chief Executive Officer  Melanie C. Lee, Research Director

NOTICE ADDRESS:                            NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.            Celltech R & D Limited
840 Memorial Drive                         Attention: Legal Department
Cambridge,  MA  02139                      208 Bath Road
USA                                        Slough, Berkshire, SLI 3WE
Phone: 617.868.1500                        England
Fax: 617.868.1515                          Phone: +44 (1753) 534655
                                           Fax: +44 (1753)447859

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      -43-<Page>

                                                                   Exhibit 10.12

                                    AGREEMENT

This Agreement (the "Agreement") is entered into as of the last date of
signature appearing below (the "EFFECTIVE DATE") between NeoGenesis Drug
Discovery, Inc., a Delaware corporation ("NEOGENESIS") and Schering-Plough Ltd.,
a Swiss corporation ("SPL"), and sets forth the terms and conditions that will
apply to the provision by NeoGenesis to SPL of certain screening and analysis
services.

                                   BACKGROUND
SPL is interested in identifying potential pharmaceutical products for treatment
of certain human diseases and wishes to identify compounds that exhibit a high
degree of chemical binding and functional activity to specific protein targets.
NeoGenesis has certain technology and know-how, including screening processes of
libraries of mass-encoded small molecule compounds, relating to the
identification, discovery, validation and optimization of novel compounds which
may be useful for development of novel therapeutics employing targets implicated
in a disease process. The parties wish to pursue a collaborative screening
process to identify compounds exhibiting a high degree of chemical binding
activity to targets designated by SPL from among the NeoGenesis libraries of
mass-encoded small molecule compounds and which have activity in target-specific
functional assays. The terms and conditions set forth below shall govern the
performance of such collaborative effort.

1.       DEFINITIONS.

     The following capitalized terms used in this Agreement, whether in the
singular or plural, shall have the meaning set forth below.

         1.1   "ACTIVE COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which (a) has Kd values of [*] and (b) has demonstrated bioactivity in
functional assays against the applicable Target as determined by the Steering
Committee following SPL's performance of the procedure specified in Paragraph 3
of ATTACHMENT A.

         1.2   "AFFILIATE" means with respect to either party, any Person that,
directly or indirectly, is controlled by, controls or is under common control
with such party. For purposes of this definition, control means, with respect to
any Person, the direct or indirect ownership of [*] or more of the outstanding
voting securities of an entity, or the right to receive [*] or more of the
profits or earnings of an entity, or the possession otherwise, directly or
indirectly, of the power to direct the management, business and affairs of an
entity.

         1.3   "ALIS" means the Automated Ligand Identification System, an
automated, ultra-high throughput ligand selection system proprietary to
NeoGenesis that is used to identify multiple classes of chemical ligands against
a target protein.

         1.4   "CHEMOTYPE"  means a family or group of  Compounds  closely
structurally  related to one or more Active Compounds.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

         1.5   "CIP" means "Carriage and Insurance Paid", as that expression is
defined in Incoterms 2000, ICC Publishing S.A.

         1.6   "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to (a)
any objective by either party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (b) with respect to any
objective relating to the development or commercialization of any Licensed
Product efforts and resources normally used by such party with respect to a
product owned by such party or to which such party has similar rights which is
of similar market potential at a similar stage in the development or life of
such product, taking into account issues of safety, efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved, profitability of the product and other
relevant commercial factors.

         1.7   "COMPOUND" shall mean all proprietary compounds contained in the
NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened
by NeoGenesis against one or more Targets in performance of the Screening
Program.

         1.8   "COMPOUND PATENT RIGHTS" shall mean any Schering Patent Rights
which claim Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Product, or the manufacture or use thereof.

         1.9   "CONFIDENTIAL INFORMATION" means any proprietary or confidential
information of either party (including but not limited to all Schering Know-How
and all NeoGenesis Know-How) disclosed to the other party pursuant to this
Agreement in written or other tangible medium and marked as confidential, or if
disclosed orally or displayed, confirmed in writing within thirty (30) days of
disclosure.

         1.10  "DERIVATIVE COMPOUND" means a compound which is derived from a
Selected Compound or a Lead Compound by or on behalf of SPL, or by NeoGenesis in
performance of medicinal chemistry optimization pursuant to Section 2.2(b), and
having activity against the same Target as such Selected Compound and/or Lead
Compound. A compound will be deemed to have been "derived" from a Selected
Compound or a Lead Compound if it (i) is the result of a chemical modification
made to a Selected Compound or Lead Compound, (ii) is otherwise derived from a
chemical synthesis program based upon a Selected Compound or Lead Compound, or
(iii) is based on proprietary structure-function data obtained from Selected
Compounds or Lead Compounds. Derivative Compounds will include, without
limitation, all Compounds contained in the NeoMorph Focused Library(ies).

         1.11  "DESIGNATED COMPOUND" means any Selected Compound or Derivative
Compound which becomes the subject of a development program conducted by SPL or
its Affiliates, as further defined in Section 2.8(b) of the Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

         1.12  "EMEA" means the European Medicines Evaluation Authority, or any
successor thereto.

         1.13  "FDA" means the United States Food and Drug Administration, or
any successor thereto.

         1.14  "FD&C ACT" means the United States Federal Food, Drug and
Cosmetic Act of 1938, as amended.

         1.15  "FIELD" means the treatment or prevention of any disease or
condition in humans or animals.

         1.16  "FIRST COMMERCIAL SALE" means, with respect to a Licensed
Product, the first sale (or other transfer for value in an arms-length
transaction) for end use of such Licensed Product in a country within the
Territory after obtaining all necessary Regulatory Approvals for the marketing
and sale of the Licensed Product in such country.

         1.17  "FTE" means the equivalent of a full time (12) months (including
normal vacations, sick days and holidays) work of an individual scientist,
carried out by one or more employees or agents of NeoGenesis, who devotes a
portion of his or her time to performing the Screening Program.

         1.18  "GOOD CLINICAL PRACTICE" means the then current standards for
clinical trials for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good clinical practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Clinical Practices.

         1.19  "GOOD LABORATORY PRACTICE" means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and
applicable regulations promulgated thereunder, as amended from time to time, and
such standards of good laboratory practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Laboratory Practices.

         1.20  "GOOD MANUFACTURING PRACTICE" means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good manufacturing practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

         1.21  "IMPROVED ACTIVE COMPOUND" means any Compound identified as a
result of initial optimization of one or more Active Compounds by NeoGenesis (as
described in paragraph 4 of ATTACHMENT A) and having binding activity when
tested against a Target pursuant to the Screening Program with a Kd value of
[*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

         1.22  "IND" means an investigational new drug application, as defined
in the FD&C Act and applicable regulations thereunder, or any equivalent
document,filed with the FDA and necessary for beginning clinical trials of any
Licensed Product in humans or any application or other documentation filed with
any Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Licensed Product in humans in that country.

         1.23  "INVENTIONS" means any and all discoveries, developments,
inventions and innovations (whether or not patentable) that are conceived and/or
reduced to practice (i) solely by one or more employees or consultants of
NeoGenesis in connection with the performance of the Screening Program; (ii)
solely by one or more employees or consultants of SPL in connection with the
performance of the Screening Program; or (iii) jointly by one or more employees
or consultants of NeoGenesis and one or more employees or consultants of SPL in
connection with the performance of the Screening Program.

         1.24  "LEAD COMPOUNDS" means those Selected Compounds which are
designated by SPL as Lead Compounds (pursuant to Section 2.2(b) of the
Agreement) for the performance of medicinal chemistry optimization by
NeoGenesis.

         1.25  "LICENSED PRODUCT(S)" means any pharmaceutical product which
contains as an active ingredient a Selected Compound or Derivative Compound, and
which is covered by one or more claims of a NeoGenesis Patent Right and/or
Compound Patent Right.

         1.26  "MAJOR MARKET COUNTRY" means the United States, Japan, or any
three or more of the following European countries, the United Kingdom, France,
Germany, Italy or Spain, as the case may be.

         1.27  "NDA" means a new drug application or product license
application,each as defined in the FD&C Act and applicable regulations
thereunder, seeking approval to market and sell a Licensed Product in the United
States.

         1.28  "NEOGENESIS KNOW-HOW" means all proprietary information, data and
know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products together with, where applicable, any analogs, derivatives or
fragments thereof, which is (i) owned or controlled by NeoGenesis as of the
Effective Date, or (ii) developed by or on behalf of NeoGenesis during the term
of this Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

         1.29  "NEOGENESIS PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by NeoGenesis
(and/or any of its Affiliates), or to which NeoGenesis (and/or any of its
Affiliates) through license or otherwise acquires rights, and which have claims
covering: (i) the NeoMorph Screening Library, the NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS or QSCD; or (ii) any Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products, or the manufacture or use of any of the foregoing; or (iii)
NeoGenesis Inventions (as defined in Section 3.5(a)); or (iv) NeoGenesis' rights
in Joint Inventions (as defined in Section 3.5(b)), as well as all divisionals,
continuations, continuations-in-part, reissues, re-examinations, extensions,
renewals, registrations, supplementary protection certificates and/or foreign
counterparts of any of the foregoing which are owned or controlled by NeoGenesis
and its Affiliates during the term of this Agreement. The NeoGenesis Patent
Rights shall include those listed in ATTACHMENT B pursuant to Section 3.8.

         1.30  "NEOMORPH CHEMISTRY" means the process, proprietary to
NeoGenesis, of forming libraries and sub-libraries of discrete compounds by
coupling a broad set of diverse cores with diverse sets of building blocks
employing proprietary mass-coding algorithms.

         1.31  "NEOMORPH FOCUSED LIBRARIES" means any and all compounds or
collections of compounds synthesized by NeoGenesis which are derived from or
based upon Lead Compounds, and which are designed to optimize the structure of
such Lead Compounds with respect to activity against one or more specific
Targets.

         1.32  "NEOMORPH SCREENING LIBRARY" means the entire collection of
libraries consisting of mass-encoded small molecule organic compounds owned by
NeoGenesis and developed with NeoMorph Chemistry, comprising at least twelve
million (12,000,000) different compounds.

         1.33  "NET SALES" means the proceeds actually received by SPL or any of
its Affiliates or sub-licensees on all sales of a Product in the Territory to an
unaffiliated third party (whether an end-user, a distributor or otherwise), and
exclusive of intercompany transfers or sales, less the reasonable and customary
deductions from such gross amounts including: (i) normal and customary trade,
cash and quantity discounts, allowances and credits; (ii) credits or allowances
actually granted for damaged goods, returns or rejections of a Product and
retroactive price reductions; (iii) sales or similar taxes (including duties,
value added taxes or other governmental charges otherwise measured by the
billing amount, when included in billing); (iv) freight, postage, shipping,
customs duties and insurance charges; (v) charge back payments and rebates
granted to managed health care organizations or to federal, state and local
governments, their agencies, and purchasers and reimbursers or to trade
customers, including but not limited to, wholesalers and chain and pharmacy
buying groups; (vi) commissions paid to third parties other than sales personnel
and sale representatives or sales agents; and (vii) rebates (or equivalents
thereof) granted to or charged by national, state or local governmental
authorities in countries other than the United States. If a Product is sold in
the form of a combination product with one or more other active ingredients, Net
Sales for such combination product with one or more active ingredients will be
calculated by multiplying actual Net Sales of such combination product by the
fraction A/(A+B) where:
         "A" is the invoice price of the Product contained in the combination
         product if sold separately by SPL or any of its Affiliates or
         sub-licensee; and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

         "B" is the aggregate invoice price of any other active component(s) in
         the combination product if sold separately by SPL or any of its
         Affiliates or sub-licensee.
If one or more of the other active ingredients in the combination product are
not sold separately, then the above formula shall be modified such that:
         "A" shall be the fully allocated manufacturing cost to SPL or any of
         its Affiliates or sub-licensee of the Product, and
         "B" shall be the fully allocated manufacturing cost to SPL or any of
         its Affiliates or sub-licensee of any other active component(s) in the
         combination,
such fully allocated manufacturing costs being determined in accordance with
generally accepted accounting principles.

         1.34  "PERSON" means any individual, corporation, association,
partnership (general or limited), joint venture, trust, estate, limited
liability company, limited liability partnership, unincorporated organization,
government (or any agency or political subdivision thereof) or other legal
entity or organization.

         1.35  "PRELIMINARY COMPOUND" means any Compound identified as having
binding activity when tested against a Target pursuant to the Screening Program
and which has Kd values of [*] or such other binding affinity threshold for a
specific Target as shall be agreed upon by the parties in writing.

         1.36  "QSCD" means Quantisized Surface Complimentary Diversity, a model
proprietary to NeoGenesis, in terms of which discrete chemical compliments to
the surfaces of a Target are defined.

         1.37  "REGULATORY APPROVAL" means, for any country in the Territory,
those authorizations by the appropriate Regulatory Authority(ies) required for
the manufacture, importation, distribution, marketing, promotion, pricing and
sale of the Licensed Product(s) in such country, including, without limitation,
any NDAs, Health Registration Dossiers, supplements, amendments, pre- and
post-approvals, marketing authorizations based upon such approvals (including
any prerequisite manufacturing approvals or authorizations related thereto) and
pricing, third party reimbursement or labeling approval(s), technical, medical
and scientific licenses, registrations or authorizations.

         1.38  "REGULATORY AUTHORITY" means any national, supra-national,
regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity in the Territory, including, without
limitation, the FDA and the EMEA.

         1.39  "SCHERING KNOW-HOW" means all information, data and know-how
which is owned or controlled by SPL or its Affiliates as of the Effective Date,
or developed by or on behalf of SPL or its Affiliates during the term of this
Agreement, related to the Screening Program, the Targets, Active Compounds,
Improved Active Compounds, Selected Compounds, Derivative Compounds, Designated
Compounds or Licensed Products. Schering Know-How includes, without limitation,
all processes, formulas, discoveries and inventions whether relating to
biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical safety, quality control and clinical data, including, without
limitation, clinical study data related to Designated Compounds and/or Licensed
Products. Schering Know-How also includes relevant medical information relating
to the Licensed Products (such as Regulatory Authority questions, responses
thereto and adverse drug event history) in the possession of SPL, its Affiliates
or sublicensees.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

         1.40  "SCHERING PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by SPL (and/or any
of its Affiliates), or to which SPL (and/or any of its Affiliates) through
license or otherwise acquires rights, which have claims covering: (i) Selected
Compounds, Derivative Compounds, Designated Compounds or Licensed Products, or
the manufacture or use of any of the foregoing; (ii) the Targets; or (iii)
Schering Inventions (as defined in Section 3.5(a)) or Joint Inventions (as
defined in Section 3.5(b)), as well as all divisionals, continuations,
continuations-in-part, reissues, re-examinations, extensions, renewals,
registrations, supplementary protection certificates and/or foreign counterparts
of any of the foregoing which are owned or controlled by SPL and its Affiliates
during the term of this Agreement.

         1.41  "SELECTED COMPOUND" means any and all Active Compounds and/or
Improved Active Compounds which have demonstrated bioactivity in secondary
functional assays against the applicable Target as determined by SPL in
accordance with Section 2.7, and which are designated by SPL pursuant to Section
2.7(a) of the Agreement.

         1.42  "SCREENING PROGRAM" means the screening program described in
ATTACHMENT A (including as it may be amended by the Steering Committee) to
identify Active Compounds and Improved Active Compounds against one or more
Targets.

         1.43  "STEERING COMMITTEE" means the joint steering committee
established by the parties pursuant to Section 2.6 of the Agreement.

         1.44  "SUCCESS CRITERIA" means the success criteria, to be defined by
the Steering Committee with respect to a given Target, for determining whether
or not Selected Compounds and/or Derivative Compounds have a certain desired
degree of chemical binding activity, activity in Target-based functional assays,
and other chemical, biological, pharmacological and toxicological properties,
suitable for drug development.

         1.45  "TARGET" means a specific biological target (including, without
limitation, nucleic acids and proteins, and/or active fragments thereof) that a
small molecule is screened against in order to determine whether the small
molecule demonstrates a specific biochemical or pharmaceutical effect, selected
by SPL and accepted by NeoGenesis in accordance with Section 2.1(b) for which
NeoGenesis will perform the Screening Program.

         1.46  "TERRITORY" means all of the countries and territories of the
world (including Puerto Rico), except for the United States and it territories,
possessions and commonwealths other than Puerto Rico.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

         1.47  "US AGREEMENT" means the contemporaneous Agreement entered into
by NeoGenesis and Schering's Affiliate, Schering Corporation relating to the
United States and its territories, possessions and commonwealths, excluding
Puerto Rico.

         1.48  "VALID CLAIM" means a composition-of-matter or method-of-use
claim of an issued and unexpired patent included within (i) the NeoGenesis
Patent Rights or (ii) Compound Patent Rights, and in each case which has not
been revoked or held unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been disclaimed, denied or
admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise.

2.       SCREENING PROGRAM

         2.1   DELIVERY OF TARGETS.

               (a) SPL shall deliver one or more of the Targets listed in
ATTACHMENT A to NeoGenesis for screening within [*] following the Effective
Date. SPL shall provide the Targets in the quantities and formats specified in
ATTACHMENT A, along with a written description of the concentration and volume
of the Target.

               (b) From time to time during the term of this Agreement, SPL may
select additional Targets for screening under the Screening Program. In such
event, SPL shall notify NeoGenesis in writing of the additional Target(s) to be
provided for screening. NeoGenesis shall notify SPL in writing within [*] of
such notice whether the Target is approved for inclusion in the Screening
Program. Subject to the terms of Section 2.1(c), the Target will be accepted for
inclusion in the Screening Program unless the proposed Target: (i) is subject to
an exclusivity period in an existing agreement between NeoGenesis and a third
party; or (ii) is the subject of an existing internal research program at
NeoGenesis. The parties shall promptly amend ATTACHMENT A to include each
additional Target added to the Screening Program pursuant to this Section
2.1(b). SPL shall thereafter provide the Targets to NeoGenesis in appropriate
quantities and formats for screening, along with a written description of the
concentration and volume of the Target. The Steering Committee shall establish a
schedule for delivery of the additional Targets to NeoGenesis based on the time
necessary to prepare and validate the approved Target; PROVIDED, that such
period shall not exceed [*] from NeoGenesis' notice to SPL that a Target is
approved.

               (c) The parties acknowledge and agree that the Screening Program
will be limited to active screening and/or optimization programs at NeoGenesis
directed to [*] distinct Targets, based upon research support for [*] FTEs at
NeoGenesis. In the event that the screening and optimization programs directed
to a specific Target are completed or discontinued, SPL shall have the right to
select an additional Target to replace such discontinued Target. Further, in the
event that the number of FTEs working on the Screening Program is increased,
pursuant to Section 2.2(f), the limit on the number of active Targets shall be
increased proportionately.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

               (d) All Targets to be supplied by SPL hereunder shall be
delivered CIP to NeoGenesis' Cambridge facility using a carrier selected by SPL.
The Targets are and shall remain the sole and exclusive property of SPL.
NeoGenesis will only use the Targets for screening in performance of the
Screening Program and will not use the Targets for any other purpose without
SPL's prior written consent.

               (e) SPL will identify to NeoGenesis all Targets provided by SPL
for use in the Screening Program. The identity of the Targets and any other
information related thereto will be considered Schering Confidential
Information. During the applicable Exclusivity Period (as defined below) for a
Target, NeoGenesis shall not screen the NeoMorph Screening Library for itself or
for any third party against the same Target, without SPL's prior written
approval. The "Exclusivity Period" for a given Target shall begin on the date
the Target is accepted for inclusion in the Screening Program pursuant to
Section 2.1(b) and shall expire:

              (i)  if NeoGenesis does not perform any medicinal chemistry
                   optimization activities pursuant to Section 2.2(b) to develop
                   NeoMorph Focused Libraries with respect to the Target, [*]
                   after NeoGenesis delivers to SPL the Final Target Report with
                   respect to such Target; or

              (ii) if NeoGenesis does perform medicinal chemistry optimization
                   activities pursuant to Section 2.2(b) to develop NeoMorph
                   Focused Libraries with respect to such Target, [*] after the
                   later of the date upon which SPL files an IND for a Licensed
                   Product directed to the Target or discontinues the
                   development of Licensed Products against such Target.

Upon the expiration of the Screening Program, and annually thereafter, SPL
shall notify NeoGenesis in writing of the list of Targets with respect to
which SPL has ongoing programs to discover and develop Licensed Products. SPL
shall promptly notify NeoGenesis in writing in the event that it discontinues
the development of Licensed Products against a Target. For purposes of this
Section 2.1(e), SPL shall be deemed to have discontinued development of
Licensed Products against a Target if it ceases to maintain a minimum of [*]
FTEs assigned full time to work on the discovery and pre-clinical development
of Licensed Products against a Target. During the term of the Screening
Program, if NeoGenesis intends to screen the NeoMorph Screening Libraries
(including all newly created Compounds contained therein) for a third party
against a Target with respect to which SPL's Exclusivity Period has expired
pursuant to subsection (i), above, NeoGenesis shall first offer SPL the
opportunity to screen the NeoMorph Screening Libraries against the Target.
SPL shall have [*]in which to accept or reject such offer. If SPL accepts the
offer, such screening shall be conducted under the terms of this Agreement
and SPL shall have a renewed Exclusivity Period with respect to such Target.
If NeoGenesis does perform medicinal chemistry optimization activities
pursuant to Section 2.2(b) to develop NeoMorph Focused Libraries with respect
to a Target, then notwithstanding the expiration of the applicable
Exclusivity Period pursuant subsection (ii), above, NeoGenesis shall be
permanently prohibited from screening the NeoMorph Screening Libraries
against the Target for itself and in such instance may only perform such
screening for third parties. In the event that NeoGenesis does screen the
NeoMorph Screening Libraries against a Target for itself or a third party as
permitted under this Section 2.1(e), NeoGenesis shall not use (i) any
Schering Know-How (including without limitation any of SPL's proprietary
information related to the existence of or uses for the Target), or (ii) any
NeoGenesis Know-How related to the Target and developed in performance of the
Screening Program, in connection with such screening activities.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

               (f) For purposes of this Agreement, and in particular with
respect to the provisions of Sections 2.1(b) and 2.1(e), a Target identified by
SPL for screening under this Agreement will encompass the nucleic acid or amino
acid sequence of the actual Target to be provided by SPL, and in the case of a
Target which is a human biological molecule, shall be further defined by the
nucleic acid or protein encoded by the specified genomic location of origin
(which will be identified by SPL in the notification to NeoGenesis of a proposed
Target pursuant to Section 2.1(b)) and natural polymorphic variants thereof such
as SNP, insertion, deletion and splice variants or the synthetic equivalent
thereof. If a Target can not be distinguished from another biological target
based on the above, then the Target shall be considered the same as another
biological target if the other biological target comprises a contiguous region
of [*] identical to the Target or is derived from such Target by modification.
If a Target is a biological molecule of non-human origin, then the Target shall
be considered the same as another target if they are both derived from the
comparable chromosomal location of related strains of the applicable species.
For example, a target defined by [*] shall be considered the same as a target
specified by the [*] including targets derived by modification. Similarly, a
target specified by a chromosomal location in one particular strain of [*] shall
be considered identical to a target specified by the analogous location in a
second strain of bacteria. If the chromosomal locations of two targets can not
be defined, then a target shall be considered the same as a second target if it
comprises a contiguous region of [*] to said second target or is derived from
such a second Target by modification. It is expressly understood that a
non-human target falling outside the criteria defined above may not be screened
using the NeoMorph Screening Libraries with the intent of developing a product
affecting the activity of a human target that would meet the identity criteria.
For clarity, a primate ortholog of a human gene or protein may not be screened
using the Neomorph Screening Libraries if the intent is to develop a product for
human use against an otherwise excluded target. Nothing in this paragraph shall
limit the screening of non-human targets for non-human usage.

         2.2   SCREENING PROGRAM.

         (a)   During the term of the Screening Program, NeoGenesis will utilize
its proprietary technology and methods, including without limitation the ALIS
method, to screen the NeoMorph Screening Library for activity with respect to
each Target for purposes of identifying Active Compounds for further evaluation
and development. Screening will be performed pursuant to the protocol for the
Screening Program, as set forth in paragraphs 1-2 of ATTACHMENT A. With respect
to each accepted Target provided by SPL under Section 2.1, NeoGenesis shall
complete the screening of the NeoMorph Screening Library within [*] following
the date that the Target is delivered to NeoGenesis. The results of such
screening shall be provided to SPL through the Steering Committee in the form of
a Preliminary Target Report (as defined in ATTACHMENT A). NeoGenesis shall
provide SPL with samples of all Preliminary Compounds selected by the Steering
Committee for further evaluation by SPL pursuant to paragraph 3 of ATTACHMENT A.
SPL will evaluate such Preliminary Compounds in Target-based functional assays
and/or secondary assays to identify Active Compounds, and will report the
results of such evaluations to the Steering Committee, and NeoGenesis will
promptly thereafter provide SPL with all available structural information for
each Active Compound so identified. NeoGenesis will, at the direction of the
Steering Committee, conduct initial optimization activities, as described in
paragraph 4, of ATTACHMENT A, to identify Improved Active Compounds. It is
acknowledged that all compounds generated from such initial optimization
activities and having activity against the relevant Target shall be deemed to be
Improved Active Compounds; provided that such optimization activities and all
Improved Active Compounds arising therefrom shall not be deemed to be
optimization of Lead Compounds for purposes of Section 2.1(e) or for determining
SPL's financial obligations under Sections 4.3 and 4.4.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

         (b)   NeoGenesis will, at the direction of the Steering Committee,
conduct a full program of medicinal chemistry optimization activities, based
upon those Selected Compounds identified as Lead Compounds that are suitable for
optimization. Such optimization activities shall include the design and
preparation of NeoMorph Focused Libraries based upon such Lead Compounds, and
the screening of the NeoMorph Focused Libraries against the relevant Target(s).
The parties acknowledge and agree that, subject to the terms of Sections 3.5(a),
and effective on the date that SPL acquires an exclusive license to the relevant
Selected Compound(s) pursuant to Sections 2.7(c), 3.1 and 3.2, any and all
Compounds which are included in NeoMorph Focused Libraries prepared against the
relevant Target shall be the exclusive property of SPL. NeoGenesis shall not use
the NeoMorph Focused Libraries, any Compounds contained therein, or any
structural information or other know-how related thereto, for any purpose other
than the performance of the Screening Program. NeoGenesis shall not provide any
NeoMorph Focused Libraries, any Compounds contained therein, or any structural
information or other NeoGenesis Know-How related thereto, to any third party
without the prior written consent of SPL. Notwithstanding the foregoing
limitations, it is expressly understood and agreed that NeoGenesis may, through
use of the NeoMorph Screening Library on behalf of third parties independently
generate results or data similar to the results or data generated in the course
of the Screening Program and that the use of such independently generated
results or data shall not constitute a breach of NeoGenesis' obligations under
this Section 2.2(b); PROVIDED, that NeoGenesis has complied with its obligations
to mask Compounds in accordance with Section 2.3 of this Agreement.

         (c)   NeoGenesis shall not perform any tests on or using any of the
Targets that are outside the scope of the Screening Program, or attempt to
modify the Targets supplied by SPL, including, without limitation, the making of
any derivatives, analogs or components thereof. In the event that NeoGenesis
does not consume all of the Targets supplied by SPL in performance of the
Screening Program, NeoGenesis will upon completion of the Screening Program
promptly, return to SPL any quantities of such Target(s) and any derivatives,
analogs or components thereof.

         (d)   The term of the Screening Program shall begin on the Effective
Date and shall continue in effect for a period of two (2) years. SPL shall have
the right to extend the term of the Screening Program for up to three additional
one (1) year terms, by providing NeoGenesis with written notice to that effect
at least sixty (60) days prior to the expiration of the then current term of the
Screening Program and subject to the provisions of Section 4.1 concerning
research funding for such extension term. The Screening Program shall remain in
effect for the period specified in this Section 2.2(d), including as it may be
extended, unless sooner terminated in accordance with Section 8.2 or Section
9.5.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

         (e)   During the term of the Screening Program, upon request,
NeoGenesis shall provide SPL with samples of Selected Compounds and Derivative
Compounds from NeoMorph Focused Libraries in a form and quantity suitable to
enable SPL to conduct additional testing to confirm the specific binding
activity of such Compounds and to evaluate and determine the functional activity
of the Selected Compounds and/or Derivative Compounds. SPL may also elect to
perform medicinal chemistry research using such Selected Compounds and/or
Derivative Compounds to discover and evaluate additional Derivative Compounds.
SPL shall keep NeoGenesis reasonably informed of the results of such activities
through the Steering Committee.

         (f)   During the term of the Screening Program NeoGenesis shall provide
appropriately trained dedicated scientific personnel to perform the Screening
Program in accordance with the terms of this Agreement. During the initial two
(2) year term of the Screening Program, NeoGenesis shall provide such support at
the level of [*] FTEs during each year of the Screening Program, it being
understood that NeoGenesis may allocate such FTE time within any calendar year
in a manner consistent with its obligations under the Screening Program based on
the workload for such Screening Program at any particular time during the
Screening Program. In addition, NeoGenesis will, upon written request by SPL,
provide additional FTE support for the Screening Program of up to an additional
[*] FTEs during the term of the Screening Program. In the event that the term of
the Screening Program is extended pursuant to Section 2.2(d), the Steering
Committee shall establish the number of FTEs to be provided by NeoGenesis for
performance of the Screening Program during the extended term.

         (g)   NeoGenesis shall monitor expenditures, in accordance with its
corporate policies, to ensure that the funds provided by SPL are spent in
accordance with this Agreement. NeoGenesis shall keep and maintain adequate
books and records to furnish information to SPL regarding calculation of the
amounts expended by NeoGenesis on the Screening Program according to the
provisions of this Agreement. During the Screening Program and for two (2)
years following the expiration of the Screening Program, NeoGenesis shall
permit SPL to examine such books and records during normal business hours,
upon thirty (30) days notice to NeoGenesis. Upon the expiration of the two
(2) year period, the calculation of the amounts expended on each year of the
Screening Program shall be binding and conclusive upon the parties and
NeoGenesis shall be released from any further accountability with respect to
the Screening Program.

         (h)   NeoGenesis will perform its screening obligations in accordance
with all applicable laws, rules and regulations.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

         2.3   COMPOUND MASKING.

         (a)   Upon the identification of Preliminary Compounds and Active
Compounds through screening of the NeoMorph Screening Library against a
particular Target, NeoGenesis shall mask such Preliminary Compounds and Active
Compounds from the NeoMorph Screening Library by removing such Compounds from
the compound resource information associated with the NeoMorph Screening Library
and shall take all other steps reasonably necessary to ensure that information
with regard to such Compounds is not available or accessible to any third party,
including third parties for which NeoGenesis is screening the NeoMorph Screening
Library against other biological targets. NeoGenesis shall similarly mask any
Improved Active Compounds which are discovered pursuant to Section 2.2(a).

         (b)   NeoGenesis shall have the right to unmask any Preliminary
Compounds which are not confirmed as Active Compounds and are not in the same
Chemotype as such Active Compounds. In addition, upon expiration of SPL's right
to designate Selected Compounds with regard to a specific Target, pursuant to
Section 2.7(a), NeoGenesis shall have the right to unmask any Active Compounds
and/or Improved Active Compounds identified through screening against that
Target which are not (i) Selected Compounds or (ii) Preliminary Compounds,
Active Compounds and/or Improved Active Compounds of the same Chemotype as such
Selected Compounds.

         2.4   GRANT OF RESEARCH LICENSES.

         (a)   SPL hereby grants NeoGenesis a nonexclusive, nontransferable,
royalty-free license under the Schering Patent Rights and to use the Schering
Know-How solely for the purpose of conducting the Screening Program. NeoGenesis
will not use Schering Know-How or Schering Patent Rights for any other purpose,
and shall not offer or grant a sub-license to use Schering Know-How or Schering
Patent Rights to any third party, without the express prior written consent of
SPL.

         (b)   NeoGenesis hereby grants SPL a nonexclusive, nontransferable,
royalty-free license under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How solely for the purpose of conducting SPL's activities under
the Screening Program. SPL will not use NeoGenesis Know-How or NeoGenesis Patent
Rights for any other purpose, and shall not offer or grant a sub-license to use
NeoGenesis Know-How or NeoGenesis Patent Rights to any third party, without the
express prior written consent of NeoGenesis (not to be unreasonably withheld).

         (c)   With respect to Selected Compounds identified pursuant to Section
2.7(a), NeoGenesis hereby grants SPL, during the relevant Option Period (as
defined in Section 2.7(b)), an exclusive, nontransferable, royalty-free license
under the NeoGenesis Patent Rights and to use the NeoGenesis Know-How solely for
the purpose of performing research and development work necessary to enable SPL
to determine whether or not to exercise its option to obtain an exclusive
license with respect to such Selected Compounds.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                                13
<Page>

         2.5   RECORD KEEPING AND REPORTS.

         (a)   NeoGenesis will keep and maintain complete and accurate records
of all laboratory data and results generated in the course of the Screening
Program, including records of all Preliminary Compounds, Active Compounds, and
Improved Active Compounds identified, and any Inventions discovered and/or
developed by NeoGenesis, during the Screening Program. All such written records
of NeoGenesis shall be open to inspection by SPL during normal business hours
upon reasonable prior written notice; provided, however, that except with
respect to (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds, NeoGenesis shall not provide SPL with access to any chemical
structures or structural data.

         (b)   NeoGenesis shall provide SPL with reasonably-detailed written
reports describing the results of the research performed pursuant to the
Screening Program including all Preliminary Compounds, Active Compounds and
Improved Active Compounds identified in the Screening Program but shall not
include any chemical structures or structural data with respect to any Compounds
which are not (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds. Such reports shall be delivered to SPL at least quarterly
during the term of the Screening Program. In addition, with respect to each
Target, promptly following the completion of screening of the entire NeoMorph
Screening Library against such Target, NeoGenesis will deliver to SPL a
Preliminary Target Report (as defined in ATTACHMENT A) with respect to any and
all Preliminary Compounds identified during the Screening Program as having
activity with respect to such Target. Each Preliminary Target Report shall
include the binding affinities for all such Preliminary Compounds, as well as
any information generated by NeoGenesis with regard to Target specificities and
functional activities of such Preliminary Compounds. NeoGenesis shall also
provide SPL with a Final Target Report (as defined in ATTACHMENT A) in
accordance with the provisions of Paragraph 4 of ATTACHMENT A. NeoGenesis shall
also provide SPL with reports at least one (1) week prior to each Steering
Committee Meeting detailing the results of any Lead Compound optimization
activities performed by NeoGenesis pursuant to Section 2.2(b) and ATTACHMENT A,
which reports shall include the chemical structures and binding affinities of
all Derivative Compounds contained in NeoMorph Focused Libraries prepared by
NeoGenesis based upon such Lead Compound(s) and other information generated by
NeoGenesis with respect thereto.

         2.6   STEERING COMMITTEE.

         (a)   Promptly after the Effective Date, the parties shall establish a
joint committee (the "STEERING COMMITTEE") having oversight responsibility for
the day-to-day management and performance of the Screening Program. The Steering
Committee shall consist of six (6) members, three (3) members to be appointed by
each of NeoGenesis and SPL. Each party shall notify the other party of the names
and contact information for its members of the Steering Committee, and
thereafter may with notice to the other substitute any of its members serving on
the Steering Committee. Each member of the Steering Committee will have one vote
and all decisions of the Steering Committee will be by [*]. The quorum for
Steering Committee meetings shall be two, provided there is at least one member
from each of NeoGenesis and SPL present. The Steering Committee will render
decisions by [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

         (b)   The Steering Committee shall be responsible for the management
and conduct of the Screening Program and shall in particular: (i) consider,
review and amend the Screening Program from time to time in such manner as may
be appropriate; (ii) monitor progress of the Screening Program; (iii) report
regularly to the management of both parties upon the progress of the Screening
Program; and (iv) be the initial medium for transfer of information between the
parties. SPL shall keep the Steering Committee reasonably informed of the status
of SPL's activties with respect to the discovery and development of Licensed
Products against each Target.

         (c)   During the term of the Screening Program, the Steering Committee
shall hold meetings as mutually agreed by the parties (but in no event less
quarterly) to review the Screening Program. The first meeting of the Steering
Committee shall be held within forty-five (45) days of the Effective Date and
shall be held in Cambridge, MA. Thereafter, meetings may be held by telephone or
video conference if requested by either party in writing to the other, PROVIDED
THAT the parties shall meet in person at least four (4) times per year during
the term of the Screening Program. Minutes of all meetings setting forth
decisions of the Steering Committee relative to the Screening Program shall be
prepared by the host party and circulated to both parties within fifteen (15)
days after each meeting, but minutes shall not become official until approved
and countersigned by both parties (which approval the parties shall use
reasonable efforts to give within thirty (30) days of receipt of such minutes).

         (d)   In the event that the Steering Committee is unable to reach
agreement, the issue in dispute shall be referred to an "OVERSIGHT COMMITTEE"
consisting of the Executive Vice President, Discovery Research of the
Schering-Plough Research Institute (an Affiliate of SPL) and NeoGenesis' Chief
Executive Officer, or their respective designees, for resolution. If the
disagreement is not resolved by the Oversight Committee within thirty (30) days,
then SPL shall have the right to make the final decision on such matter;
PROVIDED, that in the event and to the extent that any dispute concerns whether
or not budgeted FTE funding for the Screening Program has been expended in
accordance with the provisions of this Agreement such matter shall be resolved
using the procedure specified in Section 9.1.

         2.7   SELECTED COMPOUNDS.

         (a)   From time to time during the term of this Agreement, SPL may
designate, by written notice to NeoGenesis, one or more Active Compounds and/or
Improved Active Compounds identified by screening of the NeoMorph Screening
Libraries pursuant to Section 2.2 as Selected Compounds; provided, that at any
given time SPL may not designate Active Compounds and Improved Active Compounds
representing more than [*] different Chemotypes against a given Target from the
NeoMorph Screening Library. The parties acknowledge and agree that the foregoing
limitation does not apply to the NeoMorph Focused Libraries. [*] Selected
Compounds that SPL may designate from the NeoMorph Focused Libraries. With
respect to each Target, SPL shall use diligent efforts to identify and designate
at least one Selected Compound within [*] following SPL's receipt of the Final
Target Report for all screening against such Target in accordance with Section
2.5(b) and ATTACHMENT A. In the event that the SPL does not designate any
Selected Compounds with respect to such Target, then upon expiration of the
applicable [*] period, SPL's right to designate Selected Compounds with respect
to such Target shall expire. If the NeoMorph Screening Library is subsequently
re-screened against a given Target pursuant to Section 2.1(e) and new Active
Compounds and/or Improved Active Compounds are identified as a result of such
re-screening, then to the extent SPL's right to designate Selected Compounds
against such Target has previously expired, SPL shall have a renewed right to
designate Selected Compounds arising from such re-screening on the same terms as
set forth above.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

         (b)   Effective upon the date of receipt by NeoGenesis of notice from
SPL, pursuant to Section 2.7(a) that one or more Active Compounds and/or
Improved Active Compounds have been designated as Selected Compounds, NeoGenesis
grants to SPL an exclusive option to obtain the exclusive license provided for
in Article 3 with respect to such Selected Compounds and related Derivative
Compounds (including without limitation any Compounds contained in a NeoMorph
Focused Library prepared based upon such Selected Compound). The masking of the
Selected Compound(s) (and any Preliminary Compounds, Active Compounds and
Improved Active Compounds of the same Chemotype(s) as such Selected Compound(s))
from the NeoMorph Screening Library in accordance with Section 2.3 shall be
maintained during the applicable Option Period (as defined below). In addition,
within [*] following receipt of notification from SPL identifying Selected
Compounds, NeoGenesis shall amend ATTACHMENT B to identify any applicable
NeoGenesis Patent Rights not previously identified to SPL. The "OPTION PERIOD"
with respect to each Selected Compound identified pursuant to Section 2.7(a),
shall extend until the later of: (i) the [*] anniversary of the expiration of
the Screening Program for the applicable Target, or (ii) in the event that SPL
is conducting an active internal medicinal chemistry research program to
identify Derivative Compounds based upon such Selected Compound (as documented
with written notice to NeoGenesis), a period of [*] following the termination of
such medicinal chemistry program. For purposes of this Section 2.7(b), SPL shall
be deemed to be conducting an active medicinal chemistry program if [*] working
full time on the design and discovery of Derivative Compounds with respect to a
given Selected Compound. SPL shall provide NeoGenesis with written
certification, at least [*] every [*], during the performance of such medicinal
chemistry program for purposes of monitoring the expiration of the Option
Period.

         (c)   SPL shall have the right to exercise the option granted to it
under Section 2.7(b) with respect to one or more Selected Compounds (and
related Derivative Compounds, including without limitation any Compounds
contained in a NeoMorph Focused Library prepared based upon such Selected
Compound) at any time prior to the expiration of the applicable Option
Period, by providing written notice to NeoGenesis to that effect. The
exclusive licenses granted to SPL pursuant to Article 3 with respect to such
Selected Compounds (and related Derivative Compounds, including without
limitation any Compounds contained in a NeoMorph Focused Library prepared
based upon such Selected Compound) shall become effective upon NeoGenesis'
receipt of such notice, and SPL shall pay the applicable license fee under
Section 4.2 to NeoGenesis within five (5) business days of such notice. As of
such date of such notice, the masking of the applicable Selected Compound(s)
(and related Derivative Compounds, including without limitation any Compounds
contained in a NeoMorph Focused Library prepared based upon such Selected
Compound), as well as any Preliminary Compounds, Active Compounds and
Improved Active Compounds of the same Chemotype as such Selected Compound,
from the NeoMorph Screening Library in accordance with Section 2.3 shall
become permanent, and during the term of this Agreement NeoGenesis shall
continue take such other steps as are reasonably necessary to ensure that
information with regard to the Selected Compounds and the relevant Active
Compounds, Improved Active Compounds and Preliminary Compounds of the same
Chemotype as such Selected Compounds are no longer available or accessible to
any third party.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

         (d)   In the event that SPL fails to exercise its option rights with
respect to one or more Selected Compounds prior to the expiration of the
applicable Option Period, then upon expiration of the Option Period SPL's option
right shall expire with respect to the applicable Selected Compound(s), the
licenses provided for in Article 3 with respect to such Selected Compound(s)
shall be void and of no further force or effect, and NeoGenesis shall be free to
unmask such Selected Compound(s) in the NeoMorph Screening Library.

         (e)   In the event that during the applicable Option Period, one or
more Selected Compounds with respect to a given Target become Designated
Compounds and SPL has not, as of the effective date of such designation,
exercised the option and paid the license fee due under section 4.2 with
respect to Selected Compounds against such Target, then the license fee shall
be paid concurrently with the milestone payment due upon designation of such
Designated Compounds in accordance with Section 2.8.

         (f)   SPL shall not begin screening any Selected Compound or related
Derivative Compounds against any biological targets other than Targets until
such time as it has exercised its option in accordance with Section 2.7(c) and
paid the applicable licensee fee.

         2.8   PRODUCT DEVELOPMENT.

         (a)   During the term of this Agreement, SPL shall, at its expense,
conduct a research and development program to evaluate Selected Compounds and
Derivative Compounds as potential candidates for commercial development as
Licensed Products. Such efforts may include the performance of further medicinal
chemical research based upon such Selected Compounds and Derivative Compounds,
as well as biological, pharmacokinetic and toxicology studies and other
preclinical research activities. SPL shall have sole discretion over the scope
of such research and development program, and the selection of which Selected
Compounds and Derivative Compounds will be the focus of such activities.

         (b)   SPL shall notify NeoGenesis in writing in the event that SPL, in
its sole discretion (based on SPL's good faith evaluation of the satisfaction of
the applicable Success Criteria by such Selected Compound or Derivative
Compound), decides to proceed with a development program for any Selected
Compounds or Derivative Compounds as suitable candidates for drug development
(thereafter, each a "DESIGNATED COMPOUND"). A Selected Compound or Derivative
Compound will be deemed to be a Designated Compound upon the earlier of that
date on which (i) SPL (or its Affiliate) formally approves proceeding with full
development of such Compound, or (ii) SPL (or its Affiliate) initiates IN VIVO
toxicology trials necessary, and meeting U.S. FDA (or corresponding European or
Japanese) standards, for obtaining approval for use of such Compound in human
clinical trials, unless SPL sooner designates such Selected Compound or
Derivative Compound as a Designated Compound with notice to NeoGenesis. Upon
SPL's designation of a Designated Compound, SPL shall thereafter, at its
expense, use Commercially Reasonable Efforts to develop and commercialize
Licensed Products incorporating the Designated Compound in the Territory. SPL
shall be solely responsible for determining in which countries in the Territory
to develop and commercialize each Licensed Product, provided that it shall use
Commercially Reasonable Efforts to obtain Regulatory Approval and to market and
sell each Licensed Product in the Major Market Countries.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

         (c)   Subject to SPL's diligence obligations under this Agreement, the
Parties acknowledge and agree that all business decisions regarding research,
development and commercialization of Designated Compounds and Licensed Products
including, without limitation, decisions relating to the design, development,
manufacture, sale, price, distribution, marketing and promotion of Licensed
Products under this Agreement, and the decision of whether to develop a
particular Designated Compound, or to develop and commercialize a particular
Licensed Product, shall be within the sole discretion of SPL.

         (d)   SPL shall have no quotas or other minimum diligence obligations
with regard to the number of Designated Compounds and/or Licensed Products to be
developed and commercialized hereunder. The parties acknowledge and agree that
so long as SPL is using Commercially Reasonable Efforts to discover, develop and
commercialize [*] Licensed Product in the Territory, SPL shall be deemed to be
in compliance with its diligence obligations under this Agreement.

         2.9   COMMERCIALIZATION OF LICENSED PRODUCTS. With respect to each
Licensed Product developed and commercialized by SPL, or its designated
Affiliates, under this Agreement, SPL shall be solely responsible, at its sole
expense, for all aspects of the development and commercialization of the
Licensed Product in the Territory, including, without limitation:

         (i)   the manufacture of Designated Compounds and Licensed Products
               in accordance with the applicable Regulatory Approvals, laws,
               Good Laboratory Practices and Good Manufacturing Practices;

         (ii)  preparation, filing, obtaining, maintaining and supporting, in
               its own name or that of its designated Affiliate, with the
               appropriate regulatory authorities of all regulatory
               approvals, authorizations, permits and licenses (including,
               without limitation, all Regulatory Approvals) that are
               necessary to conduct clinical studies of Licensed Products
               and/or to manufacture, import, distribute, market and sell
               Licensed Products;

         (iii) the reporting all adverse events associated with any Licensed
               Product to the appropriate regulatory authorities in
               accordance with applicable laws, rules and regulations in the
               Territory; and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

         (iv)  the distribution, marketing, promotion and sale of Licensed
               Products.

Following the expiration of the Screening Program, SPL shall provide NeoGenesis
with semi-annual reports summarizing the status of SPL's development and
commercialization activities with respect to each Licensed Product being
developed under this Agreement. In addition, SPL shall notify NeoGenesis in
writing upon the filing of each application for Regulatory Approval of a
Licensed Product in the Territory.

         2.10  DILIGENCE EXCEPTIONS. All of SPL's diligence obligations
hereunder with respect to each Licensed Product being developed or
commercialized hereunder are expressly conditioned upon the continuing absence
of any adverse condition or event which warrants a delay in commercialization of
the Licensed Product due to an adverse condition or event relating to the safety
or efficacy of such Licensed Product or unfavorable pricing, pricing
reimbursement, labeling or lack of regulatory approval, and SPL shall have no
obligation to develop or market any such Licensed Product so long as in SPL's
reasonable opinion any such condition or event exists.

         2.11  THIRD PARTY LICENSES. SPL shall be solely responsible for (a)
obtaining any and all licenses from third parties necessary or desirable to
develop or commercialize any Licensed Product and (b) any and all consideration
payable with respect to such licenses. The decision as to whether or not to
obtain any such third party licenses relating to Licensed Products, and the
negotiation and acceptance of the terms and conditions for any such licenses,
shall be within the sole discretion and control of SPL, and nothing herein shall
be construed as obligating SPL to obtain any such third party licenses.

         2.12  COMPLIANCE WITH LAW. SPL shall be responsible for ensuring that
all activities related to the development and commercialization of Licensed
Products conducted by or on its behalf are performed in compliance with all
applicable laws, rules and regulations (including, but not limited to, those
related to occupational safety and health, public safety and health, protecting
the environment, the disposal of wastes, Good Clinical Practices, Good
Laboratory Practices and Good Manufacturing Practices, as applicable).

3.       LICENSES; INTELLECTUAL PROPERTY RIGHTS

         3.1   LICENSE TO LICENSED PRODUCTS. NeoGenesis hereby grants to SPL,
and SPL hereby accepts, an exclusive (even as to NeoGenesis), right and license
in the Territory and within the Field under the NeoGenesis Patent Rights and to
use the NeoGenesis Know-How to make, have made, use, distribute, promote,
market,offer for sale, sell, import and export Licensed Products. The licenses
granted to SPL under this Section 3.1 include the right to grant sublicenses to
Affiliates or third parties in accordance with the provisions of Section 3.3.
SPL shall mark or have marked all containers or packages of Licensed Products
that are the subject of the license granted under this Section 3.1 in accordance
with the patent marking laws of the jurisdiction in which such Licensed Products
are manufactured, used or sold. For purposes of clarity and avoidance of doubt,
it is acknowledged that the exclusive licenses granted hereunder shall not be
construed as encompassing Compounds other than Selected Compounds (and Active
Compounds, Improved Active Compounds and Preliminary Compounds of the same
Chemotype as such Selected Compounds), Derivative Compounds and Designated
Compounds.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

         3.2   LICENSE TO COMPOUNDS. NeoGenesis hereby grants to SPL, and SPL
hereby accepts, an exclusive (even as to NeoGenesis), right and license in the
Territory and within the Field under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How to research, develop, make, have made, import, export and
use the Selected Compounds (and Active Compounds, Improved Active Compounds and
Preliminary Compounds of the same Chemotype as such Selected Compounds),
Designated Compounds and Derivative Compounds, for research purposes and to
develop Licensed Products. The licenses granted to SPL under this Section 3.2
include the right to grant sublicenses to Affiliates or third parties in
accordance with the provisions of Section 3.3. SPL shall mark or have marked all
containers or packages of Selected Compounds Derivative Compounds and Designated
Compounds that are the subject of the license granted under this Section 3.1 in
accordance with the patent marking laws of the jurisdiction in which such
Selected Compounds, Derivative Compounds and Designated Compounds are
manufactured, used or sold.

         3.3   SUBLICENSING. SPL's shall have the right to grant sublicenses
under this Agreement to third parties and/or Affiliates; provided that all such
sublicenses shall be consistent with the terms and conditions of this Agreement,
and in particular shall include provisions to ensure that such sublicense is
subject to the obligations set forth in Section 3.1(last sentence), 4.4, 4.5,
4.6, 4.7 and 8.3(b) (last sentence) of this Agreement. SPL shall remain
responsible to NeoGenesis for all of its sublicensees financial and other
obligations under this Agreement. SPL's sublicensees shall have no further right
to grant sublicenses, and any sublicense granted by SPL under this Agreement
shall not be assigned, transferred or otherwise conveyed by the sublicensee to
any third party, as a matter of law or through any action by sublicensee,
without the prior written consent of NeoGenesis.

         3.4   RETAINED RIGHTS.

               (a)   Title to the NeoGenesis Know-How and NeoGenesis Patent
Rights shall at all times remain vested in NeoGenesis, and this Agreement does
not convey to SPL any ownership rights or other interest in any NeoGenesis
Know-How or NeoGenesis Patent Rights, by implication, estoppel or otherwise,
except for those rights and licenses expressly granted under this Agreement.

               (b)   Title to the Schering Know-How and Schering Patent Rights
shall at all times remain vested in SPL, and this Agreement does not convey to
NeoGenesis any ownership rights or other interest in any Schering Know-How or
Schering Patent Rights, by implication, estoppel or otherwise, except for the
rights and licenses expressly granted under this Agreement.

               (c)   The parties acknowledge and agree that notwithstanding the
exclusive licenses granted to SPL hereunder, with respect to the NeoGenesis
Know-How and NeoGenesis Patent Rights, NeoGenesis shall retain the right to
continue to use its NeoMorph Screening Library to screen target proteins (other
than Targets) for third parties; PROVIDED that NeoGenesis complies with all of
its obligations with respect to the masking of Preliminary Compounds, Active
Compounds, Improved Active Compounds and Selected Compounds from the NeoMorph
Screening Library.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

         3.5   INVENTIONS.

               (a)   Title to and ownership of all Inventions directly related
to (i) Selected Compounds, Derivative Compounds, Designated Compounds and
Licensed Products, or the manufacture or use thereof, or (ii) Targets provided
to NeoGenesis by SPL, in each case regardless of inventorship, as well as those
Inventions subject to Section 3.5(b)(ii), shall be the sole property of SPL
(hereinafter "SCHERING INVENTIONS") and are included in Schering Know-How and/or
Schering Patent Rights, as the case may be. NeoGenesis hereby assigns and agrees
to assign to SPL all of NeoGenesis' right, title and interest in such Schering
Inventions; such assignment to take effect with respect to particular Selected
Compounds (and related Derivative Compounds, Designated Compounds and Licensed
Products) upon the date NeoGenesis receives notice from SPL pursuant to Section
2.7(c) that SPL has decided to exercise its option to exclusively license the
Selected Compounds and related Derivative Compounds; and NeoGenesis shall use
Commercially Reasonable Efforts to perfect such assignment (at SPL's expense).
Title to and ownership of all Inventions directly related to the NeoMorph
Screening Library, ALIS screening technology or QSCD (regardless of
inventorship), as well as those Inventions subject to Section 3.5(b)(i)
(hereinafter "NEOGENESIS INVENTIONS"), shall be the sole property of NeoGenesis
and are included in NeoGenesis Know-How and/or NeoGenesis Patent Rights, as the
case may be. SPL hereby assigns and agrees to assign to NeoGenesis, all of SPL's
right title and interest (if any) in such NeoGenesis Inventions and SPL shall
use Commercially Reasonable Efforts to perfect such assignment (at the
NeoGenesis' expense).

               (b)   Title to and ownership of all other Inventions arising from
the Screening Program and which are not covered by Section 3.5(a) shall be
determined as follows:

               (i)   Inventions made solely by one or more employees or
                     agents of NeoGenesis shall be the sole property of
                     NeoGenesis are NeoGenesis Inventions and are included
                     in NeoGenesis Know-How and/or NeoGenesis Patent
                     Rights, as the case may be.

               (ii)  Inventions made solely by one or more employees or
                     agents of SPL shall be the sole property of SPL, are
                     Schering Inventions, and are included in Schering
                     Know-How and/or Schering Patent Rights, as the case
                     may be.

               (iii) Inventions made jointly by one or more employees or
                     agents of NeoGenesis and one or more employees or
                     agents of SPL shall be the joint property of
                     NeoGenesis and SPL (hereinafter "JOINT INVENTIONS").

In determining each party's contribution to Inventions arising under this
Agreement, inventorship shall be determined in accordance with United States
patent law.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

         3.6   PATENT PROTECTION FOR INVENTIONS. Each of NeoGenesis and SPL
shall promptly disclose to the other knowledge of any Inventions arising in
connection with the Screening Program. Responsibility for the preparation,
filing, prosecution and maintenance of any patent applications and patents
claiming such Inventions shall be determined based upon ownership of the
Inventions and shall be handled in accordance with the provisions of this
Section 3.6. Within forty-five (45) days following disclosure of any
Invention(s), the parties shall classify such Invention as a Schering
Invention, a NeoGenesis Invention or a Joint Invention and shall update
ATTACHMENT C to add such Invention and reflect such classification.

               (a)   NeoGenesis shall have the right and responsibility to
prepare, file, prosecute, and maintain all patent applications and patent
within the NeoGenesis Patent Rights throughout the Territory at NeoGenesis
sole expense, including, without limitation, those with respect to NeoGenesis
Inventions. NeoGenesis shall have sole discretion as to all such activities
with regard to the NeoGenesis Patent Rights. NeoGenesis shall keep SPL
currently advised as to the status of all patents and patent applications
with respect to the NeoGenesis Patent Rights and shall supply SPL promptly
with copies of all patents, patent applications, substantive patent office
actions, substantive responses received or filed in connection with such
applications. SPL may offer comments and suggestions with respect to the
matters that are the subject of this Section 3.6(a) and NeoGenesis agrees to
consider such comments and suggestions; PROVIDED that nothing herein shall
obligate NeoGenesis to adopt or follow such comments or suggestions. In the
event that NeoGenesis elects not to file for patent protection for any
NeoGenesis Inventions or elects not to continue to prosecute or maintain a
patent or patent application under the NeoGenesis Patent Rights it shall
notify SPL of such decision at least forty-five (45) days prior to the due
date of any action or payment due with respect thereto. SPL shall have the
right, but not the obligation to assume the responsibility therefor at its
own cost and expense.

               (b)   SPL and NeoGenesis, acting through the Steering Committee,
shall select and retain patent counsel mutually acceptable to each of them for
the purpose of preparing, prosecuting, issuing and maintaining appropriate
patent applications concerning Joint Inventions. NeoGenesis, in consultation
with SPL, shall be primarily responsible for the preparation, filing (including
foreign filing decisions), prosecution and maintenance of such patent
applications and patents relating to Joint Inventions. NeoGenesis shall furnish
or have furnished to SPL copies of documents relevant to the same and provide
SPL with the opportunity to review and comment on patent decisions made by
patent counsel. Any disagreements between NeoGenesis and SPL with respect to
preparation, filing, prosecution, issuance and maintenance matters will be
discussed and resolved to their mutual satisfaction using the procedures
specified in Section 9.1, if necessary; PROVIDED, that to the extent that any
disagreement regards only the costs associated with a particular proposed
action, NeoGenesis may assume responsibility for such costs and the requirement
that the parties mutually agree upon resolution of the matter shall not apply.
Each party shall be responsible for fifty percent (50%) of all expenses
associated with the preparation, filing, prosecution, issuance and maintenance
of patents or other intellectual property protection for Joint Inventions. In
the event that either party elects not to pursue a particular action with
respect to which the parties disagree regarding costs, the other party shall
have the right to assume such costs and to have such action taken; PROVIDED
FURTHER that the non-paying party's licenses hereunder shall exclude any
intellectual property rights that are the subject of such action (e.g., patent
coverage in a particular country) unless and until such party reimburses the
other party for one-half (50%) of the costs of such action.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

               (d)   SPL shall have the sole right, but not the obligation, to
file, prosecute, and maintain, at SPL's sole expense, each of the Schering
Patent Rights throughout the Territory. Upon request, and at SPL's expense,
NeoGenesis will provide SPL with reasonable assistance to prepare, file,
prosecute, maintain and defend the Schering Patent Rights, and will take all
steps necessary to enable SPL to perfect its rights and title to the Schering
Patent Rights with respect to any Schering Inventions. Reasonable assistance
shall include, without limitation, providing SPL any data and information
relating to such Schering Inventions and access to the NeoGenesis employees who
are inventors of such Schering Inventions, as well as causing the execution of
any patent assignment or other documents.

         3.7   ENFORCEMENT. Each party shall promptly notify the other of its
knowledge of any actual or potential infringement of the NeoGenesis Patent
Rights, the Schering Patent Rights or any Joint Inventions.

               (a)   NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights. SPL shall be
solely responsible for the defense and enforcement of Schering Know-How and
Schering Patent Rights. In the event that either party recovers any sums in such
litigation by way of damages or in settlement thereof, such party shall have the
right to retain all such sums; PROVIDED that any recovery of ordinary damages by
SPL to the extent based upon third party sales of products that infringe upon
Compound Patent Rights shall be deemed to be Net Sales and SPL shall pay
NeoGenesis an amount calculated in accordance with Section 4.4 to reimburse
NeoGenesis for royalties due on lost sales of Licensed Product represented by
such ordinary damages; PROVIDED FURTHER that this allocation shall not apply
with respect to special or punitive damages, and that SPL shall be entitled to
deduct all litigation costs incurred by it in connection therewith from such
settlement or award prior to calculating such royalties.

               (b)   SPL shall have the first option to pursue any
enforcement or defense of any patents claiming Joint Inventions within the
Field and the Territory ("JOINT PATENT RIGHTS"); PROVIDED, that SPL pays all
costs and expenses related thereto. SPL shall have three (3) months from the
date it receives notice of such infringement to obtain a discontinuance of
such infringement or bring suit against the third party infringer. SPL shall
keep NeoGenesis reasonably informed of the status of such activities.
NeoGenesis shall provide reasonable assistance to SPL in any suit for
infringement of a Joint Patent Right brought by SPL against a third party,
and shall have the right to consult with SPL and to participate in and be
represented by independent counsel in such litigation at its own expense. For
purposes of this Section 3.7(b), reasonable assistance shall mean providing
SPL reasonable access to information, materials and NeoGenesis personnel
which SPL reasonably determines is necessary to enable SPL to conduct the
suit. SPL shall periodically reimburse NeoGenesis for its out-of-pocket costs
(excluding the costs of retaining independent counsel) incurred in
cooperating with SPL. SPL shall incur no liability to NeoGenesis as a
consequence of such litigation or any unfavorable decision resulting
therefrom, including any decision holding any of the Joint Patent Rights
invalid or unenforceable. In the event that SPL recovers any sums in such
litigation by way of damages or in settlement thereof, SPL shall have the
right to retain all such sums; PROVIDED that any recovery of ordinary damages
to the extent based upon third party sales of products that infringe upon the
Joint Patent Rights shall be deemed to be Net Sales and SPL shall pay
NeoGenesis an amount calculated in accordance with Section 4.4 to reimburse
NeoGenesis for royalties due on lost sales of Licensed Product represented by
such ordinary damages; PROVIDED FURTHER that this allocation shall not apply
with respect to special or punitive damages and that SPL shall be entitled to
deduct all litigation costs incurred by it in connection therewith from such
settlement or award prior to calculating such royalties.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

               (c)   If, after the expiration of the three (3) month period
specified in Section 3.6(b), SPL has not overcome the allegation of
infringement, obtained a discontinuance of such infringement, or brought suit
against the third party infringer, then, provided such infringement is
substantial, NeoGenesis shall have the right, but not the obligation, to
bring suit against such infringer under the Joint Patent Right, provided that
NeoGenesis shall bear all the expenses of such suit. SPL shall provide
reasonable assistance to NeoGenesis in any suit for infringement of a Joint
Patent Right brought by NeoGenesis against a third party, and shall have the
right to consult with NeoGenesis and to participate in and be represented by
independent counsel in such litigation at its own expense. For purposes of
this Section 3.6(c), reasonable assistance shall mean providing NeoGenesis
reasonable access to information, materials and SPL personnel which
NeoGenesis reasonably determines is necessary to enable NeoGenesis to conduct
the suit. NeoGenesis shall periodically reimburse SPL for its out-of-pocket
costs (excluding the costs of retaining independent counsel) incurred in
cooperating with NeoGenesis. NeoGenesis shall incur no liability to SPL as a
consequence of such litigation or any unfavorable decision resulting
therefrom, including any decision holding any of the Joint Patent Rights
invalid or unenforceable. In the event that NeoGenesis recovers any sums in
such litigation by way of damages or in settlement thereof, NeoGenesis shall
have the right to retain all such sums.

               (d)   Each party shall immediately give written notice to the
other of any certification of which it becomes aware filed pursuant to the
Waxman-Hatch Act (21 U.S.C. Section355(b)(2)(A), or Section355(j)(2)(A)(vii)),
or any amendment or successor statute thereto, at least fourteen (14) days prior
to expiration of the forty five (45) day period set forth in 21 U.S.C.
Section355(c)(3)(c) (or any amendment or successor statute thereto).

         3.8   LIST OF NEOGENESIS PATENT RIGHTS. The NeoGenesis Patent Rights
exclusively licensed to SPL pursuant to Sections 3.1 and 3.2 shall be listed in
ATTACHMENT B, which shall be amended from time to time during the term of this
Agreement to reflect additions or changes to the NeoGenesis Patent Rights in
accordance with Section 2.7. For the avoidance of doubt, to the extent that
ATTACHMENT B is not updated to include any NeoGenesis Patent Rights that are
directly related to any Selected Compounds (and Active Compounds and Improved
Active Compounds of the same Chemotype as such Selected Compounds), Designated
Compounds, Derivative Compounds and/or Licensed Products within the scope of an
exclusive license granted to SPL under Sections 3.1 and 3.2, NeoGenesis agrees
that it shall not have any action against SPL in relation thereto and shall
automatically amend ATTACHMENT B to include such NeoGenesis Patent Rights.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

4.             CONSIDERATION

         4.0   ADDITIONAL PAYMENT OBLIGATIONS. The parties acknowledge that
SPL's payment obligations as set forth in Sections 4.1, 4.2, 4.3 and 4.4 of this
Agreement are in addition to the payment obligations of Schering Corporation set
forth in Sections 4.1, 4.2, 4.3 and 4.4 of the US Agreement.

         4.1   RESEARCH FUNDING. In consideration for the performance of the
Screening Program and activities related thereto by NeoGenesis, SPL shall pay
to NeoGenesis research funding during the term of the Screening Program at
the rate of [*] per FTE per year during the initial two year term of the
Screening Program. Such payments constitute [*] payment for FTEs at a rate of
[*] per year per FTE, with [*] of such funding to be paid by Schering
Corporation under the terms of the US Agreement. The amount of such funding
shall be based upon the actual number of FTEs assigned by NeoGenesis to work
on the Screening Program pursuant to Section 2.2(f), it being understood that
except as otherwise agreed by the parties in writing, research funding shall
be paid based upon [*] FTEs. Research funding shall be payable in equal
quarterly installments during the term of the Screening Program, with the
first such payment due within [*] after the Effective Date and each
successive payment due quarterly in advance on the first day of each calendar
quarter starting on October 1, 2001. It is understood and agreed by the
parties that first two research funding payments due under this Agreement [*]
represents payment for work performed by NeoGenesis in connection with the
Screening Program during the entire 2001 calendar year, including activities
performed during the period extending from January 1, 2001 until the
Effective Date. In the event that the term of the Screening Program is
extended, the FTE rate payable under this Section 4.1 in each such extension
year shall be increased by the CPI (as defined below). If SPL is unwilling to
provide funding for such documented cost increases and the parties are unable
to resolve such funding matter to their mutual satisfaction within forty-five
(45) days then the Screening Program shall not be extended for such extension
year. If in any quarterly funding period, actual expenditures by NeoGenesis
with respect to FTE's exceed the amount budgeted for the period, the overrun
will be carried forward for the next period and paid for from the next
payment(s); PROVIDED, that SPL payment obligations for any year of the
Screening Program shall not exceed the budgeted amount for such year unless
SPL has agreed to fund additional FTE work beyond that budgeted for such year
by means of a written amendment to this Agreement approved in writing by the
parties. For purposes of this Section 4.1, "CPI" means the Consumer Price
Index [*], as published by the Bureau of Labor Statistics of the United
States Department of Labor. In the event that the Bureau of Labor Statistics
ceases to publish the CPI or substantially changes its content or format in a
manner that precludes its further use hereunder, SPL and NeoGenesis shall
substitute therefor another comparable measure published by an agreed-upon
source.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

         4.2   LICENSE FEES.

               (a)   In partial consideration for the licenses and other rights
granted to SPL hereunder, SPL shall pay to NeoGenesis a license fee of [*] with
respect to each Target for which one or more Selected Compounds are designated
pursuant to Section 2.7. Each such license fee shall be payable within [*] after
the effective date of the licenses to such Selected Compounds, as provided under
Section 2.7(b). The license fee shall be payable [*], irrespective of the number
of Selected Compounds, Designated Compounds or Licensed Products which may be
identified and/or developed with respect thereto. Payment of any license fees
under this Section 4.2(a) shall be made concurrently with payment of the
corresponding license fees under Section 4.2(a) of the US Agreement.

         4.3   MILESTONES. In partial consideration for the licenses and other
rights granted to SPL hereunder, SPL shall pay to NeoGenesis the following
payments upon the occurrence of the indicated milestone event.

               (a)   with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, and was discovered as a result
of optimization of one or more Lead Compounds by NeoGenesis pursuant to Section
2.2(b):

               (i)     [*] upon designation of such Designated Compound pursuant
                       to Section 2.8;

               (ii)    [*] upon initiating treatment of the first patient in
                       a Phase I clinical trial for the applicable Licensed
                       Product under an approved IND (or its equivalent);

               (iii)   [*] upon  initiating  treatment of the first  patient in
                       a Phase III clinical  trial for the applicable Licensed
                       Product;

               (iv)    [*]  upon  filing  and  acceptance  of the  first  NDA
                       (or its  European  or  Japanese equivalent) for the
                       applicable Licensed Product; and

               (v)     [*] upon receipt of the first  Regulatory  Approval for
                       the applicable  Licensed Product in a Major Market
                       Country.

               (b)   with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, but was not discovered as a
result of optimization of one or more Lead Compounds by NeoGenesis pursuant to
Section 2.2(b):

               (i)     [*] upon designation of such Designated Compound pursuant
                       to Section 2.8;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

               (ii)    [*] upon initiating treatment of the first patient in
                       a Phase I clinical trial for the applicable Licensed
                       Product under an approved IND (or its equivalent);

               (iii)   [*] upon  initiating  treatment of the first  patient in
                       a Phase III clinical  trial for
                       the applicable Licensed Product;

               (iv)    [*]  upon  filing  and  acceptance  of the  first  NDA
                       (or  its  European  or  Japanese
                       equivalent) for the applicable Licensed Product; and

               (v)     [*] upon receipt of the first  Regulatory  Approval for
                       the applicable  Licensed Product
                       in a Major Market Country.

               (c)     All payments made to NeoGenesis by SPL pursuant to
Section 4.3(a) or (b) shall be due within thirty (30) days after the achievement
of the corresponding milestone and shall be nonrefundable and not creditable
against other amounts due to NeoGenesis. The payments provided for under this
Section 4.3 shall only be payable once upon the first achievement of the
indicated milestone with respect to Designated Compound and/or Licensed Product
developed against a particular Target and no additional payments shall be due on
subsequent or repeated achievement of the same milestone for another Designated
Compound and/or Licensed Product developed against the same Target. No
milestones shall be payable under this Section 4.3 with respect to (i) any
compounds or products other than Designated Compounds and Licensed Products, or
(ii) any Designated Compounds or Licensed Products being developed based upon
[*].

               (d)     In the event that SPL ceases all clinical development for
a Designated Compound/Licensed Product (a "Discontinued Product") for which one
or more milestones have been paid pursuant to this Section 4.3, no payment shall
be due under this Section 4.3 with respect to the achievement of the same
milestone(s) with respect to the another Designated Compound or Licensed Product
discovered or developed against the same Target as the Discontinued Product (a
"Back-up Product"). In the event that the Back-up Product achieves milestones
which were not previously achieved by the relevant Discontinued Product, such
milestone payments will be paid in accordance with this Section 4.3.

         4.4   ROYALTIES. In partial consideration for the licenses and other
rights granted to SPL hereunder, SPL shall pay royalties to NeoGenesis based
upon Net Sales of Licensed Products in the Territory.

               (a)     The royalties payable to NeoGenesis on Net Sales of
Licensed Products in the Territory by SPL, its Affiliates and sublicensees,
shall be determined as follows:

               (i)     [*] of Net Sales of Licensed Products in the
                       Territory where the Designated Compound in such
                       Licensed Product was discovered as a result of
                       optimization of one or more Lead Compounds by
                       NeoGenesis pursuant to Section 2.2(b); or

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

               (ii)    [*] of Net Sales of Licensed Products in the
                       Territory where the Designated Compound in such
                       Licensed Product was not discovered as a result of
                       optimization of one or more Lead Compounds by
                       NeoGenesis pursuant to Section 2.2(b); or

               (iii)   [*] of Net Sales of Licensed Products in the
                       Territory where the Designated Compound in such
                       Licensed Product is a Derivative Compound derived
                       from an Selected Compound identified through SPL's
                       screening of a Selected Compound against a target
                       other than the specific Target(s) for which the
                       Selected Compound was screened by NeoGenesis.

               (b)     Starting with the First Commercial Sale of each Licensed
Product in the Territory, SPL shall provide NeoGenesis with quarterly reports of
Net Sales by country of each Licensed Product in the Territory. Each such
quarterly report shall be provided to NeoGenesis not later than sixty (60) days
following the close of the relevant calendar quarter, (i.e., following each
March 31, June 30, September 30 and December 31). Concurrently with the making
of such reports, SPL shall pay to NeoGenesis royalties due for such period at
the rates specified in Section 4.4(a). The report due for the quarter ending
December 31 of each year shall also include the aggregate royalties due
NeoGenesis for the entire year.

               (c)     SPL's obligation to pay royalties with respect to each
Licensed Product shall expire on a country-by-country basis upon the later of
(i) the expiration (or revocation or complete rejection) of the last to expire
(or to be revoked or to be completely rejected) of any NeoGenesis Patent Right
and/or Compound Patent Right having a Valid Claim covering such Licensed Product
in the country, or (ii) [*] from the First Commercial Sale of the Licensed
Product in such country. No royalties shall accrue on the disposition of any
Licensed Product in reasonable quantities by SPL, its Affiliates or its
sublicenses at no charge as samples (promotional or otherwise) or as donations
(for example, to non-profit institutions or government agencies for a
non-commercial purpose) or for clinical studies.

         4.5   REMITTANCE.

               (a)     All royalties, milestone and other payments required
under this Article 4 shall be made by bank wire transfer in United States
dollars in immediately available funds to an account designated by NeoGenesis.
Royalties shall be deemed payable by the entity making the Net Sales from the
country in which earned in local currency and subject to foreign exchange
regulations then prevailing. Royalty payments shall be made in United States
dollars to the extent that free conversion to United States dollars is
permitted. The rate of exchange to be used in any such conversion from the
currency in the country where such Net Sales occurs shall be in accordance with
the policy set forth in ATTACHMENT D attached hereto.

               (b)     In the event that any payment due NeoGenesis under this
Agreement is not made when due, the amount due shall accrue interest beginning
on the fifth day following the final date on which such payment was due,
calculated at the annual rate equal to two percent (2%) above the prime interest
rate reported in the WALL STREET JOURNAL for the due date, calculated from the
due date until paid in full. Such payment when made shall be accompanied by all
interest so accrued.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

               (c)     If at any time legal restrictions or prohibitions imposed
by national or international authority prevent the conversion of the local
currency and such currency cannot be removed from such country such that prompt
remittance by SPL of any royalties owed by SPL to NeoGenesis in respect of sales
in such country is prevented, the parties shall consult with a view to finding a
prompt and acceptable solution, and SPL or its designated Affiliates will make
payment through any means as NeoGenesis may lawfully direct at no additional
out-of-pocket expense to SPL.. Notwithstanding the foregoing, if royalties in
any country cannot be remitted to NeoGenesis for any reason within three (3)
months after the end of the calendar quarter during which they are earned, then
SPL shall be obligated to pay NeoGenesis in the local currency of such country
and shall deposit the relevant royalties in a bank account in such country
designated by NeoGenesis and in the name of NeoGenesis.

         4.6   RECORDS. SPL, its Affiliates and sublicensees shall keep and
maintain complete, true and accurate books of account and records (prepared in
accordance with United States Generally Accepted Accounting Principles,
consistently applied) sufficient to determine the amounts of Net Sales and any
royalty payments due with respect thereto. All such books and records shall be
maintained in accordance with SPL's records retention policies consistently
applied but for a period of at least thirty six (36) months from the date of
each payment of royalties.

         4.7   INSPECTION. Upon prior written notice SPL and its Affiliates
shall, within a period not to exceed forty-five (45) days, permit an independent
certified public accounting firm of nationally recognized standing selected by
NeoGenesis and reasonably acceptable to SPL, at NeoGenesis' expense, to have
access during regular business hours to examine pertinent books and records of
SPL and its Affiliates necessary to verify the accuracy of the royalty reports
and payments by SPL hereunder. The examination shall be limited to pertinent
books and records for any calendar year ending not more than twenty-four (24)
months prior to the date of such request. Such inspection right shall not be
exercised more than once in any calendar year. The accounting firm employees
shall sign confidentiality agreements reasonably acceptable to SPL as a
condition precedent to their inspection. SPL may designate competitively
sensitive information which such auditor may not disclose to NeoGenesis;
PROVIDED, HOWEVER, that such designation shall not encompass the auditor's
conclusions. The accounting firm shall disclose to NeoGenesis only whether the
royalty reports are correct or incorrect and the specific details concerning any
discrepancies. No other information shall be provided to NeoGenesis. In the
event that the accounting firm correctly concludes that a variation or error has
occurred resulting in an underpayment of royalties by SPL of five percent (5%)
or more of the amount actually due for the period covered by the inspection, SPL
shall pay to NeoGenesis in addition to such underpayment, the costs relating to
the inspection, within thirty (30) days of receipt of an invoice for such
amounts. Any overpayment of royalties by SPL discovered through such audit shall
be fully creditable against royalties subsequently due hereunder. SPL shall
include in each sublicense granted by it pursuant to this Agreement a provision
requiring the sublicensee to make reports to SPL, to keep and maintain records
of sales made pursuant to such sublicense and to grant access to such records by
NeoGenesis' independent accountant to the same extent required of SPL under this
Agreement. Upon expiration of the twenty-four (24) month period immediately
following the receipt by NeoGenesis of SPL's fourth quarter royalty report for a
given calendar year, the calculation of royalties payable with respect to such
year shall be binding and conclusive upon NeoGenesis, and SPL, its Affiliates
and its sublicensees shall be released from any liability or accountability with
respect to royalties for such year, except for instances of fraud or other
intentional misconduct.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

         4.8   TAXES. If at any time, any jurisdiction within the Territory
requires the withholding of income taxes or other taxes imposed upon payments
set forth in this Article 4, SPL shall make such withholding payments as
required and subtract such withholding payments from the payments to be made to
NeoGenesis as set forth in this Article 4, or if applicable, NeoGenesis will
promptly reimburse SPL or its designee(s) of the amount of such withholding
payments that are not subtracted from the payments made to NeoGenesis as set
forth in this Article 4. SPL shall provide NeoGenesis with documentation of such
withholding and payment in a manner that is satisfactory for purposes of
reporting to the U.S. Internal Revenue Service. Any withholdings paid when due
hereunder shall be for the account of NeoGenesis. Withholding payments made by
SPL pursuant to this Section 4.8 shall be made based upon financial information
provided to SPL by NeoGenesis, and to the extent that such information is
incorrect, NeoGenesis shall be liable for any deficiency, and any fine,
assessment or penalty imposed by any taxing authority in the Territory for any
deficiency in the amount of any such withholding or the failure to make such
withholding payment. If SPL is required to pay any such deficiency, or any fine,
assessment or penalty for any such deficiency, NeoGenesis shall promptly
reimburse SPL for such payments.

5.       CONFIDENTIALITY

         5.1   PUBLICITY. Each of the parties hereto agrees not to disclose to
any third party the existence or the terms of this Agreement without the prior
written consent of the other party hereto. Notwithstanding the foregoing, the
parties may agree upon an initial press release to announce the execution of
this Agreement, together with a corresponding Q&A outline for use in responding
to inquiries about the Agreement. In the event of such agreed upon press
release, each party may thereafter disclose to third parties the specific
information contained in such press release and Q&A without the need for further
approval by the other party. Nothing in this Section 5.1 shall prohibit a party
from making such disclosures to the extent required under applicable federal or
state securities laws or any rule or regulation of any nationally recognized
securities exchange. In such event, however, the disclosing party shall use good
faith efforts to notify and consult with the other party prior to such
disclosure and, where applicable, shall diligently seek confidential treatment
to the extent such treatment is available under applicable securities laws.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

         5.2   CONFIDENTIALITY.

               (a)     Confidential Information received by one party (the
"RECEIVING PARTY") from the other party (the "DISCLOSING PARTY") in connection
with this Agreement will be used by the Receiving Party solely for the
performance of the Screening Program or as otherwise expressly permitted by this
Agreement. All Confidential Information will be received and held in confidence
by the Receiving Party, and shall not be disclosed to any third party without
the prior written consent of the Disclosing Party. Each party acknowledges that,
except as expressly set forth herein, it will not obtain any rights of any sort
in or to the Confidential Information of the Disclosing Party as a result of
such disclosure.

               (b)     The Receiving Party will restrict disclosure of the
Disclosing Party's Confidential Information to those of the Receiving Party's
and its Affiliates' employees, officers, directors, consultants and agents to
whom it is necessary to disclose such Confidential Information in connection
with the performance of its obligations under this Agreement. The Receiving
Party shall use all reasonable efforts, which shall be at least fully
commensurate with those employed by the Receiving Party for the protection of
its own Confidential Information, to protect the Confidential Information of the
Disclosing Party.

               (c)     The confidentiality and use restrictions set forth in
this Article 5 shall not apply to Confidential Information to the extent such
information:

                     (i)   was  already  known to the  Receiving  Party,  other
                           than under an  obligation  of
                           confidentiality, at the time of disclosure;

                     (ii)  was  generally  available to the public or otherwise
                           part of the public  domain at
                           the time of its disclosure to the Receiving Party;

                     (iii) became generally available to the public or
                           otherwise part of the public domain after its
                           disclosure and other than through any act or
                           omission of the Receiving Party in breach of
                           this Agreement;

                     (iv)  was independently developed by the Receiving
                           Party without the aid, application or use of the
                           Disclosing Party's Confidential Information, as
                           demonstrated by documented evidence prepared
                           contemporaneously with such independent
                           development; or

                     (v)   was subsequently lawfully disclosed to the
                           Receiving Party, other than under a duty of
                           confidentiality, by a third party that had the
                           right to make such disclosure.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

               (d)     Each party hereto may use or disclose Confidential
Information disclosed to it by the other party to the extent (i) such use or
disclosure is reasonably necessary and permitted in the exercise of the rights
granted hereunder in filing or prosecuting patent applications and prosecuting
or defending litigation, (ii) such disclosure is reasonably required to be made
to any institutional review board of any entity conducting clinical trials with
Designated Compound(s) and/or Licensed Product(s), or to any governmental or
other regulatory agency, in order to gain approval to conduct clinical trials or
to market Designated Compound(s) and/or Licensed Products, (iii) such disclosure
is required by law, regulation, rule, act or order of any governmental
authority, court, or agency, or is made in connection with submitting required
information to tax or other governmental authorities, or (iv) such disclosure or
use is reasonably required in conducting clinical trials, or making a permitted
sublicense or otherwise exercising license rights expressly granted to it by the
other party pursuant to the terms of this Agreement; in each case, provided that
if the Receiving Party is required to make any such disclosure of the Disclosing
Party's Confidential Information, other than pursuant to a confidentiality
agreement, it will give reasonable advance notice to the Disclosing Party of
such disclosure and, except to the extent inappropriate in the case of patent
applications, will use its reasonable diligent efforts to secure confidential
treatment of such Confidential Information in consultation with the Disclosing
Party prior to its disclosure (whether through protective orders or otherwise)
and disclose only the minimum necessary to comply with such requirements.

               (e)     Following the termination of this Agreement, or at any
time upon written request by the Disclosing Party, the Receiving Party shall
promptly return to the Disclosing Party all of the Disclosing Party's
Confidential Information, including all copies thereof, in its possession;
provided that the Receiving Party's legal counsel may retain one (1) copy of the
Disclosing Party's Confidential Information in a secure location solely for the
purpose of determining its obligations under this Agreement.

         5.3   PUBLICATION. Each of SPL and NeoGenesis acknowledges the other
party's interest in publishing its results to obtain recognition within the
scientific community and to advance the state of scientific knowledge. Each
party also recognizes the mutual interest in obtaining valid patent protection
and in protecting business interests and trade secret information. Consequently,
either party, its Affiliates, employees or consultants wishing to make a
publication relating to the results of the Screening Program shall deliver to
the other party a copy of the proposed written publication or an outline of an
oral disclosure at least sixty (60) days prior to submission for publication or
presentation. For purposes of this Agreement, the term "publication" shall
include, without limitation, abstracts and manuscripts for publication, slides
and texts of oral or other public presentations, and texts of any transmission
through any electronic media, any computer access system such as the internet,
world wide web, or similar medium. The reviewing party shall have the right to
(i) propose modifications to the publication for patent reasons, trade secret
reasons or business reasons or (ii) delay the publication or presentation in
order to protect patentable information. If the reviewing party requests a
delay, the publishing party shall delay submission or presentation for a period
not to exceed eighteen (18) months from the filing date of the first patent
application covering the information contained in the proposed publication, or
shall modify such Publication to eliminate such patentable information. If the
reviewing party requests modifications to the publication, the publishing party
shall edit such publication to prevent disclosure or trade secret or proprietary
business information prior to submission of the publication or presentation.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       32
<Page>

6.       REPRESENTATIONS AND WARRANTIES.

         6.1   REPRESENTATIONS  AND  WARRANTIES OF EACH PARTY.  Each of
NeoGenesis and SPL hereby  represents,  warrants and covenants to the other
party hereto as follows:

                  (a)  it is a  corporation  or entity duly  organized and
validly  existing  under the laws of the state or other jurisdiction of its
incorporation or formation;

                  (b)  the  execution,  delivery and  performance of this
Agreement by such party has been duly authorized by all requisite corporate
action;

                  (c)  it has the power and  authority  to execute and deliver
this  Agreement  and to perform its obligations hereunder;

                  (d)  the execution, delivery and performance by such party of
this Agreement and its compliance with the terms and provisions hereof does not
and will not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) a loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or
instrument binding or affecting it or its property; (ii) the provisions of its
charter or operative documents or bylaws; or (iii) any order, writ, injunction
or decree of any court or governmental authority entered against it or by which
any of its property is bound;

                  (e)  except for the governmental and regulatory approvals
required to market the Licensed Product(s), the execution, delivery and
performance of this Agreement by such party does not require the consent,
approval or authorization of, or notice, declaration, filing or registration
with, any governmental or regulatory authority and the execution, delivery or
performance of this Agreement will not violate any law, rule or regulation
applicable to such party;

                  (f)  this Agreement has been duly authorized, executed and
delivered and constitutes such party's legal, valid and binding obligation
enforceable against it in accordance with its terms subject, as to enforcement,
to bankruptcy, insolvency, reorganization and other laws of general
applicability relating to or affecting creditors' rights and to the availability
of particular remedies under general equity principles; and

                  (g)  it shall  comply  with all  applicable  material  laws
and  regulations  relating to its activities under this Agreement.

         6.2   NEOGENESIS'  REPRESENTATIONS.  NeoGenesis  hereby
represents, warrants and  covenants to SPL as follows:

                  (a)  to the best of NeoGenesis' knowledge, as of the Effective
Date, NeoGenesis is the sole and exclusive owner of the NeoMorph Screening
Library, the NeoGenesis Patent Rights and the NeoGenesis Know-How free and clear
of all liens, charges and encumbrances and no other person, corporate or other
private entity, or governmental entity or subdivision thereof, has or shall have
any claim of ownership with respect thereto;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

                  (b)  as of the Effective Date it has the full right, power and
authority to grant all of the right, title and interest in the licenses and
other rights granted to SPL under this Agreement;

                  (c)  to the best of NeoGenesis' knowledge, as of the Effective
Date the NeoMorph Screening Library, NeoGenesis Patent Rights and NeoGenesis
Know-How, and the use thereof in performance of the Screening Program as
contemplated hereunder, do not infringe on any intellectual property rights
owned or possessed by any third party;

                  (d)  during the term of this Agreement, NeoGenesis shall not
grant or attempt to grant any licenses, options or other rights to any third
party that are contrary to or otherwise inconsistent with the licenses and other
rights granted to SPL hereunder;

                  (e)  as of the Effective Date there are no claims, judgments
or settlements against or owed by NeoGenesis or pending or, to the best of
NeoGenesis' knowledge, threatened claims or litigation against NeoGenesis
relating to the NeoMorph Screening Library, NeoGenesis Patent Rights and
NeoGenesis Know-How;

                  (f)  as of the Effective Date, it is in compliance in all
material respects with any agreements with third parties, and during the term of
this Agreement (i) it will use diligent efforts not to diminish the rights under
the NeoGenesis Patent Rights and NeoGenesis Know-How granted to SPL hereunder,
including without limitation, by not committing or permitting any actions or
omissions which would cause the breach of any agreements between itself and
third parties which provide for intellectual property rights applicable to the
performance of the Screening Program, and (ii) it will provide SPL promptly with
notice of any such alleged breach; and

                  (g)  during the term of this Agreement it will not use in any
capacity, in connection with any activities to be performed under this
Agreement, any individual who has been debarred pursuant to the United States
Food, Drug and Cosmetic Act.

         6.3   SPL'S REPRESENTATIONS.  SPL hereby represents, warrants and
covenants to NeoGenesis as follows:

                  (a)  during the term of this Agreement it will not use in any
capacity, in connection with any services to be performed under this Agreement,
any individual who has been debarred pursuant to the United States Food, Drug
and Cosmetic Act;

                  (b)  to the best of SPL's knowledge, as of the Effective Date
it is the sole and exclusive owner or licensee of the Schering Patent Rights and
the Schering Know-How, all of which is free and clear of any liens, charges and
encumbrances, and no other person, corporate or other private entity, or
governmental entity or subdivision thereof, has or shall have any claim of
ownership with respect thereto;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       34
<Page>

                  (c)  to the  best  of  SPL's  knowledge,  as of the  Effective
Date it is the  owner  of the Targets and any other tangible materials to be
provided to NeoGenesis hereunder for use in the Screening Program;

                  (d)  to the best of SPL's  knowledge,  as of the  Effective
Date,  the use of the Targets in performance of the Screening  Program as
contemplated  hereunder,  does not infringe a valid and enforceable  claim
of any issued U.S. patent owned or possessed by any third party; and

                  (e)  as of the Effective Date, there are no claims, judgments
or settlements against or owed by SPL or pending or, to the best of SPL's
knowledge, threatened claims or litigation against SPL relating to the Schering
Patent Rights and Schering Know-How.

         6.4   DISCLAIMER.

                  (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.3, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE
NEOMORPH FOCUSED LIBRARIES, QSCD, THE COMPOUNDS, THE ACTIVE COMPOUNDS, THE
IMPROVED ACTIVE COMPOUNDS, THE SELECTED COMPOUNDS, THE DESIGNATED COMPOUNDS, THE
TARGETS, THE LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE SCHERING KNOW-HOW,
THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE
SCHERING PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

                  (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS
AND SPL EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY
CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT
PROVIDED IN SECTIONS 7.2-7.3.

7.       INDEMNIFICATION.

         7.1   INDEMNIFICATION BY SPL. SPL shall indemnify, defend and hold
harmless NeoGenesis and its Affiliates, and each of its and their respective
employees, officers, directors and agents from and against any and all
liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the discovery, development, manufacture, use, testing,
marketing, sale or other disposition of Designated Compounds and/or Licensed
Products by or on behalf of SPL or its Affiliates or sublicensees, (ii)
performance of the Screening Program by SPL, (iii) the use of any and all
Targets with respect to which screening or other research activities are
conducted in the Screening Program, or (iv) any breach by SPL of its
representations and warranties under this Agreement, except, in each case, to
the extent such liability, loss, claims, damage, cost or expense is caused by
the negligence or willful misconduct of NeoGenesis, its Affiliates, or any of
their respective employees, officers, directors or agents.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

         7.2   INDEMNIFICATION BY NEOGENESIS. NeoGenesis shall indemnify, defend
and hold harmless SPL and its Affiliates, and each of its and their respective
employees, officers, directors and agents from and against any and all
liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the performance of the Screening Program by NeoGenesis, except
to the extent directly related to the use of Targets provided by SPL, (ii) any
breach of NeoGenesis' contractual obligations to third parties, or (iii) any
breach by NeoGenesis of its representations and warranties made under this
Agreement, except, in each case, to the extent such liability, loss, claims,
damage, cost, and expense is caused by the negligence or willful misconduct of
SPL, its Affiliates, or any of their respective employees, officers, directors
or agents.

         7.3   PROCEDURE. As a condition to the indemnification provided for
under Sections 7.1 and 7.2, the indemnified party shall promptly notify the
party from whom indemnification is sought (the "INDEMNIFYING PARTY") in writing
of any claim or suit; PROVIDED, that failure to give such notice shall not
relieve Indemnifying Party of its indemnification obligations under this Article
7,except to the extent such failure actually and materially prejudices the
rights of Indemnifying Party to defend against such claim or suit. The
Indemnifying Party shall have the right to assume the defense of any suit or
claim related to the liability if it has assumed responsibility for the suit or
claim in writing; however, if in the reasonable judgment of the indemnified
party, such suit or claim involves an issue or matter which could have a
materially adverse effect on the business operations or assets of the
indemnified party, the indemnified party may retain control of the defense or
settlement thereof by providing written notice of such effect to the
Indemnifying Party, but in no event shall such action or notice be construed as
a waiver of any indemnification rights that the indemnified party may have at
law or in equity. If the Indemnifying Party defends the suit or claim, the
indemnified party may participate in (but not control) the defense thereof at
its sole cost and expense. If Indemnifying Party elects to compromise or defend
a claim that is the subject of this Article 7, it shall notify the indemnified
party of its decision within thirty (30) days after delivery of the notice
described above (or sooner if the nature of the third party claim requires). If
Indemnifying Party elects not to defend the indemnified party or fails to notify
the indemnified party of its election as provided in this Section 7.3, the
indemnified party may pay, compromise or settle such claim (subject to the
provisions of Section 7.5) and the indemnified party shall be free to pursue
such remedies as may be available under applicable law to recover from
Indemnifying Party.

         7.4   LIMITATIONS ON LIABILITY. With respect to any claim by one party
against the other arising out of the performance or failure of performance of
the other party under this Agreement, the parties expressly agree that the
liability of such party to the other party for such breach shall be limited
under this Agreement or otherwise at law or equity to direct damages only and in
no event shall a party be liable for punitive, exemplary or consequential
damages; PROVIDED that this limitation shall not apply to the extent arising
under third party claims which are subject to indemnification under Section 7.1
or Section 7.2.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

         7.5   SETTLEMENTS. Neither party may settle a claim or action related
to a liability, loss, claims, damage, cost or expense arising in connection with
this Agreement without the consent of the other party, which consent shall not
be unreasonably withheld, if such settlement would impose any monetary
obligation on the other party or require the other party to submit to an
injunction or otherwise limit the other party's rights under this Agreement. Any
payment made by a party to settle any such claim or action shall be at its own
cost and expense; PROVIDED, that in the event and to the extent that an
indemnified party enters into a settlement of a matter with respect to which it
believes it is entitled to indemnification under this Article 7 after the other
party has refused to assume the defense of such matter, the provisions of this
Section 7.5 shall not constitute a waiver of such party's right to seek remedies
from the other party concerning such matter.

         7.6   INSURANCE. Each party acknowledges and agrees that during the
term of this Agreement it shall maintain adequate insurance and/or a
self-insurance program for liability insurance, including products liability and
contractual liability insurance, to cover such party's obligations under this
Agreement.Each party shall provide the other party with evidence of such
insurance and/or self-insurance program, upon request.

8.       TERM AND TERMINATION

         8.1   TERM. This Agreement shall take effect as the Effective Date and
shall, unless sooner terminated in accordance with Section 8.2 or Section
9.5(a), expire on a Licensed Product-by -Licensed Product and country-by-country
basis upon the later of: (i) the expiration of the last-to-expire of the
NeoGenesis Patent Rights having a Valid Claim covering the Licensed Product in
such country, or (ii) [*] following the First Commercial Sale of the Licensed
Product in such country. Upon expiration of this Agreement with respect to a
Licensed Product in a given country, the licenses granted to SPL hereunder with
respect to such Licensed Product in such country shall become fully paid,
royalty-free, irrevocable licenses.

         8.2   TERMINATION.

                  (a)  SPL shall have the right to terminate this Agreement,
with or without cause at any time following the first anniversary of the
Effective Date upon one hundred and eighty (180) days written notice.

                  (b)  During the term of the Screening Program, either party
may terminate the Screening Program and this Agreement (i) upon thirty (30) days
written notice to the other party if the other party fails to pay any amounts
properly due and owing under this Agreement, unless such amount is paid prior to
the expiration of such thirty (30) day period, or (ii) upon ninety (90) days
written notice to the other party if the other party commits a material breach
of this Agreement (other than non-payment), unless such breach is cured within
the ninety (90) day notice period, or if such breach is not capable of being
cured within ninety (90) days unless such party during such ninety (90) day
period initiates actions reasonably expected to cure the breach and thereafter
diligently proceeds to cure the breach.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

                  (c)  Following completion of the Screening Program, either
party may terminate this Agreement (i) upon thirty (30) days written notice to
the other party if the other party fails to pay any amounts properly due and
owing under this Agreement, unless such amount is paid prior to the expiration
of such thirty (30) day period, or (ii) upon ninety (90) days written notice to
the other party if the other party commits a material breach of this Agreement
(other than non-payment), unless such breach is cured within the ninety (90) day
notice period, or if such breach is not capable of being cured within ninety
(90) days unless such party during such ninety (90) day period initiates actions
reasonably expected to cure the breach and thereafter diligently proceeds to
cure the breach. Notwithstanding the foregoing, in the event that the
non-payment or breach is related to a Licensed Product, any such termination
shall be effective only with respect to such Licensed Product and this Agreement
shall remain in full force and effect with respect to any other Licensed
Products being developed and commercialized by SPL under this Agreement.

                  (d)  This Agreement may be terminated by either party upon the
filing or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other party, or in the event a receiver or
custodian is appointed for such party's business, or if a substantial portion of
such party's business is subject to attachment or similar process; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to
terminate shall only become effective if the proceeding is not dismissed within
sixty (60) days after the filing thereof.

         8.3  EFFECT OF TERMINATION.

                  (a)  Upon termination of this Agreement pursuant to Section
8.2: (i) NeoGenesis will terminate all tasks then in process in an orderly
manner, as soon as practical and in accordance with a schedule agreed to by SPL
and NeoGenesis; (ii) NeoGenesis shall deliver to SPL all materials developed
through the termination of this Agreement; (iii) SPL shall pay NeoGenesis any
monies due and owing NeoGenesis up to the time of termination for services
actually performed (including all work-in process), and (iv) within thirty (30)
days following termination (including expiration) of this Agreement, NeoGenesis
shall deliver to SPL a reasonably-detailed written report describing the results
of the research performed up to the date of such termination. In addition, upon
termination (including expiration) of this Agreement each party shall return to
the other party or certify in writing to the other party that it has destroyed
all Confidential Information of the other party in its possession.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

                  (b)  The licenses granted by NeoGenesis under Article 3 shall
survive any expiration or termination of the Screening Program or the
termination of this Agreement with respect to any Designated Compound or
Licensed Product for which the applicable service fees and milestone fees and
royalties have been paid (when due in accordance with the terms of this
Agreement) and SPL shall continue to have the right to develop, have developed,
make, have made, use, distribute, offer for sale, import, export and sell
Licensed Products relating to such Designated Compounds; PROVIDED that SPL
continues to pay NeoGenesis milestone fees and royalties as required by Sections
4.3 and 4.4 and complies with Sections 4.5-4.8. In the event the licenses
granted to SPL under Article 3 terminates for any reason, each of SPL's
sublicensees at such time shall continue to have the rights and license set
forth in their sublicense agreements, PROVIDED such sublicensee agrees in
writing that NeoGenesis is entitled to enforce all relevant provisions directly
against such sublicensee.

                  (c)  Nothing herein shall be construed to release either party
of any obligation which matured prior to the effective date of any termination.
SPL's liability for any charges, payments or expenses due to NeoGenesis that
accrued prior to the termination date shall not be extinguished by termination,
and such amounts (if not otherwise due on an earlier date) shall be immediately
due and payable on the termination date.

                  (d)  Termination of this Agreement by either party pursuant to
Section 8.2 or 9.5(a) hereof shall constitute termination of the U.S. Agreement
under the corresponding provisions thereof.

         8.4   SURVIVAL. Articles 1, 5, 6, 7 and 9 and Sections 2.2(b), 2.2(c),
2.2(g), 2.5, 3.4, 3.5, 3.6, 3.7, 4.6, 4.7, 4.8 and 8.3(a-c), and the second and
third sentences of Section 2.1(c), shall survive any termination or expiration
of this Agreement.

9.       GENERAL PROVISIONS.

         9.1   DISPUTE RESOLUTION. Any controversy or dispute that arises under
or relates to this Agreement (with the exception to disputes relating to the
performance of the Screening Program which are governed by the terms of Section
2.6(d)) shall be referred to the Oversight Committee (as defined in Section
2.6(d)) for resolution. If the Oversight Committee is unable to resolve the
dispute within thirty (30) days, the dispute shall be resolved by binding
arbitration pursuant to the provisions of Schedule 9.1 (attached hereto).
Nothing herein shall prevent the parties from settling any dispute by mutual
agreement at any time.

         9.2   GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the State of New York without regard for any
conflict of laws rule or provision thereof that would result in the application
of the substantive laws of any other jurisdiction. Notwithstanding the
foregoing, the parties (and the arbitrators) shall use United States (Federal)
patent and copyright laws for purposes of governing and construing Sections 3.5,
3.6 or 3.7 of this Agreement. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply to the transactions contemplated by
this Agreement.

         9.3   AMENDMENT AND WAIVER. This Agreement may only be modified or
amended by a written instrument signed by authorized representatives of each
party. No provision of or right under this Agreement shall be deemed to have
been waived by any act or acquiescence on the part of either party, its agents
or employees, but only by an instrument in writing signed by an authorized
officer of each party. No waiver by either party of any breach of this Agreement
by the other party shall be effective as to any other breach, whether of the
same or any other term or condition and whether occurring before or after the
date of such waiver.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

         9.4   INDEPENDENT CONTRACTORS. Each party represents that it is acting
on its own behalf as an independent contractor and is not acting as an agent for
or on behalf of any third party. This Agreement and the relations hereby
established by and between SPL and NeoGenesis do not constitute a partnership,
joint venture, franchise, agency or contract of employment. Neither party is
granted, and neither party shall exercise, the right or authority to assume or
create any obligation or responsibility on behalf of or in the name of the other
party or its Affiliates. NeoGenesis shall be solely responsible for compensating
all its personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes.

         9.5   ASSIGNMENT. (a) This Agreement, and any of a party's rights and
obligations under this Agreement, may not be assigned, delegated, sold,
transferred, sublicensed (except as otherwise provided herein) or otherwise
disposed of, by operation of law or otherwise, to any third party without the
prior written consent of the other party; PROVIDED, that either party may assign
this Agreement to an Affiliate or in connection with the transfer or sale of all
or substantially all of its assets related to the division or the subject
business, or in the event of its merger or consolidation or change in control or
similar transaction PROVIDED, FURTHER, that in each instance the assignee
expressly assumes all obligations imposed on the assigning party by this
Agreement in writing. This Agreement shall be binding upon, and inure to the
benefit of, each party, its Affiliates, and its permitted successors and
assigns. Each party shall be responsible for the compliance by its Affiliates
with the terms and conditions of this Agreement.

                  (b)  In the event that any (i) third party or "group" (within
the meaning of Section 13(d) or 14(d) of the Exchange Act of 1934, as amended)
other than the current officers and directors of NeoGenesis or SPL, as the case
may be, has acquired, directly or indirectly, the beneficial ownership, by way
of merger, consolidation or otherwise of 50% of the voting power of NeoGenesis
or SPL, as the case may be, on a fully-diluted basis or (ii) the sale, lease or
transfer of all or substantially all of the assets of NeoGenesis or SPL to any
third party or group not controlled directly or indirectly by such party (each,
a "CHANGE IN Control") during the term of the Screening Program causes either
party's rights and obligations hereunder to pass to any third party, the other
party shall have the right to terminate the Screening Program and this Agreement
upon written notice within thirty (30) days of receipt of actual knowledge of
such Change of Control, without providing the party that is the subject of such
Change in Control any opportunity to cure. Thereafter, such party shall also
have the right to terminate this Agreement if the assignee of the party that is
the subject of such Change in Control does not provide the writing required
under Section 9.5(a). In addition, if the beneficial ownership (in the manner
described in Section 9.5(b)(i)-(ii)) of more than fifty percent (50%) of the
voting or income interest in NeoGenesis or SPL, as applicable, on a fully
diluted basis, is acquired by a third party or group that is reasonably regarded
as a competitor of the other party, such determination being made with reference
to the products and services that such third party then markets or for which it
has made regulatory submissions with the FDA or an equivalent Regulatory
Authority in another Major Country or for which it has publicly announced its
intention to do either of the foregoing, the other party shall have the right,
but not the obligation, to terminate the Screening Program with six (6) months
notice to the party being acquired.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

         9.6   NOTICES. Any notice required or permitted to be given or sent
under this Agreement shall be hand delivered or sent by express delivery service
or certified or registered mail, postage prepaid, or by facsimile transmission
(with written confirmation copy by registered first-class mail) to the parties
at the addresses and facsimile numbers indicated below.

   If to NeoGenesis, to:

                        NeoGenesis Drug Discovery, Inc.
                        840 Memorial Drive
                        Cambridge, Massachusetts 02139
                        Attention: Satish Jindal, President and CSO
                        Fax: (617) 868-1515

   If to SPL, to:

                        Schering-Plough Ltd.
                        Toepferstrasse 5
                        CH 6004 Lucerne
                        Switzerland
                        Attention: President
                        Facsimile No.: (011) (41) (41) 418 16 32

         with copies to:

                        Schering Corporation
                        2000 Galloping Hill Road
                        Kenilworth, New Jersey  07033
                        Attention: Vice President, Business Development
                        Facsimile No.: (908) 298-7366

                 and

                        Schering Corporation
                        2000 Galloping Hill Road
                        Kenilworth, New Jersey  07033
                        Attention: Law Department - Staff Vice-President,
                        Licensing
                        Facsimile No.: (908) 298-2739

Any such notice shall be deemed to have been received on the earlier of the date
actually received or the date five (5) days after the same was posted or sent.
Either party may change its address or its facsimile number by giving the other
party written notice, delivered in accordance with this Section 9.6.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

         9.7   PROVISIONS FOR INSOLVENCY.

                  (a)  All rights and licenses granted under or pursuant to this
Agreement by NeoGenesis to SPL are, for all purposes of Section 365(n) of Title
11 of the United States Code ("TITLE 11"), licenses of rights to "intellectual
property" as defined in Title 11. NeoGenesis agrees during the term of this
Agreement to create and maintain current copies or, if not amenable to copying,
detailed descriptions or other appropriate embodiments, to the extent feasible,
of all such intellectual property. If a case is commenced by or against
NeoGenesis under Title 11, then, unless and until this Agreement is rejected as
provided in Title 11, NeoGenesis (in any capacity, including
debtor-in-possession) and its successors and assigns (including, without
limitation, a Title 11 Trustee (as defined therein)) shall, as SPL may elect in
a written request, immediately upon such request:

                  (i)  perform all of the obligations provided in this
                       Agreement to be performed by NeoGenesis including,
                       where applicable and without limitation, providing to
                       SPL portions of such intellectual property (including
                       embodiments thereof) held by NeoGenesis and such
                       successors and assigns or otherwise available to
                       them; or

                  (ii) provide to SPL all such intellectual property
                       (including all embodiments thereof) held by
                       NeoGenesis and such successors and assigns or
                       otherwise available to them.

                  (b)  If a Title 11 case is commenced by or against NeoGenesis,
and this Agreement is rejected as provided in Title 11, and SPL elects to retain
its rights hereunder as provided in Title 11, then NeoGenesis (in any capacity,
including debtor-in-possession) and its successors and assigns (including,
without limitation, a Title 11 Trustee) shall provide to SPL all such
intellectual property (including all embodiments thereof) held by NeoGenesis and
such successors and assigns, or otherwise available to them, immediately upon
SPL's written request. Whenever NeoGenesis or any of its successors or assigns
provides to SPL any of the intellectual property licensed hereunder (or any
embodiment thereof) pursuant to this Section 9.7, SPL shall have the right to
perform the obligations of NeoGenesis hereunder with respect to such
intellectual property, but neither such provision nor such performance by SPL
shall release NeoGenesis from any such obligation or liability for failing to
perform it.

                  (c)  All rights, powers and remedies of SPL provided herein
are in addition to and not in substitution for any and all other rights, powers
and remedies now or hereafter existing at law or in equity (including, without
limitation, Title 11). In the event of the commencement of a Title 11 case by or
against NeoGenesis, SPL, in addition to the rights, power and remedies expressly
provided herein, shall be entitled to exercise all other such rights and powers
and resort to all other such remedies as may now or hereafter exist at law or in
equity (including, without limitation, Title 11) in such event. The parties
agree that they intend the foregoing SPL rights to extend to the maximum extent
permitted by law, including, without limitation, for purposes of Title 11:

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       42
<Page>

                  (i)  the right of access to any intellectual property
                       (including all embodiments thereof) of NeoGenesis, or
                       any third party with whom NeoGenesis contracts to
                       perform an obligation of NeoGenesis under this
                       Agreement, and, in the case of the third party, which
                       is necessary for the development, registration,
                       manufacture and marketing of Designated Compounds
                       and/or Licensed Products; and

                  (ii) the right to contract  directly  with any third party
                       described  in (i) to complete the
                       contracted work.

         9.8   SEVERABILITY. In the event any provision of this Agreement shall
for any reason be held to be invalid, illegal or unenforceable in any respect,
such invalidity, illegality or unenforceability shall not affect any other term
or provision hereof. The parties agree that they will negotiate in good faith to
replace any provision hereof so held invalid, illegal or unenforceable with a
valid provision which is as similar as possible in substance to the invalid,
illegal or unenforceable provision.

         9.9   CAPTIONS. Captions of the sections and subsections of this
Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or
construction of the terms and conditions hereof.

         9.10  ENTIRE AGREEMENT. This Agreement (including the Attachments or
Schedules hereto) constitutes the entire understanding of the parties with
respect to the transactions and matters contemplated hereby and supersedes all
previous communications, representations, agreements and understandings, whether
written or verbal, relating to the subject matter hereof. No representations,
inducements, promises or agreements, whether oral or otherwise, between the
parties not contained in this Agreement shall be of any force or effect.

         9.11  RULES OF CONSTRUCTION. The parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be construed against either party by
reason of the extent to which such party or its professional advisors
participated in the preparation of this Agreement.

         9.12  COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

         9.13  FORCE MAJEURE. Failure of any party to perform its obligations
under this Agreement (except the obligation to make payments when properly due)
shall not subject such party to any liability or place them in breach of any
term or condition of this Agreement to the other party if such failure is due to
any cause beyond the reasonable control of such non-performing party ("FORCE
MAJEURE"), unless conclusive evidence to the contrary is provided. Causes of
non-performance constituting force majeure shall include, without
limitation,acts of God, fire, explosion, flood, drought, war, riot, sabotage,
embargo,strikes or other labor trouble, failure in whole or in part of suppliers
to deliver on schedule materials, equipment or machinery, interruption of or
delay in transportation, a national health emergency or compliance with any
order or regulation of any government entity acting with color of right. The
party affected shall promptly notify the other party of the condition
constituting force majeure as defined herein and shall exert reasonable efforts
to eliminate, cure and overcome any such causes and to resume performance of its
obligations with all possible speed; provided that nothing herein shall obligate
a party to settle on terms unsatisfactory to such party any strike, lockout or
other labor difficulty, any investigation or other proceeding by any public
authority or any litigation by any third party. If a condition constituting
force majeure as defined herein exists for more than ninety (90) consecutive
days, the parties shall meet to negotiate a mutually satisfactory resolution to
the problem, if practicable. If the parties cannot in good faith reach a
satisfactory resolution to the problem within sixty (60) days of meeting, the
matter shall be referred to binding arbitration pursuant to Section 9.1.

         9.14  RELATIONSHIP TO US AGREEMENT, CONTROLLING PROVISIONS. The parties
acknowledge that this Agreement and the US Agreement are intended to operate
together as a single worldwide agreement governing the rights and obligations of
NeoGenesis, SPL and Schering Corporation. For purposes of clarity and avoidance
of doubt, the parties agree that rights and obligations of the parties under
Sections 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7 and 2.8 of this Agreement shall be
controlled by the corresponding provisions of the U.S. Agreement. The parties
further agree that SPL's rights and obligations under Sections 3.5, 3.6 and 3.7
of this Agreement shall be exercised and performed by the employees and/or
agents of Schering Corporation having responsibility for Schering Corporation's
rights and obligations under Sections 3.5, 3.6 and 3.7 of the US Agreement, and
that all such activities will be performed in a coordinated manner.

         9.15  FURTHER ASSURANCES. Each party agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives.

NEOGENESIS DRUG DISCOVERY, INC.                        SCHERING-PLOUGH LTD.

BY:   /S/  SATISH JINDAL                               BY:   /S/ DAVID POORVIN
-------------------------------                        ------------------------
Satish Jindal                                          David Poorvin, Ph.D.
President and CSO                                      Prokurist

Date:    AUGUST 2, 2001                                Date:    AUGUST 2, 2001
-------------------------------------                  -----------------------

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       44

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]